[go: up one dir, main page]

CA2351187A1 - Tetrahydroisoquinoline derivatives as lhrh antagonists - Google Patents

Tetrahydroisoquinoline derivatives as lhrh antagonists Download PDF

Info

Publication number
CA2351187A1
CA2351187A1 CA002351187A CA2351187A CA2351187A1 CA 2351187 A1 CA2351187 A1 CA 2351187A1 CA 002351187 A CA002351187 A CA 002351187A CA 2351187 A CA2351187 A CA 2351187A CA 2351187 A1 CA2351187 A1 CA 2351187A1
Authority
CA
Canada
Prior art keywords
tetrahydro
amino
propionyl
diphenylheptane
fluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002351187A
Other languages
French (fr)
Inventor
Fortuna Haviv
Wesley J. Dwight
Bradley W. Crawford
Rolf E. Swenson
Milan Bruncko
Michele A. Kaminski
Lisa M. Frey
John Demattei
Jonathan Greer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/191,511 external-priority patent/US5981521A/en
Application filed by Individual filed Critical Individual
Publication of CA2351187A1 publication Critical patent/CA2351187A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Tetrahydroisoquinoline derivatives of formula (I): or a pharmaceutically acceptable salt, ester, or prodrug thereof, having activity as an LHRH
antagonist, as well as pharmaceutical compositions containing the same, and methods for their use and preparation.

Description

TETRAHYDROISOOUINOLINE DERIVATIVES
AS LHRH ANTAGONISTS .
Technical Field of the Invention f The present invention relates to novel tetrahydroisoquinoline derivatives having activity as luteinizing hormone releasing hormone (LHRH) antagonists. In particular, the invention relates to pharmaceuticals containing these compounds, a process for making them, as well as a method for treating various hormone dependent diseases, including prostate cancer, endometriosis, uterine fibroids, precocious puberty, benign prostate hypertrophy, and in vitro fertilization.
Background of the Invention The gonadotropin hormones, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) regulate the fundamental reproductive processes, such as ovarian release and gamete maturation. LHItH released from the hypothalamus binds to a receptor on the pituitary gland causing the release of gonadotropin hormones. The ongoing system of feedback plays a major role in regulating the synthesis of the steroidal reproductive hormones from the gonads, ie.
estrogen and progesterone in females and testosterone in males. Consequently, controlling the pulsatile release of LHRH providea an avenue for the design of novel compounds useful in treating various conditions related to dysfunction of the reproductive cycle and hormone dependent diseases.
Natural mammalian releasing hormone LHRH isolated and purified from porcine and human hypothalamus has been cht~racterized as having the sequence:
(gyro)GIu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 as described in A.V. Schally, Science, 202:6 (1978). Substitutions and derivatizations of amino acyl residues have been developed to achieve novel compounds useful in treating various disorders related to mammalian reproductive systems. Some derivatives of natural compounds have been shown to exhibit activity as LHRH agonists or as antagonists of LHRH.
Synthetic analogs evidencing activity in modulating LH12H secretion typically comprise peptides of naturally-occurring or :non-naturally occurring amino acid residues. Peptide LHRH
antagonists characterized by substitution of the nitrogen atom of at least one amide bond are described in U.S. Pat. Na. 5, I 10,91J4, and U.S. Pat. No. 5,502,035.
Truncated peptide compounds developed as a series of smaller peptide analogs also exhibit biological activity and afford the added advantage of possibly improving oral bioavailability. "Pseudo" peptide compounds, see for example U.S. Pat. No.
5,140,009, are recognized LHRH antagonists. lZ.educed-size pentapeptides LHRH antagonists are described in pending U.S. Application Ser. No. 132,999. Pending application U.S. Ser. No.
133,055 discloses heptapeptide analogs which proviide active compounds truncated from the C-terminus of a :> decapeptide antagonist sequence.
Non-peptide heterocyclic reproductive hormone regulators have been reported in the literature, see for example, WO 95/29900 and WO 97/21704. Macrolide LHRH
antagonists are described in the pending U.S. Application Ser. No. 049,963; see also pending U.S. Application Ser. No. 140,805. European Patent EP 0712845 discloses amine compounds exhibiting LHRH
receptor antagonist activity; see also European Patent EP 0 i 87700.
The non-peptide LHRH antagonists of the present invention comprise tetrahydro-isoquinoline derivatives not previously described by the prior art. The compounds are useful in the treating a variety of sex hormone related conditions including precocious puberty, benign prostatic hyperplasia, breast and ovarian tumors, prostate tumors, cryptorchidism, hirsutism in women, gastric motility disorders, dysmenorrhea and endometriosis.
Summary of the Invention In one aspect, the present invention relates to a compound having the formula:
O
RZ / W
UH2)n""N
v 'Z
R~
(I) ~:0 or a pharmaceutically acceptable salt, ester, or prodrug thereof, wherein:
l, m, and n are each independently 1, 2, 3, or 4;
p is 1 or 2;
_2_ R~ is selected from the group consisting of:
(a) alkyl, (b) cycloalkyl, (c) aryl, (d) cyano, (e) -(CHZ)9 R4, wherein q is 0 to 10, (f) -cycloalkyl-Rs, and (g) -~'Yl-Rs;

RZ is selected from the group consisting of:

10~ (a) alkyl, (b) hydrogen, (c) alkoxycarbonyl, (d) hydroxymethyl, and (e) -(CH2)9-R4, wherein q is 0 to 10;

1 R, is selected from the group consisting ~~ of:

(a) alkyl, (b) alkoxy, (c) aryl, (d) aryloxy, 20 (e) cyano, (fJ cycloalkyl, (g) hydroxy, (h) halogen, (i) phthalirnido, 25 (j) -cycloalkyl-Rs, (k) -aryl-Rs, and (1) NR6R7;' Rs is selected from the group consisting of:

(a) alkyl, 3 (b) alkoxy, (c) cyano, (d) hydroxy, (e) halogen, (f) trifluoromethyl, and (g) -(CHZ)q NR6R~~, wherein q is 0 to 10;
R6 and R~ are independently selected from the group consisting of (a) hydrogen, (b) alkyl, (c) cycloalkyl, and (d) aryl, or R6 is hydrogen and R7 is a group of the formula -CORE, wherein Rs is selected from the group consisting of:
(a) alkyl, (b) aryl, and (c) heterocycle;
X and Y are independently selected from the group consisting of:
(a) hydrogen, 1 _'i (b) halogen, (c) alkoxy, (d) alkyl, and (e) trifluoromethyl; and W and Z are independently selected from the group consisting of 21) (a) hydrogen, (b) hydroxy, (c) alkyl, (d) alkoxy, (e) alkoxycarbonyl, 25 (f) nitro, (g) N acyl, (h) halogen, and (i) trifluoromethyl, or W and Z taken together form a cyclic ring.
30 The compounds of the inwention bind to LHRH receptors and are effective LHRH
antagonists. Compounds within the scope of the invention are effective in the treatment of prostate cancer, endometriosis, precocious puberty and other types of diseases which are related to sex hormones.

In another aspect, the invention relates to a process of preparing a compound of the invention comprising treating a di.phenyl-substituted aminoalkanol with an activated carboxylic acid to obtain an N substituted aminoalkanol, oxidizing alcohol moiety of the N substituted aminoalkanol to an aldehyde moiety, and alkylating the aldehyde moiety with a '.> tetrahydroisoquinoline ring to affi~rd a tetrahydroisoquinoline derivative of formula (I).
Another aspect of the invention relates to pharmaceutical compositions which are useful as LHRH antagonists and modulating levels of sex hormones in mammals.
Yet another aspect of the :invention relates to a method of modulating levels of sex hormones in male and female mammals comprising admininstering to a host in need of such 1 ~D treatment a therapeutically effective amount of an LHRH compound of the invention.
Detailed Description of the Invention The terms "alkyl" and "lower alkyl" as used herein refer to straight or branched chain alkyl radicals containing from 1 1:0 10 carbon atoms, sometimes represented as Cx-Cy-alkyl 15 where x and y respectively represent the minimum and maximum number of carbon atoms in the alkyl radical. Examples of lower alkyl include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, 1-methylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 2,2-dimethylpropyl, n-hexyl, n-octyl, n-nonyl, n-decyl, and the like.
The term "alkoxy" as used herein refers to a lower alkyl group of one to three carbons, as ~!0 defined above, which is bonded to an oxygen atom in an ether linkage.
Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, isopropoxy, n-pentyloxy, t-butoxy, n-octyloxy and the like. This alkoxy radical can also contain a ring which includes, but is not limited to, a five or six atom ring; composed of carbons, and up to one or two heteroatoms such as nitrogen, oxygen, or sulfur.
:ZS The term "alkoxycarbon;yl" as used herein refers to an alkoxy group as described above wherein an oxygen atom is linked to the parent molecular moiety via a carbonyl group.
The term "cyclic ring" as used herein refers to hydrocarbon chain of one to four carbon atoms carbon-carbon bonded to a,~3-adjacent carbons on the parent molecular moiety or respectively linked by an ether linkage at the a- or Vii- carbon, for example, acetonido.
30 The term "cycloalkyl" as used herein refers to a saturated monocyclic hydrocarbon groups having from three to six carbon atoms in the ring, including, but not limited to, eyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.
The cyclic group may be optionally substituted with, for example, alkyl, alkoxy, cyano, hydroxy, halogen, trifluoromethyl; amino, or N substituted aminoalkyl. The cycloalkyl may be carbon-carbon bonded directly to the parent molecular moiety or linked to the parent molecule via an appended substituent.
The term "aryl" as used herein refers to a mono-, fused bicyclic or fused tricyclic carbocyclic ring system having one or more aromatic rings including, but not limited to, phenyl, naphthyl, tetrahydronaphthyl, phenanthrenyl, biphenylenyl, indanyl, indenyl and the like. The term "bicyclic aryl" as used herein includes naphthyl, tetrahydronaphthyl, indanyl, indenyl and the like. The term "tricyclic aryl" as used herein includes anthracenyl, phenanthrenyl, biphenylenyl, fluorenyl, and the like. Aryl groups (including bicyclic and tricyclic aryl groups) can be unsubstituted or substitul:ed with one, two or three substituents independently selected from lower alkyl, haloalkyl, alkoxy, thioalkoxy, amino, N-substituted aminoalkyl, alkenyloxy, hydroxy, halo, mercapto, nitro, carboxaldehyde, carboxy, alkoxycarbonyl and alkylamido.
Substituents also include methylenedioxy and ethylenedioxy. In addition, substituted aryl groups include tetrafluorophenyl and pentafluorophenyl. Aryl and substituted aryl groups may be carbon-carbon bonded directly to the parent molecular moiety or linked to the parent molecule via an appended substituent.
The term "aryloxy" as used herein refers to an aryl group as described above wherein the aryl group is linked to the parent molecular moiety via an oxygen atom in an ether linkage.
The terms "heterocyclic ring" or "heterocyclic" or "heterocycle" as used herein refers to any 3- or 4-membered ring containing a heteroatom selected from oxygen, nitrogen and sulfur, or a 5-, 6- or 7-membered ring containing one, two or three nitrogen atoms, one nitrogen and one sulfur atom, or one nitrogen and one oxygen atom. The 5-membered ring has 0-2 double bonds and the 6- and 7-membered ring have 0-3 double bonds. The nitrogen heteroatoms can be optionally quaternized. The term "heterocyclic" also includes bicyclic groups in which any of the above heterocyclic rings is fused to a benzene ring or a cyclohexane ring or another heterocyclic ring (for example., indolyl, quinolyl, isoquinolyl, tetrahydroquinolyl, decahydroquinolyl, benzofuryl. or benzothienyl, imidazopyridyl, pyrrolopyridyl and the like).
The term "heterocyclic" also uicludes tricyclic groups in which any of the above heterocyclic rings is fused to two benzene rings or two cyclohexane rings or two other heterocyclic rings (for example, carbazolyl, iminodibenzyl and the like). Heterocyclics include:
azetidinyl;
benzimidazolyl; 1,4-benzodio:~canyl; 1,3-benzodioxoiyl; benzoxazolyl;
benzothiazolyl;
benzothienyl; carbazolyl; dihydropyranyl; dihydrofuranyl; dioxanyl;
dioxolanyl; furyl;
homopiperidinyl; imidazolyl; imidazolinyl; imidazolidinyl; imidazopyridyl;
iminodibenzyl;

indolinyl; indolyl; isoquinolinyl; isothiazolidinyl; isothiazolyl;
isoxazolidinyl; isoxazolyl;
morpholinyl; naphthyridinyl; oxazolidinyl; oxazolyl; piperazinyl; piperidinyl;
pyranyl; pyrazinyl;
pyrazolidinyl; pyrazolinyl; pyrazolyl; pyridazinyl; pyridyl; pyrimidinyl;
pyrrolidinyl;
pyrrolindinylpyridyl; pyrrolinyl; pyrrolopyridyl; pyrrolyl; quinolinyl;
tetrahydrofuranyl;
S tetrahydropyranyl; thiazolidinyl; thiazolyl; and thienyl.
Heterocycles can be unsubstituted or monosubstituted or disubstituted with substituents independently selected from hydroxy, halo, oxo (=O), alkylimino (R*N= wherein R* is a loweralkyl group), amino, N substituted aminoalkyl, alkoxy, alkoxyalkoxy, haloalkyl, cycloalkyl, aryl, arylalkyl, -COCIH, -SO,H and loweralkyl. In addition, nitrogen containing 1.0 heterocycles can be N protected.
The term "hydroxymethyl"' as used herein refers to a lower alkyl of one to ten carbon atoms substituted at one or more carbon atoms with a hydroxy group.
The term "N-acyl" as used herein refers to an N substituted aminoalkyl group wherein the nitrogen atom is linked to the parent molecular moiety via a carbonyl group.
The term l 5 "N-substituted aminoalkyl" refers to an amino group substituted with one, two or three lower alkyl groups of one to ten carbons, for example, ethylamino, butylamino, and the like. Amino groups which are substituted with two or three lower alkyl groups as defined above, include for example, diethylamino, methyl propylamino, and the like. The lower alkyl groups are optionally substituted with, for example, alkoxy, aryl, substituted aryl, carbonyl, cycloalkyl, hydroxy, 20 halogen or amino. Exemplary N-acyl groups include, but are not limited to, methylcarbamoyl, 1-cyclopentyl ethylcarbamoyl, and the like.
The term "pharmaceutically acceptable salts" as used herein refers to those carboxylate salts, esters, and prodrugs of the; compound of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower 25 animals with undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention. Pharmaceutically acceptable salts are well known in the art and refer to the relatively non-toxic, inorganic and organic acid addition salts of the compound of the present invention. For example, S. M. Berge, et al. describe 30 pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66: 1-19 (1977) which is incorporated herein by reference. The salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or separately by reacting the free base function with a suitable organic acid. Examples of pharmaceutically acceptable, nontoxic acid _7_ addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, malefic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in th.e art such as ion exchange. Other pharmaceutically acceptable _'i salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoat:e, hexanoate, hydroiodide, 2-hydroxyethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 1 ~) 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, palmoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like.
Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, I S nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.
The term "pharmaceutically acceptable esters" as used herein refers to non-toxic esters of the compounds of this invention. Examples of pharmaceutically acceptable esters include C, to f,0 C6 alkanoyl esters wherein the alkanoyl group is a stxaight or branched chain. Esters of the compounds of the present invention may be prepared according to conventional methods.
The term "pharmaceutica.lly acceptable prodrugs" as used herein refers to those prodrugs of the compounds of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue :>.5 toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention. The term "prodrug" refers to compounds that are rapidly transformed in vivo to yield the parent compound of the above formula, for example by hydrolysis in blood. A thorough discussion is provided in T. Higuchi and V.
Steila, Pro-drugs as 30 Novel Deliverlr Systems, Vol. 14 of the A.C.S. Symposium Series, and in Edward B. Roche, ed., Bioreversible Carriers in Drue Desien, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference.
_g_ Where appropriate, prodrugs of derivatives of compounds of the present invention may be prepared by any suitable method. For those compounds in which the prodrug moiety is an amino acid or peptide functionality, the condensation of the amino group with amino acids and peptides may be effected in accordance with conventional condensation methods such as the azide method, the mixed acid anluydride method, the DCC
(dicyclohexylcarbodiimide) method, the active ester method (p-nitrophenyl ester method, N hydroxysuccinic acid imide ester method, cyanomethyl ester method and the like), the Woodward reagent K method, the DCC-HOBT
(1-hydroxybenzotriazole) method and the like. Classical methods for amino acid condensation reactions are described in M. Bodansky, Y.S. Klausner and M.A. Ondetti, Peptide Synthesis, Second Edition, NY, 1976, which is incorporated herein by reference.
Numerous asymmetric centers may exist in the compounds of the present invention.
Except where otherwise noted, the present invention contemplate the various stereoisomers and mixtures thereof. Accordingly, whenever a bond is represented by a wavy line, it is intended that a mixture of stereo-orientations or an individual isomer of assigned or unassigned orientation may be present.
Preferred Embodiment Preferred compounds of the invention are those compounds of formula (I) wherein 1 is 2, mis3,nis3,andpis 1.
~:0 Additional preferred compounds of the invention are compounds represented by the formula (I) wherein R~ is selected from the group consisting of alkyl, cycloalkyl, and -(CH2)9 Ra, wherein g is 0 to 10, and R4 is a ;group of the formula -NR6R~, wherein R6 and R~ are each independently selected from hydrogen, alkyl, and cycloalkyl.
Preferred compounds of the invention are also include compounds of formula (I) wherein :>_5 R2 is selected from the group consisting of hydrogen and methyl.
Other preferred compounds of the invention are those compounds represented by the formula (I) wherein X and Y are: independently selected from the group consisting of hydrogen and halogen.
Additional preferred compounds of the invention are compounds of formula (I) wherein 30 W and Z are independently selected from the group consisting of hydrogen and methoxy.
The more preferred compounds of the invention are those compounds as represented by formula (I) wherein R, is selected from the group consisting of methyl, cyclopropyl, cyclobutyl, aminomethyl, aminoethyl, aminopropyl, aminobutyl, N
[cyclopropylmethyl]aminobutyl, and N
[bis-cyclopropylmethyl]-aminobutyl.
Representative compounds within the scope of the invention are selected from the group consisting of (R,S) 7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-methyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
(R) 7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-methyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
IO
(S'~ 7-[N 3-(4-fluorophenyl)propionyl]amino-I-[N (1,2,3,4-tetrahydro-1-methyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-cyclopropyl-15 6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-ethyl-6,7-dimethoxy-isoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-isopropyl-f.0 6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-phenyl-6,7-dimethoxy-isoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-I-[N (1,2,3,4-tetrahydro-1-cyclopentyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
2:5 7-[N 3-(4-fluorophenyl)prop:ionyl]amino-1-[N (I,2,3,4-tetrahydro-1-cyclobutyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-cyclohexyl-?~0 6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N (4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-cyanomethyl-6,7-dimethoxyisoquinolinyl)]-4;1-diphenylheptane hydrochloride;
a5 7-[N (4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-methoxymethyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-benzyloxymethyl-b,7-dimethoxyisoquinolinyl)]-4,~4-diphenylheptane hydrochloride;
<t0 7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-I-(p-methoxy)phenyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propio~nyl]amino-1-[N (1,2,3,4-tetrahydro-1-(4-aminophenyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-[N 3-{4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-[4-(N
isopropyl-amino)phenyl]-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-benzyl-6,7-dimethoxy-isoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-(4-chlorobenzyl)-IO 6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-(4-methoxybenzyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-phenethyl-6,7-di-I S methoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (I,2,3,4-tetrahydro-1-(4-aminobenzyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-[N 3-{4-fluorophenyl)propionyl]amino-I-[N (1,2,3,4-tetrahydro-1-aminomethyl-6,7-di-methoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
20 7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-(N
isopropyl-aminomethyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
?-[N 3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-I-(4-N
phthalimido-butyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-I-[N (1,2,3,4-tetrahydro-I-(4-aminobutyl)-25 6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-[4-(N
isopropyl-arnino)butyl]-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-I-[N-(1,2,3,4-tetrahydro-1-[4-(N
cyclopropyl-methylamino)butyl]-b,7-dimethox;yisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
30 7-[N 3-(4-fluorophenyl)propio:nyl]amino-1-[N-(1,2,3,4-tetrahydro-1-[4-(N
cyclobutyl-amino)butyl]-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-1-jN-(1,2,3,4-tetrahydro-1-[4-(N
isobutyl-amino)butyl]-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-[N 3-(4-fluorophenyl)propio:nyl]amino-1-[N (1,2,3,4-tetrahydro-I-[4-(N
isopentyl-35 amino)butyl]-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;

7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (I,2,3,4-tetrahydro-1-[4-(N alpha-methyl-benzylamino)butyl]-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-[4-(N,N
dicyclopropyl-methylamino)butyl)-6,7-dimetho~s:yisoquinolinyl)]-4,4-diphenylheptane dihydrochlor~ide;
7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-[4-(N,N
dimethyl-amino)butyl]-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-[N 3-(4-fluorophenyl)propicrnyl]amino-1-[N (1,2,3,4-tetrahydro-1-[4-(N
acetyl-amino)butyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-[4-(N
nicotinyl-la~ amino)butyl]-6,7-dimethoxyisoquinolinyl]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-[4-(N
phthalimido-methyl]cyclohexyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-(4-aminomethyl-cyclohexyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
15 7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-(4-N
isopropylamino methyl)cyclohexyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-(4-N
phthalimido-methyl)phenyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-(4-aminomethyl-20 phenyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-(4-N
isopropylamino-methyl)phenyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-[N 3-{4-fluorophenyl)propio~nyl]amino-1-[N (1,2,3,4-tetrahydro-1-(4-N
cyclobutylamino-methyl)phenyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
25 7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-(4-N
cyclopropyl-methylaminomethyl)phenyl-6,7-dimethoxyisoquinolinyl))-4,4-diphenylheptane dihydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-(4-N
biscyclopropyl methylaminomethyl)phenyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-[N 3-(4-fluorophenyl)propio~nyl]amino-1-[N (1,2,3,4-tetrahydro-1-(4-N
acetylamino-3a~ methyl)phenyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-methyl-6,7-dihydroxy-isoquinolinyl)]-4,4-diphenylheptaJ~e hydrochloride;

7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-methylisoquinolinyl)J-4,4-diphenylheptane hydrochloride;
7-[N 3-{4-fluorophenyl)propionyl]amino-I-[N (1,2,3,4-tetrahydro-I-methyl-6,7-dioxalane-isoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-I-[N-{1,2,3,4-tetrahydro-I-methyl-6,7-dioxane-isoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-I-[N {1,2,3,4-tetrahydro-1-methyl-6-methoxy-isoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl) propionylJamino-1-[N (1,2,3,4-tetrahydro-I-methyl-7-methoxy-isoquinolinyl))-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-I-[N {1,2,3,4-tetrahydro-1-methyl-7-chloro-isoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-I-[N-(1,2,3,4-tetrahydro-I-methyl-7-fluoro-isoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-I-[N (1,2,3,4-tetrahydro-1-methyl-7-nitro-isoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-{4-fluorophenyl)propionyl]amino-I-[N (1,2,3,4-tetrahydro-I-methyl-7-acetylamino-isoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-{4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-I-methyl-6,7-dichloro-isoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propio~nyl]amino-I-[N (1,2,3,4-tetrahydro-I-methyl-6-chloro-7-fluoroisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-methyl-6,7-diacetoxy-isoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-methyl-6-bromo-7-methoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionylJamino-1-[N (1,2,3,4-tetrahydro-I-methyl-6-fluoro-7-methoxyisoquinolinyl)J-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-I-methyl-6-methoxy-7-bromo-isoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionylJamino-1-[N {1,2,3,4-tetrahydro-1,6-dimethyl-7-methoxy-isoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionylJamino-1-[N (1,2,3,4-tetrahydro-1-methyl-6-carbo-methoxy-7-methoxyisoquinolinyl;>]-4,4-diphenylheptane hydrochloride;

7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-cyclobutyl-6-bromo-7-methoxy-isoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-I-[N (1,2,3,4-tetrahydro-1,3-dimethyl-6,7-di-methoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-I-[N (1,2,3,4-tetrahydro-3-methyl-6,7-dimethoxy-isoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-I-[N (1,2,3,4-tetrahydro-1,1-dimethyl-6,7-di-methoxyisoquinolinyl}]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-I-[N (1,2,3,4-tetrahydro-I,3-dimethyl-7-methoxy-1 (I isoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]-I-[N (2,3,4,5-tetrahydro-1-methyl-7,8-dimethoxy-1 H-2-benzazepinyl)]-4,4-dipheny heptane hydrochloride;
6-[N 3-(4-fluorophenyl)propionyl]amino-I-[N-(1,2,3,4-tetrahydro-1-methyl-6,7-methoxy-isoquinolinyl)]-3,3-diphenylhexane hydrochloride;
1~~ 8-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-methyl-6,7-di-methoxy-isoquinolinyl)]-5,5-diphenyloctane hydrochloride;
8-[N 3-(4-fluorophenyl)acetyl]amino-I-[N (1,2,3,4-tetrahydro-1-methyl-6,7-dimethoxy-isoquinolinyl)]-5,5-diphenyloctane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-methyl-7-methoxy-2(I 3-methoxycarbonylisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-I-[N (1,2,3,4-tetrahydro-3-(2-hydroxyethyl-aminocarbonyl)-I-methyl-7-methoxyisoquinolinyl))-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-I-[N (1,2,3,4-tetrahydro-(3-hydroxypropyl-aminocarbonyl)-1-methyl-7-methoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
2_'i 7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-3-(4-hydroxybutyl-aminocarbonyl)-1-methyl-7-methoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-I-[N (1,2,3,4-tetrahydro-1-methyl-7-methoxy-3-(2-(N pyrrolidinyl)ethylaminocarbonyl)isoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-methyl-3-hydroxy-3(? methyl-7-methoxyisoquinolinyl)]~-4,4-diphenylheptane hydrochloride;
7-[N 3-(phenyl)propionyl]amino-I-[N (1,2,3,4-tetrahydro-I-methyl-6,7-dimethoxy-isoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(3,4-dichlorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-methyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;

7-[N 3-{3,4-difluorophenyl)propionyl]amino-1-[N {1,2,3,4-tetrahydro-I-methyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(3-fluoro-4-chloro-phe:nyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-methyl-6,7-dimethoxy-isoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluoro-3-chloro-phenyl)propionyl]amino-I-[N {1,2,3,4-tetrahydro-I-methyl-6,7-dimethoxy-isoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(3,4-dimethoxyphenyl)propionyl]amino-1-[N (I,2,3,4-tetrahydro-I-methyl-6,7-dimethoxyisoquinolinyI)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-methoxyphenyl)propionyl]arnino-1-[N (1,2,3,4-tetrahydro-1-methyl-1 (1 6,7-dimethoxyisoquinolinyl)J-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-chlorophenyl)propivnyl]amino-I-[N (1,2,3,4-tetrahydro-I-methyl-6,7-dimethoxy-isoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)acetyl]amino-1-[N (1,2,3,4-tetrahydro-1-methyl-6,7-dimethoxy-isoquinolinyl)]-4,4-diphenylheptane hydrochloride;
1~~ 7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-(3-N
phthalimido-propyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-I-[N (1,2,3,4-tetrahydro-1-(3-aminopropyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-I-[N (1,2,3,4-tetrahydro-I-[3-N
(biscyclobutyl-2CI amino)propyl]-6,7-dimethoxyisoquinolinyl)J-4,4-diphenylheptane dihydrochloride;
7-[N 3-(4-fluorophenyl)propivnyl]amino-I-[N (1,2,3,4-tetrahydro-1-[3-N
(biscyclopropyl-methylamino)propyl]-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-I-[3-N
{dimethylamino)-propyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
2~~ 7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-I-[3-N
(isopropyl)propyl]-6,7-dimethoxyisoquinolinyl)]-4,4--diphenylheptane dihydroehloride;
7-[N 3-{4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-(5-N
phthalimido-~entyl)-6,7-dimethoxyisoquinolinyl))-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)prvpionyl]amino-I-[N (1,2,3,4-tetrahydro-1-{5-aminopentyl)-3(1 6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-(N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-[S-N
(biscyclobutyl-amino)pentyl]-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-[N 3-(4-fluorophenyl)propionyi]amino-I-[N (1,2,3,4-tetrahydro-1-[5-N
(biscyclopropyl-methylamino)pentyl]-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;

7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-[5-N
(dimethylamino)-pentyl]-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-I-[5-N
(isopropylamino)-pentyl]-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
5~ 7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-cyclobutyl-6-fluoro-7-methoxyisoquinolinyl))-4,4-dip:henylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (I,2,3,4-tetrahydro-1-(4-N
phthalimidobutyl)-6-methyl-7-methoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-(4-aminobutyl)-1 CI 6-methyl-7-methoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-(4-N
isopropylamino-butyl)-6-methyl-7-methoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
and 7-[N 3-(4-fluorophenyl)propionyl]amino-1-jN-(1,2,3,4-tetrahydro-1-cyclobutyl-6-methyl-7-methoxyisoquinolinyl)]-4,4-dip:henylheptane hydrochloride.
1 ~~
Effects and Utilities of LHRH Anta~g,.onists In practicing the method of the invention, a therapeutically effective amount of a compound of the invention or a pharmaceutical composition containing the same is administered to the human or animal in need of; or desiring, such treatment. The compound may be employed 2() in pure form or, where such forms exist, in pharmaceutically acceptable salt, ester or prodrug form. By a "therapeutically effective amount" of the compound of the invention is meant a sufficient amount of the compound to treat the targeted disorder, at a reasonable benefit/risk ratio applicable to any medical treatment, which is administered in such quantities and over such a period of time as is necessary to obtain the desired therapeutic effect. It will be understood, 2.'i however, that the total daily usagc; of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment.
The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder;
activity of the specific compound employed; the specific composition employed;
the age, body 3n weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts. For example, it is well within the skill of the art to WO 00/293$0 PCT/US99/26584 start doses of the compound at levels lower than required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.
The total daily dose of the compound of this invention administered to a human or lower animal may range from about 0.1 to about 100 mg/kg/day or for topical administration from _'~ about 0.1 to about 10% in cream, ointment or other topical formulation or for rectal or vaginal administration from about 10 to about 500 mg per dose in a suitable vehicle.
For purposes of oral administration, doses may be in the range of from about 1 to about 100 mg/kg/day or, more preferably, of from about 10 to about 20 mg/kg/day. If desired, the effective daily dose may be divided into multiple doses for purposes of administration; consequently, single dose compositions may contain such amounts or submultiples thereof as make up the daily dose.
Compounds and pharmaceutical compositions of the invention may be administered by a variety of routes depending on the; specific end use. Exemplary methods of administration include, but are not limited to, orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, or as an oral or nasal 1 '.i spray. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intracisternal, subcutaneous and intraarticular injection and infusion.
The pharmaceutical compositions of the present invention comprise a compound of the invention in combination with a pharmaceutically acceptable carrier or excipient. The term "pharmaceutically acceptable carrier" refers to a non-toxic solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
Pharmaceutical compositions of this invention for parenteral injection include pharmaceutically acceptable sterile nonaqueous solutions or aqueous dispersions, suspensions or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or 2:5 dispersions just prior to use. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), carboxymethylcellulose and suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the 3~0 maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
These compositions may also contain adjuvants such as preservative, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents such as sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.
In some cases, in order to prolong the effect of the drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility.
The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the parl:icular polymer employed, the rate of drug release can be 1 '.i controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides) Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.
The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.
Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or Garner such as sodium citrate or dicalcium phosphate 2:i and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption 3n accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols and sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage foam may also comprise buffering agents.
Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such e:xcipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
The active compounds can also be in micro-encapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch.
Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the ease of capsules, tablets and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredients) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.
The active compounds can also be in micro-encapsulated form, if appropriate, with one or more of the above-mentioned ex:cipients.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, groundnut, corn, olive, castor and sesame oils), glycerol, tc~trahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring and perfuming agents.
Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, and tragacanth, and mixtures thereof.
Topical administration includes administration to the skin or mucosa, including surfaces of the lung and eye. Compositions for topical administration, including those for inhalation, may ~~ be prepared as a dry powder which may be pressurized or non-pressurized. In non-pressurized powder compositions, the active ingredient in finely divided form may be used in admixture with a larger-sized pharmaceutically acceptable inert carrier comprising particles having a size, for example, of up to 100 micrometers in diameter. Suitable inert carriers include sugars such as lactose. Desirably, at least 95% by weight of the particles of the active ingredient have an effective particle size in the range of 0.01 to 10 micrometers.
Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams" lotions, gels, powders, solutions, sprays, inhalants or patches.
The active component is admixed under sterile conditions with a pharmaceutically acceptable Garner and any needed preservatives or buffers as may be required. Ophthalmic formulation, ear drops, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.
Alternatively, the composition may be pressurized and contain a compressed gas, such as nitrogen or a liquified gas propellant. The liquified propellant medium and indeed the total composition is preferably such that the active ingredient does not dissolve therein to any 2C~ substantial extent. The pressurized composition may also contain a surface active agent. The surface active agent may be a liquid or solid non-ionic surface active agent or may be a solid anionic surface active agent. It is preferred to use the solid anionic surface active agent in the form of a sodium salt.
Compositions for rectal or vaginal administration are preferably suppositories which can 2~~ be prepared by mixing the compounds of this invention with suitable non-irritating excipients or Garners such as cocoa butter, polyethylene glycol or a suppository wax which are solid at room temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
The therapeutically effective amount of the compound can also be administered in the 3(I form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposornes are formed by mono- or multilamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes can be used. The present compositions in liposome form can contain, in addition to a compound of the present invention, stabilizers, preservatives, excipients, and the like. The preferred lipids are the phospholipids and the phosphatidyl cholines (lecithins), both natural and synthetic. Methods to form liposomes are known in the art. See, for example, Prescott, Ed., Methods in Cell BioloQV, Volume XIV, _'> Academic Press, New York, N.Y..,1976, p. 33 et seq.
Synthetic Methods The process of preparing compounds of the invention may be better understood in connection with the following Schemes 1-5. In describing the processes and the Examples 1 (1 which are following, certain abbreviations are used in describing reagents and methods commonly used in the process. V~Jhere used herein the abbreviations substitute for the following:
DBU for 1,8-diazabicyclo[5.4.0)undec-7-ene; DMAP for 4-dimethylaminopyridine;
DMF for dimethylformamide; EDCI for 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide;
HOBt for 1-hydroxybenzotriazole hydrate; 1~AH for lithium aluminum hydride; OMe for methoxy; PCC
1 s~ for pyridinium chlorochromate; arid THF for tetrahydrofuran.
As summarized below and. further described herein in accordance with the Examples, Schemes 1-5 illustrate processes within the scope of the invention. Scheme 1 describes the general method for preparing tetrahydroisoquinoline derivatives of the general formula (I), which is followed by more prefewed syntheses carried out in accordance with Schemes 2-5.
2(I The tetrahydroisoquinoline derivatives are prepared from a substituted aminoalkanol, wherein a single carbon of the alkyl chain is disubstituted with an aryl moiety, preferably a phenyl group.
Procedures for obtaining the aminoalkanol are readily ascertained by those of skill in the art from methods previously described, for example EP 0712845 for the preparation of 6-amino-4,4-diphenylhexanol. Exemplary synthesis of the diphenyl-substituted aminoalkanol is more 2-'i particularly illustrated and further detailed in Schemes 2-5 and in the Examples.
As illustrated by Scheme 1, Step (i) represents the N substitution of the amino moiety by acylating the nitrogen of the amino group or by coupling with an activated carboxylic acid.
PCC or Swem oxidation of the alcohol to the aldehyde is shown in Step (ii).
Alkylation of an isoquinoline ring as represented b;y Step (iii) affords the tetrahydroisoquinoline derivative.
30 Alternatively, a reactive leaving group R9 is prepared from the alcohol, Step (ii-a), which is alkylated with the isoquinoline ring or the hydroiodide salt of the isoquinoline moiety represented in Step (iii-a). R9 is selected from the group consisting of halide and mesylate.

The variables 1, m, n, p, W., X, Y, Z, R,, and R2 described in Scheme 1 are as defined in Claim 1. R3 is selected from hydroxy, halo, or an aryl ring substituted with an electron withdrawing group to obtain an activated ester as illustrated by Scheme 1 below.
Scheme 1 i H2 xv o {CH2)m Step (1) ~ ~ (CH2)~NH
--(CH2)n"OH X O Y (CHy)m (CHZh~R / ~ (CH2)n-OH
~r r v X O
Step (ii-a) ~(CH2)~ NH Step (ii) Y (CH2)m , X O
/ ~ (CHy)n-Rs ~
(CH2)/ _ NH
(CH2)m (CH2)n-CHO
Step (iii-a) R2 .~ Z
H,N~~W
R~
X O Step (iii) ~ Rz ~ ~ Z
(CH2)f 'NH ~ N w ~
R ~ _ H W
Y {CH2)m Ry / Z
/ ~ (CHz)n-N ~ W
R~
I(I) The following Schemes 2- ~ further describe methods of preparing compounds within the scope of the general formula (I). In particular, Scheme 2 represents a process for preparing a compound of formula (iI) starting with the condensation of diphenylacetaldehyde and acrylonitrile and followed by additional chemical transformations well known in the art. Scheme 3 involves a coupling reaction of an aryl-substituted (aryl)alkylamine with a carboxylic acid, I 0 followed by cyclization to form a tetraisoquinoline moiety which is an intermediate suitable for alkylating compound 7 8, or 9 of Scheme 2. A compound of the formula (III) is prepared from 4,4-diphenyl-formylbutyronitrile as illustrated in Scheme 4. Scheme 5 represents a process for WO 00/29380 ~ PCT/US99/26584 preparing a compound of general formula (IV) via a Wittig reaction of 4,4-diphenyl-5-formyl-pentanonitrile followed by conventional chemical steps. The variables Rl, R2, W, X, Y, and Z
described in the schemes are the groups defined in Claim 1. The group R3 is selected from hydroxy, halo, or an aryl ring substituted with an electron withdrawing group to obtain an activated ester.
Scheme 2 Condensation of diphenylacetaldehyde and acrylonitrile is carried out in the presence of base to afford a 4,4-diphenyl-formylbutyronitrile 1. The aldehyde is converted to a 6-cyano-4,4,-diphenyl-a,~i-unsaturated ester 2 via Wittig reaction. Hydrogenation of 2 in the presence of 10%
Pd/C affords compound 3. Treating the ester 3 with lithium aluminum hydride reduces the ester as well as the cyano moiety to fornn a 4,4-diphenyl-substituted aminoalkanol 4. N acylation of compound 4 with an acid or acid halide of formula S affords an N acyl-4,4-Biphenyl-amino-alkanol b. Swern oxidation of compound 6 oxidizes the alcohol moiety to an aldehyde of compound 7. Reductive alkylation of a tetrahydroisoquinoline with compound 7 in the presence of sodium cyanoborane affords the tetrahydroisoquinoline derivative of formula {II).
Alternatively, displacement of the alcohol moiety with a halide in compound _8 is obtained by Mitsunobu reaction of compound 6. Treatment of compound 6 with methanesulfonyl chloride results in hydroxy displacement with a mesylate moiety to form compound 9. Direct alkylation of the tetrahydroisoquinoline moiety with compound 8 or compound 9 affords the tetrahydroisoquinoline derivative (II).
Scheme 3 Condensation of aryl-substituted (aryl)alkylamine 10 with an activated carboxylic acid ll foams an amide of formula 12. TrE;atment of compound 12 with oxalyl chloride affords compound 13. Treatment of compound 13 with acid and FeCl3 forms compound 14.
Compound 14 is decarboxylated to provide compound 1 S. Reduction of 1 S with sodium cyanoborohydride affords an isoquinoline intermediate of formula (A).
Another known method to :form isoquinoline ring (A) is by the cyclization of compound 12 with POCl3 to afford compoundl 1 S. Reacting compound 1 S with sodium cyanoborane yields the isoquinoline derivative (A).
Optionally treating the isoquinoline ring with hydriodic acid affords a hydroiodide salt of the isoquinoline ring.

Scheme 4 Wittig reaction of 4,4-diph.enyl-formylbutyronitriIe followed by acid hydrolysis of 16.
with HCl affords aldehyde 17. Treatment of 17 with lithium aluminum hydride reduces the cyano and the aldehyde moieties to the amine and hydroxy moieties, respectively, affording compound 18. N substitution of 18 with an activated carboxylic acid of formula S from Scheme 1 affords a compound of i:ormula 19. N mesylation of compound 19 in the presence of methanesulfonyl chloride yields 2~1. Direct alkylation of 20 results in a compound of formula (III).
Scheme 5 Wittig reaction of 17 affords an a,(3-unsaturated ester 21. Hydrogenation of the a,~i-unsaturated double bond forms 22. Compound 22 is reduced to compound 23 with lithium aluminum hydride to the amino alcohol, which is N substituted with an acyl group to form a 1 S compound of formula 24. Direct alkylation of a tetraisoquinoline hydroiodide salt with mesylate 25 affords a compound of formula (I~.

Scheme 2 CN
H
+ ~~CN --~ / \ O
/ \
H
CN
,''CH2CH3 Nu,.
~H
X O
_ /~ \ Rs C_ Y -X O
N
C_ Y
O~
v / \

H

Scheme 2 (continued) X~ \ N F ~ \ N
Y
H
H

O
x\ \
Y

N \I
H~ ~ ~W
Z R
8 R4 =1 ~ ' (A) 9 R4 = OMs h'I ~ N ~ W
R~ (A) O
v~
x~ \ N
z Y /
N \ W
R~
(II) Scheme 3 _ NH2 H
/ ~ N~R~
[~Z
+ ~ Z ~ 12 HO
11 Z w O
N
CI~ O
'O
R~

z / z /
I 1 ~ ~ I

R~ O

Z /
I i N
.. wH
R~
(A) WO 00/2938(1 PCT/US99/26584 Scheme 4 I
Nu_ CN
H
l7 O
F~' Rs (Compound S, Scheme 2) O
F ~ ~ NH
19 RS = OH Rs 20 RS = ON(s N ~I
H~ ~ ~W
R~
(A) O
F~~ NH
Z
N ~I
W
R~
(III) Scheme 5 CN
---~ OCH3 f~J
l_l O
~R

(Compound S, Scheme 2) O
F ~ ~ v _NH
24 R6 = OH
25 R6 = OMs Z
W
O
F- ~ ~ . _NH
U
Z
N ~I
_ W
R~
(I~

CN

The foregoing Schemes 1-S will be better understood in connection with the Examples, which are intended as an illustration of and not a limitation upon the scope of the invention. The following Examples further describe compounds prepared in accordance with the invention.
Modification of the disclosed embodiments to achieve additional compounds having LHRH
antagonist activity will be apparent to those skilled in the art. Such substitution, modification, and change are within the purview of the scope and limitations of the present invention and do not depart from the spirit of the invention thereof.
EXAMPLES
Example 1 ~R.S~-jN 3-(4-Fluoro~henyl)propionyl~amino-1-j~1.,2,3,4-tetrahydro-1-methvl-6 7-dimethoxYisoquinolinyl)]-4,4-diphen~he,ptane hydrochloride Step 1: 4.4-Diphenyl-4-fozmylbutyronitrile (Compound 1, Scheme 2) To a stirred solution of diphenylacetaldehyde (11.0 mL) and acrylonitrile {4.5 mL) in dioxane (125 mL) was added 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (10.5 mL).
The solution was heated under reflux overnight and then concentrated in vacuo. The residue was purified by a silica gel column eluting with (95:5) hexane/ethyl acetate. The desired product 20~ (8.115 g) was obtained a colorless crystals, mp 80-82 °C: MS showed (M+ NH4)+ @ 267; ~H-NMR (CDC13, 8): 2.05-2.15 (cn, 2 H), 2.65-2.75 (m, 2H), 7.11-7.45 (m, 1 OH), 9.80 (s, 1 H); Anal.
Calcd for Ci~Hi5N0: C, 81.90; H, 6.60; N, 5.61. Found: C, 81.83; H, 6.64; N, 5.65.
Step 2: Ethyl 6-cyano-4,4-diphenyl-hex-2-enoate (Compound 2, Scheme 2) 25~ A mixture of 4~,4-diphenyl-4-formylbutyronitrile (8.04 g) and (carbethoxymethylene)-triphenylphosphorane (20.85 g) in toluene (200 mL) was heated under reflux for 3 days. The reaction mixture was concentrated. in vacuo and the residue was purified by a silica gel column chromatography to give the desired product as a yellow-orange oil (12.10 g):
MS showed (M+ NH4)+ @ 337;'H-NMR (CDC13, 8): 1.25-1.32 (t, 3H), 2.10-2.18 (m, 2H), 2.65-2.75 {m, 30 2H), 4.15-4.23 (q, 2H), 5.60-5.66 (d, 1 H), 7.05-7.75 (m, 11 H).

Step 3 : Ethyl 6-c~rano-4,4-di,~hewyl-hexanoate f Compound 3, Scheme 2~
A solution of eahyl 6-cyano-4; 4-diphenyl-hex-2-enoate (22.06 g) in ethanol (500 mL) was hydrogenated in the presence of l l)% Pd/C (2.2 g) under 4 atmospheric pressure for I7 hr. The catalyst was filtered and the filtrate was concentrated in vacuo. The residue was purified by a silica gel column chromatography eluting with (95:5) hexane/ethyl acetate. The desired product (19.49 g) was obtained as colorless oil: MS showed (M+ NH4)+ @ 339; ~H-NMR
(CDC13, b):
1.20-1.25 (t, 3H), 1.95-2.06 (m, 4H), 2.38-2.52 (m, 4H), 4.03-4.12 (m, 2H), 7.10-7.36 (m, lOH).
Step 4: 7-Amino-4,4-diphenvlheptan-I-of Compound 4, Scheme 21 To a solution crf ethyl 6-cyano-4,4-diphenyl-hexanoate (5.476 g) in anhydrous THF (195 mL) was added portionwise lithium aluminum hydride (LAH) ( 1.686 g). A large evolution of gas was observed. The mixture was stirred at rt for 1.5 hr. The reaction mixture was quenched by a careful addition of water (4.5 mL)., followed by I N NaOH (4.5 mL) and additional water (15 mL). The mixture was stirred at rt for IO min and then filtered and the solid was washed three times with THF. The organic filtrates were combined, dried (Na2S04) and concentrated to give the desired product as a solid foam (4.56 g): MS showed (M+ H)+ @ 284; ~H-NMR (CDC13, 8): 1.05-1.3 {m, 4H), 2.0-2.20 (m, 4H), 2.30-2.42 {t, 2H), 2.82-3.0 (t, 2H), 3.0-3.25 (m, 2H), 3.50-3.65 (t, 2H), :5.10-5.20 (broad m, 1H), 6.86-7.36 (m, 14H).
Step 5: 7-jN 3-(4-Fluorophen,~rl)nropionvl]amino-4,4-diphenvlheptan-1-of (Compound 6, Scheme 2) To an ice-cold and stirred solution of 7-amino-4,4-diphenylheptan-1-of (4.14 g) in (9.5:0.5) methylene chloride/DMF solution (42 mL) was added 4-fluorophenylpropionic acid (2.70 g) (Compound S, Scheme 2) followed by 1-hydroxybenzotriazole hydrate (HOBt) (2.38 g), triethylamine (5.0 mL), and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDCI) (3.36 g).
The reaction mixture was stirred at rt overnight and then diluted with methylene chloride (150 mL). The solution was washed first with water and then with brine. The organic phase was dried (Na2S04) and concentrated i:n vacuo. The residue was purified by a silica gel column using (1:1) ethyl acetate/hexane. It yielded the desired compound as an amorphous solid (2.10 g): MS
30~ showed (M+ H)+ (~ 434; ~H-NMR (CDCl3, 8): 1.05-1.28 (m, 4H), 1.7-1.8 (m, 1H), 2.0-2.2 (m, 4H), 2.3-2.4 (t, 2Ha}, 2.85-2.92 (m, 2H), 3.08-3.2 (q, 2H), 3.5-3.6 (q, 2H), 5.3-5.35 (m, 1H), 6.85-7.30 (m, 14H).

Step 6: 7-fN 3-(4-Fluorophenvl)propionyl]amino-4.4-diphen~ptan-1-al ICompound 7, Scheme 2) To a stirred slurry of silica gel (2.03 g) and celite (2.02 g) in methylene chloride (80 mL) was added pyridinium chlorochromate (PCC) (2.06 g) followed by a dropwise addition of a solution of 7-[N 3-(4-fluorophenyl)propionyl]amino-4,4-diphenylheptan-1-of (2.085 g) in methylene chloride (30 mL). The reaction mixture was stirred at rt for 3.5 hr and then diluted with anhydrous ether (5~0 mL) and stirred for 10 min. The mixture was filtered through a celite pad and the filtrate was concentrated in vacuo. The brown residue was dissolved in ethyl acetate and the solution was washed with sodium bicarbonate, water and brine solutions.
The organic extracts were dried (Na2S04) and concentrated in vacuo. The desired product was obtained as a heavy oil (1.7 g): MS showed (M-+- H)+ @ 432 and (M+ NH4)+ @ 449; ~H-NMR
(CDCl3, 8):
1.05-1.18 (m, 2H),. 1.95-2.08 (m, 2H), 2.1-2.2 (t, 2H), 2.3-2.5 (m, 4H), 2.8-3.0 (t, 2H), 3.08-3.20 (q, 2H), 5.08-5.20 (m, 1H), 6.87-7.35 {m, 14H), 9.b (s, 1H).
Step 7: (R. S) 7-fly'-3-l4-Fluorophenvl)nropionyljamino-1-jN (1.2 3 4-tetrah~rdro-1-methyl-6 7 dimethoxvisoguinolinvl)]-4,4-d~r~envlheptane hydrochloride (Compound II Scheme 2) To a solution o~f 7-[N 3-(4-fluorophenyl)propionyl]amino-4,4-diphenylheptan-1-al (0.796 g) in methanol (30 m:L) was added (R,S) 1,2,3,4-tetrahydro-1-methyl-6,7-dimethoxyisoquinoline (0.658 g) followed by sodium cyanoborohydride (0.235 g) and three drops of acetic acid. The mixture was stirred at rt overnight and then concentrated in vacuo. The residue was treated with ethyl acetate and washed with sodium bicarbonate and brine solutions. The organic phase was dried (Na2S04) and concentrated in vacuo. The residue was purified by a silica gel column chromatography eluting with a gradient of hexane/ethyl acetate. The desired product was obtained as a viscous oil (0.30 g): :MS showed (M+ H)+ @ 623;'H-NMR (CDCl3, 8): 1.06-1.3 (m, 7H), 2.0-2.18 (m, 4H), 2.30-2.40 (t, 2H), 2.40-2.85 (m, 6H), 2.85-2.98 (t, 2H), 3.10-3.20 (q, 2H), 3.6-3.7(m,, 1H), 3.8-3.88 (two s, 6H), 6.45 (s, 1H), 6.55 (s, 1H), 6.88-6.97 (m, 2H),. 7.08-7.32 (m, 12H). This compound was treated with methanolic HCI, the solution was concentrated in vacuo and the residue was dissolved in {1:1) acetonitrile/water and lyophilized to give (R,S) 7-[N 3-(4-fluorophenyl)prop~ionyl]amino-1-[N (1,2,3,4-tetrahydro-1-methyl-6,7-di-methoxy-isoquinolinyl)]-4,4-diphe:nylheptane hydrochloride: mp 113-115 °C; IR (KBr) v 3400, 3300, 2950, 1750 c;m'~; Anal. Calcd for C4°H47N203F~HC1~H20: C, 70.93;
H, 7.44; N, 4.13;
Found: C, 71.04; H, 7.32; N, 3.91.

Example 2 R 7- ~V 3-(4-Fluorophenyl)propionyl]-1 jN yl 2 3 4-tetrahydro-1-methyl 6 7-dimethoxyisoc~uinolinyl)1-4 4-di~henvlheptane l~drochloride Step 1: 7_jN~4-Fluorophenyl)~ropion~]amino-4 4-diphenylhept~rl iodide (Compound 8, Scheme 2) To a solution of 7-[N 3-(4-fluorophenyl)propionylJamino-4,4-diphenylheptan-I-of (0.78 g) in toluene {40 mL) was added methyltriphenoxyphosphonium iodide (0.93 g) and the mixture was stirred at rt for 2 hr. The reaction mixture was washed with sodium bicarbonate and brine solutions. The organic phase was dried (Na2S04) and concentrated in vacuo. The residue was purified by a silica gel column chromatography yielding the desired compound (0.912 g) as a semisolid compound: ~H-NMR (CDC13, 8): 1.05-1.2 (m, 2H), 1.32-1.5 (m, 2H), 1.96-2.05 (m, 2H), 2.1-2.2 (m, 21i), 2.32-2.4 (t, 2.H), 2.85-2.95 (t, 2H), 3.05-3.20 (m, 4H), 5.02-5.12 (m, 1H), 6.88-7.35 (m, 14H;1.
Step 2: (R 7-fN 3~-(4-Fluoronhenyl)nronionyllamino-I-[N (1.2 3 4-tetrahydro-I-methyl-6 7-di-methoxvisoquinolinvl)]-4 4-diphenylhentane hydrochloride (Compound II Scheme 2) To a solution o:f 7-[N 3-(4-fluorophenyl)propionyl]amino-4,4-diphenylheptyl iodide (0.912 g) in dioxane (30mL) was added (R) 1,2,3,4-tetrahydro-I-methyl-6,7-dimethoxy-isoquinoline (0.33 g) followed by a solution of potassium carbonate (0.230 g) in water (2 mL).
The mixture was heated at 70 °C for 34 hr and then cooled to rt and diluted with ethyl acetate.
The organic phase 'was washed twice with brine, dried (Na2S04) and concentrated in vacuo. The residue was purified using a silica gel column chromatography eluting with (95:5) ethyl acetate/methanol. 'The desired product (R) 7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-methyl-6,'7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane (0.693 g) was obtained as a dry foam: [a]CSC, = -11.0° (c = 1, EtOH): MS showed (M+ H)+ @ 623; 1H-NMR (CDC13, 8): 1.06-1.32 (m, 7H), 2.03-2.18 (m, 4H), 2.32-3.0 (m, 10 H) 3.10-3.20 (q, 2H), 3.60-3.72 (m, 1 H), 3.82-3.88 (two a, 6H), 6.48 (s, I H), 6.53 (s, 1 H), 6.87-6.97 (t, 2H), 7.08-7.30 (m, 12H). This compound was treated with methanol/HCI solution and the solvent was removed in vacuo. The residue was dissolved in ( 1:1 ) acetonitrile/water and lyophilized to give the 8(1 PC'T/US99/26584 hydrochloride salt of the desired product: mp 113-115 °C; IR (KBr) v 3400, 3300, 2950, 1750 crri'; Anal. Calcd for C4pH4~N2O3F~HCl: C, 72.87; H, 7.33; N, 4.24; Found: C, 72.61; H, 7.33; N, 4.13.
Example 3 ~,5~ 7-IN 3-(4-Fluorophenyl)propionvliamino-1 jN (1,2,3.4-tetrahvdro-1-methyl-6 7-dimethoxvisoquinolinvl)1-4.4-diphen~ptane hydrochloride The procedure described in example 2 was used but substituting (S') 1,2,3,4-tetrahydro-1-methyl-4,5-dimethoxyisoquinoline for (R) 1,2,3,4-tetrahydro-1-methyl-4,5-dimethoxy-isoquinoline. After chromatography purification the desired product (5~ 7-[N 3-(4-fluorophenyl-propionyl)]-1-[N (1,2,3,4-tetrahyd.ro-1-methyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenyl-heptane was obtained as a dry foam; [a] =+12.8° (c = 1, EtOH): MS
showed (M+ H)+ @ 623;
~H-NMR (CDC13, 8): 1.1 (m, 2H) 1.22-1.32 (m, 5H), 2.05-2.18 (m, 4H), 2.38-2.45 (t, 2H), 2.50-2.82 (m, 5H), 2.90-2.95 (t, 2H), 2.95-3.08 (m, 1 H), 3.10-3.22 (q, 2H), 3.72-3.82(m, 1 H) 3.82-3.90 (s, 6H), 5.5-5.65 (broad rn, 1 H), 6.50 (s, 1 H), 6.58 (s, 1 H), 6.88-6.97 (t, 2H), 7.08-7.32 (m, 12H). This compound was treated with methanol/HCl solution and the solvent was removed in vacuo. The residue was dissolved in (1:1) acetonitrile/water and lyophilized to give the hydrochloride salt of the desired product: mp 113-115 °C; IR (KBr) a 3400, 3300, 2950, 1750 cm's; Anal. Calcd for C4°Ha~N203F~HC1: C, 72.87; H, 7.33; N; 4.24;
Faund: C, 72.24; H, 7.18; N, 4.18.
Example 4 7-[N 3-(4-Fluorophenyl)Rropionyll-1-[N (1.2.3,4-tetrahydro-1-c ~~clopropyl-25. 6 7-dimethoxyisoc~uinolinyl)14,4-diphenylheptane h~rdrochloride Step 1: 1N 2-(3,4-Dimethoxyphenvl)ethyllc~pronylcarboxvl amide (Compound 12. Scheme 3) To a solution of 3,4-dimethoxyphenethylamine (5.0 g) in methylene chloride ( 1 OOmL), 3(1 cooled to 0 °C, was slowly added cyclopropylcarbonyl chloride (2.5 mL) followed by triethylamine (7 mL) and 4-dimethylaminopyridine (DMAP) (0.173 g). The reaction mixture was stirred at rt for 2 hr and then washed with sodium bicarbonate, 0.5 M
citric acid and brine solutions. The organic phase was dried (NazS04) and concentrated in vacuo. The residue was crystallized from ethyl acetate to yield the desired product (4.98 g) as yellow powder: MS
showed (M+ H)+ @ 250; 'H-NMR (CDCl3, 8): 0.68-0.78 (m, 2H), 0.93-1.0 (m, 2H), 1.22-1.35 (m, 1H), 2.73-2.8.2 (t, 2H), 3.48-3.57 (q, 2H), 3.88 (two s, 6H), 5.68 (broad s, 1H), 6.72-6.87 (m, 3H).
S
S_teu 2: 3,4-Dihydro-1-cvclopropyl-6 7-dimethox~riso9uinoline (Compound IS
Scheme 3) To a solution of [2-(3,4-dimethaxyphenyl)ethyl]cycIopropylcarboxyl amide (4.9713 g) in toluene (200 mL) was added P0C:13 (10 mL). The mixture was heated under reflux with stirring under nitrogen for 2 hr, cooled to rt, poured over ice, basified to pH 10 with 1M NaOH and 11) extracted three tunes with ethyl acetate. The organic phase was washed with brine, dried (Na2S04) and concentrated in vacuo to give the desired product as a colored hard foam: MS
showed (M+ H)+ @ 232;'H-NMR (CDCl3, 8): 1.48-1.59 {m, 2H), 1.95-2.05 (m, 2H), 2.30-2.41 (m, 1H), 2.96-3.07 (t, 2H), 3.82-3.92 (m, 2H), 3.98 (s, 3H), 4.03 (s, 3H), 6.85 (s, 1H), 7.45 (s, 1 H).
1.'i Step 3: 1.2.3,4-Tetrahvdro-1-cyclonroavl-6 7-dimethox isoquinoline (Compound A
Scheme 3) To a stirred solution of 3,4-dihydro-1-cyclopropyl-6,7-dimethoxyisoquinoline (3.9318 g) in methanol ( 100 mI,) was added under nitrogen NaCNBH3 ( 1.28 g) in the presence of three drops of acetic acid. The mixture was stirred at rt for 2 hr and then concentrated in vacuo and the 20 residue was taken in ethyl acetate and washed with sodium bicarbonate and brine solutions. The organic phase was dried and concentrated in vacuo to give the desired product as a tan solid: MS
showed (M+ H)+ @ 234; 'H-NMR (CDC13, 8): 0.3-0.41 (m, 1 H), 0.5-0.65 (m, 2H), 0.77-0.9 (m, i H), 1.02-1.16 (m., 1 H), 2.25 (broad s, 1 H), 2.6-2.75 (m, 1 H), 2.85-3.08 {m, 2H), 3.28-3.36 (m, 1 H), 3.88 (two s, 6H), 6.60 (s, 1. H), 7.08 (s, 1 H).
2-'i Sten 4: 1.2.3.4-Tetrahydro-1-cvcLo~propyl-6 7-dimetho~isoquinoline hvdroiodide To a solution of 1,2,3,4-tetrah:ydro-1-cyclopropyl-6,7-dimethoxyisoquinoline (0.802 g) in ethanol (10 mL) cooled to 0 °C was added dropwise a solution of 57% HI
solution (0.5 mL).
The ice bath was removed and the solution was stirred at rt for 20 min in the dark. To the bright 30 orange solution was added ether (:Z50 mL} and the mixture was stirred for 10 min. The light yellow precipitate was filtered and dried in vacuo under P2O5 to give the desired salt (0.958 g).

Step 5: 7-fN 3-(4-Fluorophenyl'Ipropionyliamino-1-fN (1.2.3.4-tetrahvdro-1-cvclo"pronvl-6,7-dimethoxvisoquinolinvl)]-4,4-diphenylheptane (Compound II, Scheme 2) To a solution o~F7-amino-4,4-d:iphenylheptan-1-of (1.016 g) (Compound 6, Scheme 2) in methylene chloride (i0 mL) was added at 0 °C methanesulfonyl chloride (0.22 mL) followed by triethylamine (0.5 rnL). The solution was stirred at 0 °C for 30 min.
The reaction mixture was washed with 0.5 N citric acid, water and brine. The organic phase was dried and concentrated in vacuo to give the desired product as an oil (1.1015 g). This was used in the next step without further purification, To a solution oiF7-[N 3-(4-fluorophenyl)propionyl]amino-4,4-diphenylheptyl mesylate (1.35 g) (Compound 9, Scheme 2) in acetonitrile (25 mL) was added in the dark 1,2,3,4-tetrahydro-1 cyclopropyl-6,7-dimethoxy-isoquinoline hydroiodide (0.958 g) and triethylamine (2 mL). The mixture was kept in the dark and heated under reflux overnight. The reaction mixture was cooled to rt and concentrated in vacuo. The residue was dissolved in ethyl acetate and the solution was washed with water and brine, dried (NaZSO4) and concentrated in vacuo. The foamy residue was purified by a silica gel column chromatography eluting with (98:2) methylene chloride/methanol.
This yielded 7-[N 3-(4-fluorophenyl)propionyl]amino-I-[N (1,2,3,4-tetrahydro-I-cyclopropyl-6,7-dimethoxy-isoquinolinyl)]-4,4-diphenylheptane (0.47 g): MS showed (M+ H)+ @
649; ~H-NMR
(CDC13, 8): 0.22-0.3 (m, 1H), 0.5-CL6 (m, 1H,), 0.92-1.25 (m, 3H), 1.98-2.07 (m, 4H), 2.3-2.42 (m, 2H), 2.42-2.95 (m, 12H), 3.08-3.3 I;m, 3H), 3.83 (s, 6H), 6.53 (s, 1H), 6.6 (s, IH), 6.86-6.98 (m, 2H), 7.07-7.3 (m, 12H). This compound was dissolved in methanol/HCI, the solution was concentrated in vac.uo and the residue was dissolved in (1:1) acetonitrile/water to give 7-[N 3-(4-fluorophenyl-propionyl)]amino-1-[N (1,2,3,4-tetrahydro-1-cyclopropyl-6,7-dimethoxy-isoquinolinyl)]-4,4-diphenylheptane hydrochloride (0.470 g): mp 122-129 °C; IR (CHCl3) a 3300, 2942, 1646 cm ~; Anal. Calcd for C;q2H49N2U3F~HC1: C, 73.61; H, 7.35; N, 4.09;
Found: C, 73.73;
H,7.21;N,3.86.
Example 5 7-[N 3-(4-Fluoro~hen~)propionyl]amino-1-[N (1,2,3.4-tetrahydro-I-ethyl-6 7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride 1,2,3,4-Tetrahydro-1-ethyl-6,7-dimethoxyisoquinoline was prepared by a procedure analogous to that described in example 4 for 1,2,3,4-tetrahydro-1-cyclopropyl-6,7-WO 00/29380 Pt~T/US99/26584 dimethoxyisoquinoline but substituting in the first step propionyl chloride for cyclopropyl-carbonyl chloride.
1,2,3,4-tetrahydro-1-ethyl-6,7-dimethoxyisoquinoline (0.195 g) was reacted with 7-[N 3-(4-fluorophe:nyl)propionyl]~unino-4,4-diphenylheptan-1-al (0.4182 g) in the presence of sodium cyanoborohydride as described in example 1 to give the desired product 7-[N 3-(4-fluorophenyl)propionyl]-1-[N (1,2,:3,4-tetrahydro-1-ethyl-6,7-dimetoxyisoquinolinyl)]-4,4-diphenylheptane as a glassy residue. (0.0685 g): MS showed (M+ H) + @ 637; 'H-NMR (CDCl3, b): 0.85-0.93 (t, 3H;), 1.05-1.08 (m, 4H), 1.55-1.75 (m, 4H), 2.0-2.17 (m, 4H), 2.3-2.40 (t, 2H), 2.40-2.55 (m, 4H), :2.87-2.93 (t, 2H), 2.97-3.31 (m, 3H), 3.93 (s, 6H), 6.47 (s, 1H), 6.53 (s, 1H), 6.86-6.98 (t, 2H), 7..08-7.30 (m, 1210. The hydrochloride salt of the desired product was prepared as described in example 1 to give 7-[N 3-(4-fluorophenylpropionyl)amino-1-[N (1,2,3,4-tetrahydro-1-ethyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride:
mp 98-105 °C; IR (CHCI3) a 3300, 2942, 1646 cm''; Anal. Calcd for C41Ha9Nz03F~HCl: C, 73.13; H, 7.48; N, 4.16; Found: t::',, '77.21; H, 7.79; N, 4.35.
Example 6 7-IN 3-(4-Fluorophenylpropionyllamino-1-(N (1.2.3,4-tetrahvdro-1-isopropvl-6~7-~dimethoxyisoauinolinyl)1-4,4-diphenylheptane hydrochloride 1,2,3,4-Tetrahydro-1-isopropyl-6,7-dimethoxyisoquinoline was prepared by a procedure analogous to that described in example 4 for 1,2,3,4-tetrahydro-1-cyclopropyl-6,7-dimethoxy-isoquinoline but substituting in the first step isobutyryl chloride for cyclopropylcarbonyl chloride.
The 1,2,3,4-tetrahydro-1-isopropyl-6,7-dimethoxyisoquinoline was reacted with 7-[N 3-(4-fluorophenyl)propionyl]amino-4,4-diphenylheptan-1-al in the presence of sodium cyanoborohydride as described in example 1 to give the desired product as glassy residue (0.135 g): MS showed (M+ H)+ @, 651;'H-NMR (CDCI3, 8): 0.8-0.88 (d, 3H), 0.92-1.02 (d, 3H), 1.02-1.20 (m, 3H), 1.52-1.70 (m, 2H), 1.7-1.9 (m, 1H) 1.97-2.2 (m, 4H), 2.3-2.50 (m, 4H), 2.50-2.72 (m, 2H), :2.85-2.96 (m, 313), 3.02-3.20 (m, 3H), 3.8-3.9 (two s, 6H), 5.08 (broad s, 1 H), 6.43 (s, 1 H), 6.53 (s, 1 H), 6.9-6.97 (m, 2H), 7.05-7.32 (m, 12H). The hydrochloride salt was prepared as in exarr~ple 1 to give 7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N
(1,2,3,4-tetra-hydro-1-isopropyl-ti,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride: mp 96-103 °C; IR (CHCl3) a 3:350, 2950, 1650, 1510 cm''.

Example 7 7- N 3- 4-Fluorophenyl)propion~]amino-1-[N jl 2 3 4-tetrahydro-1-phenyl-6 7 dimethoxvisoquinolinyl)]-4,4-diphenylhentane hydrochloride 1,2,3,4-Tetrahydro-1-phenyl-6,'7-dimethoxyisoquinoline was prepared by a procedure analogous to that dEacribed in example 4 for 1,2,3,4-tetrahydro-1-cyclopropyl-6,7-dimethoxy-isoquinoline but substituting in the first step benzoyl chloride for cyclopropylcarbonyl chloride.
The 1,2,3,4-tetr,ahydro-1-phenyl-6,7-dimethoxyisoquinolinyl was reacted with 7-[N 3-(4-fluorophenyl)propionyl)amino-4,4-diphenylheptan-1-aI in the presence of sodium cyanoborohydride as described in example 1 to give the desired product as glassy residue: MS
showed (M+ H)+ @ 685;'H-NMR (CDCl3, 8): 1.0-1.2 (m, 4H), 1.65-1.75 (m, 1H), 1.95-2.05 (m, 2H), 2.06-2.15 ( (m, 1H), 2.15-2.25 (m, 1H), 2.32-2.36 (t, 2H), 2.36-2.45 (m, 2H), 2.62-2.70 (m, 1H), 2.85-2.95 (m, ~4H), 3.08-3.17 (q, 2H), 3.58 (s, 3H), 3.83 (s, 3H), 4.36 (s, 1H), 5.01 (broad t, 1H), 6.13 (s, 1H), 6.58 (s, 1H), 6.88-6.94 (m, 2H), 7.06-7.33 (m, 17H); IR
(CHC13) a 3300, 2950, 1645, 1 SOS cm''. The hydrochloride salt was prepared as in example 1 to give 7-[N 3-(4-fluorophE;nylpropionyl]amino-1-[N (1,2,3,4-tetrahydro-1-phenyl-6,7-dimethoxy-isoquinolinyl)]-4,4-diphenylheptane hydrochloride: mp 117-120 °C; Anal.
Calcd for C45H49N2~3F~HCI~f.SH2O: C, 74w0; H, 7.30; N, 3.83; Found: C, 73.14; H, 6.74;
N, 3.71.
Example 8 7-(N 3-(4-Fluorophenyl)nropionyl]amino-1-fN (1.2,3,4-tetrahvdro-1-c~clopentyl-6.7-dimethox~quinolinyl)]-4.4-diphenvlheptane hydrochloride 1,2,3,4-Tetrahydro-1-cyclopent;yl-6,7-dimethoxyisoquinoline was prepared by a procedure analogous to that described in example 4 for 1,2,3,4-tetrahydro-1-cyclopropyl-6,7-dimethoxyisoquinoline but substituting in the first step cyclopentylcarbonyl chloride for cyclopropylcarbonyl chloride.
The 1,2,3,4-tetrahydro-1-cyclopentyl-6,7-dimethoxyisoquinoline was reacted with 7-[N 3-(4-fluorophenyl)propionyl]amino-4,4-diphenylheptan-1-al in the presence of sodium cyanoborohydride as described in example 1 to give the desired product as a solid foam: MS
showed (M+ H)+ @ 677; 'H-NMR (CDC13, b): 1.05-1.72 (m, 12H), 1.75-2.17 (m, 6H,), 2.28-256 (broad m, SH), 2.65.-2.85 (m, 2H), 2.85-2.96 (t, 2H), 3.10-3.35 (m, 3H), 3.78-3.88 (two s, 6H), 6.42 (s, 1H), 6.52 (s,, 1H), 6.88-6.98 (m, 2H), 7.05-7.30 (m, 12H); IR (KBr) a 3450, 2950, 1650, 1510 cm ~. The hydrochloride salt was prepared as in example 1 to give 7-[N 3-(4-fluoro-phenyl)propionyl]-1-[N (1,2,3,4-tetrahydro-1-cyclopentyl-6,7-dimethoxyisoquinolinyl)}-4,4-diphenylheptane hydrochloride: mp 92 °C (dec.); Anal. Calcd for C44Hs3N2~3F'HC1~0.5H20: C, 73.15; H, 7.67; N, 3.87; Found: C, '13.45; H, 7.78; N, 3.87.
Example 9 7-fN 3-(4-F'luoronhenvl)propionvllamino-1-jN (1,2.3.4-tetrahvdro-1-cvclobutvl-6 7 dimethoxvisoq-uinolinvl)j-4,4-diphenylheptane hydrochloride 1,2,3,4-Tetrahydro-1-cyclobutyl-6,7-dimethoxyisoquinoline was prepared by a procedure analogous to that described in example 4 for 1,2,3,4-tetrahydro-1-cyclopropyl-6,7-dimethoxy-isoquinoline but substituting in the first step cyclobutylcarbonyl chloride for cyclopropyl-carbonyl chloride.
The 1,2,3,4-tetrahydro-1-cyclobutyl-6,7-dimethoxyisoquinoline was reacted with 7-[N 3-(4-fluorophenyl)propionyl]amino-4,4-diphenylheptan-1-al in the presence of sodium cyanoborohydride as described in example 1 to give the desired product as a solid foam: MS
showed (M+ H)+ @ 663; ~H-NMR I;CDCl3, b): 1.05-1.28 (m, 4H), 1.62-2.18 (m, lOH), 2.30-2.62 (m, 6H), 2.65-2.82 (m, 2H), 2.83-2.'95 (t, 2H), 3.02-3.25 (rn, 4H), 3.80-3,88 (two s, 6H), 6.45 (s, 1H), 6.53 (s, 1H), 6..88-6.98 (m, 2H), 7.08-7.32 (m, 12H); IR (KBr) a 3415, 2937, 1646, 1510 cm''. The hydrochloride salt was prepared as in example 1 to give 7-[N 3-(4-fluorophenyl-propionyl]-1-[N (1,2,3,4-tetrahydro-1-cyclobutyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenyl-heptane hydrochloride: mp 112-12a °C (dec.); Anal. Calcd for C43HsiN203F~HC1~2Hz0: C, 72.88; H, 6.99; N, 3.46; Found: C, ',72.56; H, 7.38; N, 3.83.
Example 10 7-j~4-F'luorophenyl)prypionlrl]amino-1-[.N~ 1,2,3,4-tetrahydro-1-cyclohe~l-6-7-.7-~dimethoxyisoc~uinolinlrl)]-4,4-diphen~Qtane hydrochloride 1,2,3,4-Tetrahydro-1-hexyl-6,7-dimethoxyisoquinoline was prepared by a procedure analogous to that described in example 4 for 1,2,3,4-tetrahydro-1-cyclopropyl-6,7 dimethoxyisoquinoline but substituting in the first step 2-methoxyacetyl chloride for cyclopropylcarbonyl chloride.

The 1,2,3,4-tetrahydro-1-cyclohexyl-6,7-dimethoxyisoquinoline was reacted with 7-[N 3-(4-fluorophe~nyl)propionyl]amino-4,4-diphenylheptan-I-al in the presence of sodium cyanoborohydride a.s described in example 1 to give the desired product as a solid foam: MS
showed (M+ H)+ @ 691;'H-NMR (CDC13, 8): 0.8-1.3 (m, 8H), 1.3-1.8 (m, 7H), 1.85-2.2 (m, SH), 2.3-2.45 (m, SH), 2.5-2.75 (m, 2H), 2.84-3.0 (m, 3H), 3.03-3.2 (q, 2H), 3.83 (two s, 6H), 5.06 (broad s, 1H), 6.39 (s, 1H), 6.53 (s, 1H), 6.87-6.98 (m, 2H), 7.08-7.32 (m, 12H); IR (KBr) a 3415, 2937, 1646, 1510 crri'. The hydrochloride salt was prepared as in example 1 to give 7-[N 3-(4-fluorophe;nyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-cyclohexyl-6,7-dimethoxy-isoquinolinyl)]-4,4-diphenylheptane hydrochloride: mp 104 °C; Anal.
Calcd for lO C45HSSN2~3F~HCl: C, 74.30; H, 7.75; N, 3.85; Found: C, 73.86; H, 7.83; N, 3.63.
Example 11 7-[N 3-(4-Fluorophen~)proaionvl]amino-I-IN (1,2,3,4-tetrahydro-I-cyanomethyl 6-7~~dimethoxyiso4uinolin~]-4,4-diphenylheptane hydrochloride 1,2,3,4-Tetrahydro-I-cyanomethylene-6,7-dimethoxyisoquinoline was reacted with 7-[N 3-(4-fluorophenyl)propionyi]amino-4,4-diphenylheptan-1-al in the presence of sodium cyanoborohydride as described in example 1 to give the desired pxoduct as a clear film: MS
showed (M+ H)+ C), 648;'H-NMR (CDC13, b): 1.08-1.3 (m, 4H), 2.02-2.12 (m, 2H), 2.12-2.25 (m, 2H), 2.32-2.40 (t, 2H), 2.45-2.80 (m, 7H), 2.85-3.0 (m, 3H), 3.06-3.2 (m, 2H), 3.75-3.85 (m, 7H), 5.38 (broad m, 1H), 6.75 (d, 2H), 6.88-6.95 (m, 2H), 7.10-7.30 (m, 12H);
IR (CHC13) a 3400, 2939, 2240, '1650, 1510 cni'. The hydrochloride salt was prepared as in example I to give 7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-cyanomethyl-6,7-di-rnethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride: mp 106-114 °C; Anal. Calcd for Ca~I-ia6N303F'HCI: C, 71.97; H, 6.92; N, 6.14; Found: C, 71.82; H,~6.86; N, 5.95.
Example 12 7-jN 3-(4-FluoroQheny_llpropionYllamino-1-fN (1.2,3,4-tetrahydro-1-methoxymethyl 6 7-dimethoxyisoquinolinvl)1-4,4-diphenylheptane hydrochloride 1,2,3,4-Tetrahydro-1-methoxymethyl-6,7-dimethoxyisoquinoline was prepared by a procedure analogous to that described in example 4 for 1,2,3,4-tetrahydro-I-cyclopropyl-6,7-dimethoxy-isoquinoline but substituting in the first step 2-methoxyacetyl chloride for cyclopropylcarbonyl chloride.
The 1,2,3,4-te~trahydro-1-mett~oxymethyl-6,7-dimethoxyisoquinoline was reacted with 7-[N 3-(4-fluorophenyl)propionyl]amino-4,4-diphenylheptan-1-al in the presence of sodium 5~ cyanoborohydride as described in example 1 to give the desired product as a clear film: MS
showed (M+ H)+ (~ 653; 'H-NMR (CDCI3, 8): 1.I-1.3 (m, 2H), 1.4-1.7 (broad m, 3H), 2.0-2.22 {m, 4H), 2.45-2.57 (t, 2H), 2.75-3..0 (m, SH), 3.15-3.28 (m, 4H), 3.37 (broad s, 3H), 3.5-3.65 {m, 2H), 3.65-3.8 (broad m, 1 H), 3.8-3.88 (two s, 6H), 3.98-4.10 (broad m, 1 H), 6.45 (s, 1 H), 6.59 (s, 1H), 6.88-6.97 (t, :2H), 7.10-7.30 (m, 12H); IR (KBr) a 3331, 2937, 2240, 1646, 1510 cm'. The hydrochloride salt was prepared as in example 1 to give 7-[N 3-(4-fluorophenyl)propionyl]-amino-1-[N ( 1,2,3.,4-tetrahydro-1-:methoxymethyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenyl-heptane hydrochloride: mp 102-110 °C (dec.); Anal. Calcd for C4~H5°N204F'2HCl: C, 67.75; H, 7.21; N, 3.85; Found: C, 67.39; H, 6.78; N, 4.22.
1 S Example 13 7-fN 3-l4-Fluorophenyl)nropionvllamino-1-fN (1 2 3 4-tetrahydro-1-benzvloxvmethvl 6 7-dimethoxyisoauinolinvl)1-4 4-diphenvlhentane hydrochloride 1,2,3,4-Tetrahydro-1-benzylox:ymethyl-6,7-dimethoxyisoquinoline hydroiodide was prepared by a procedure analogous to that dc;scribed in step 4 of example 4 but substituting 1,2,3,4-tetra-hydro-1-benzyloxymethyl-6,7-dimethoxyisoquinoline for 1,2,3,4-tetrahydro-1-cyclopropyl-6,7-dimethoxyisoquinoline.
The 1,2,3,4-tetrahydro-1-benzyloxymethyl-6,7-dimethoxyisoquinoline hydroiodide was reacted with 7-[N 3-(4-fluorophenyl)propionyl]amino-4,4-diphenylheptyl mesylate as described in step 5 of example 4 to give the desired product as a clear film: MS showed (M+ H)+ @ 730;
'H-NMR (CDCl3, Fi): 1.05-1.33 (m., 4H), I.98-2.20 (m, 4H), 2.3-2.38 (t, 2H), 2.38-2.8 (m, SH), 3.0-3.2 (m, 3H), 3.48-3.60 (m, 1H)., 3.72 (m, 2H), 3.75 (s, 3H), 3.$3 (s, 3H), 4.43-4.55 (q, 2H), 5.28 (broad s, 1 H), 6.53 (s, 1 H), 6.~8 (s, 1 H), 6.85-6.95 {m, 2H), 7.05-7.34 (m, 17H). The hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluorophenyl-propionyl)]-amino-I-[N (1,2,3,4-tetrahydro-1-benzyloxymethyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenyl-heptane hydrochloride: mp 1 I 8- t 3:3 °C (dec.); IR (MIC) a 3330, 2950, 1650, 1 S 10 cm'; Anal.
Calcd for C47H53N2~4F~ HCI. 1.25 H20: C, 71.64; H, 7.22; N, 3.55; Found: C, 71.85; H, 7.09; N, 3.69.

Example 14 7-IN 3-(4-Fluorophenyllpropionyl]amino-1-[N (1.2,3,4-tetrahydro-1-~4-methoxyphen~l) 6.7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride 1,2,3,4-Tetrahydro-1-(4-methox;yphenyl)-6,7-dimethoxyisoquinoline was prepared by a procedure analogous to that described in example 7 for 1,2,3,4-tetrahydro-I-phenyl-6,7-di-methoxyisoquinoline, but substituting in the first step 4-methoxybenzoic acid for benzoic acid.
The 1,2,3,4-tetrahydro-1-(4-methoxyphenyl)-6,7-dimethoxyisoquinoline was reacted with 7-[N 3-(4-fluorophe:nyl)propionyl]amino-4,4-diphenylheptanal in the presence of sodium cyanoborohydride as described in example 1 to give the desired product as a clear film: MS
showed (M+ H)+ @ 715;'H-NMR (CDC13, 8): 1.0-1.2 (m, 3H), 1.65-1.78 (m, 2H), 1.93-2.26 (m, 4H), 2.3-2,48 (m, 4H), 2.6-2.75 (m, 1H), 2.82-2.97 (m, 4H), 3.06-3.18 (q, 2H), 3.6 (s, 3H), 3.83 (s, 3H), 4.33 (broad s, 1 H), 5.07 (broad m, 1 H), 6.12 (s, 1 H), 6.57 (s, 1 H), 6.78-6.98 (m, 4H), 7.05-7.32 (m, I4H); IR (film) a 3300, 2950, 1650, 1510 cm''. The hydrochloride salt was prepared as in example 4 to give ?-[.N 3-(4-fluorophenyl)propionyl]amino-1-[N
(1,2,3,4-tetra-hydro-1-(4-methoxyphenyl)-6,7-dirr~ethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride:
mp 114-120 °C; Anal. Calcd for Cq6H5IN2~4F~ HCI. 0.5 H20: C, 72.66; H, 7.20; N, 3.68; Found:
C, 72.33; H, 6.82; N, 3.50.
Example 15 7-[N 3-(4-Fluor~henyl)nropion~]amino-1-[N (1,2.3,4-tetrahydro-I-L4-aminophen~)-6,7-dimethoxyisoquinolinyl)]-4.4-diphenylheptane dihydrochloride 1,2,3,4-Tetrahydro-1-(4-nitrophenyl)-6,7-dimethoxyisoquinoline was prepared by a procedure analogous to that described in example 7 for 1,2,3,4-tetrahydro-1-phenyl-6,7-di-methoxyisoquinoline, but substituting in the first step 4-nitrobenzoic acid for benzoic acid.
The 1,2,3,4-tetrahydro-1-(4-nitrophenyl)-6,7-dimethoxyisoquinoline was reacted with 7-[N 3-(4-fluorophenyl)propionyl]amino-4,4-diphenylheptanal in the presence of sodium cyanoborohydride as described in example 1 to give 7-[N 3-(4-fluoropheny)lpropionyl]-I-[N (1,2,3,4-tetrahydro-I-(4-nitrophe.nyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane as a solid: MS showed (M+ H)+ @ 730;'H-NMR (CDCl3, 8): 0.97-1.2 (m, 4H), 1.6-1.77 (m, 1H), 1.93-2.12 (m, 2H), 2.18-2.48 (m, 6I-1), 2.6-2.75 {m, 1H), 2.8-3.0 (m, 4H), 3.03-3.16 (q, 2H), 3.59 (s, 3H), 3.85 (s, 3H ), 4.48 (s, 1 H), 5.0-5.08 (m, 1 H), 6.04 (s, 1 H), 6.6 (s, 1 H), 6.87-6.96 (m, 2H), 7.03-7.3 (m, 12H), '7.33-7.38 (d, 2I-i). 'This compound was dissolved in methanol and hydrogenated in the: presence of 10'% Pd/C under 4 atm pressure of hydrogen gas for 21 hr. The crude product was purified by preparative HPLC to give 7-[N 3-(4-fluorophenyl)propionyl]-amino-1-[N (1,2,3,4-tetrahydro-1-(~4-aminophenyl)-6,7-dimethoxyisoquinolinyl)]-4,4-di-phenylheptane was obtained as a yellow solid: MS showed (M+ H)+ @ 700. tH-NMR
(CDCl3, 8): 0.96-1.18 (m, 4H), I.63-I.8 (m, 1H), 1.93-2.26 (m, 4H), 2.26-2.50 (m, 4H), 2.6-2.74 (m, 1H), 2.82-2.95 (m, 4H), :3.03-3.18 (m, 2H), 3.62 (s, 3H), 3.83 (s, 3H), 4.26 (broad s, 1H), 5.05-5.15 (m, 1H), 6.18 (s, 1H), 6.55 (s, 1H), 6.56-6.64 (d, 2H), 6.87-7.0 (m, 4H), 7.06-7.30 (m, 12H). The dihydrochloride sale: was prepared as in example 4 to give 7-[N 3-(4-fluorophenyl-propionyl)]-amino-1-[N (1,2,3,4-tetrahydro-1-(4-amino)phenyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenyl-heptane hydrochloride: mp 168-175 °C; IR (ICBr) a 3269, 2934, 2578, 1635, 1612, 1510 cm's.
Example 16 7-fN 3-(4-Fluoroohenvl)propionv~llamino-1-fN (1.2,3.4-tetrahydro-I-f4-(N
isoprowlamino)-phen~rl-6,7-dimethoxvisoauinolin~)]-4.4-diphenylheutane dihydrochloride To a solution of 7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-(4-aminophenyl)-6,7-dimethoxyis;oquinolinyl)]-4,4-diphenylheptane (0.168 g) in methanol (10 mL) was added acetone (0.2 rnI,) followed by sodium cyanoborohydride (0.031 g) and three drops of acetic acid. The mixture was stirred under nitrogen overnight and then concentrated in vacuo. The residue was taken in ethyl acetate and washed with sodium bicarbonate and brine solutions. The organic phase was dried (Na2S04) and concentrated in vacuo. The crude product was purified by preparative HPLC to give 7-[N 3-(4-fluorophenyl)propionyI]amino-1-[N (1,2,3,4-tetrahydro-1-[4-(N isopropylamino)phenyl-6,7-dimethoxyisoquinolinyl]-4,4-diphenylheptane: MS showed (M+ H)+ @ 742; 'H-NMR (CDC13, 8): 0.98-1.16 (broad m, 4H), 1.16-1.24 (d, 6H), 1.26 (m, 1 H), 1.65-1.83 (broad m, 1 H), 1.93-2.26 (m, 5H), 2.26-2.50 (m, 4H), 2.6-2.75 (m, 1H), 2.8-2.97 (m, 4H), 3.04-3.18 (m, 2H), 3.61 (s, 3H), 3.83 (s, 3H), 4.28 (broad s, IH), 5.0-5.10 (broad m 1H), 6.19 (s, 1H), 6.44-6.53 (d, 2H), 6.56 (s, 1H), 6.85-6.97 (t, 4H), 7.03-7.30 (m, 12H). The dihydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluoro-phenyl-propionyl]amino-1-[N (1,2,:3,4-tetrahydro-1-[4-(N isopropylamino)phenyl-6,7-di-methoxyisoquinolinyl]-4,4-diphenylheptane dihydrochloride: mp 153-161 °C; IR (ICBr) a 3275, 2934, 2588, 2459, 1653, 1510 cm'c.

Example I7 7- N 3- 4-Fluorophenyl propionyl]amino-I-fN (1 2 3 4-tetrahydro-1-benzyl 6-7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride S
1,2,3,4-Tetrahydro-1-benzyl-6,'7-dimethoxyisoquinoline was prepared by a procedure analogous to that described in example 7 for 1,2,3,4-tetrahydro-I-phenyl-6,7-dimethoxy-isoquinoline but substituting in the first step phenylacetyl chloride for benzoyl chloride.
The 1,2,3,4-tetrahydro-I-benzy(-6,7-dimethoxyisoquinoline was reacted with 7-[N 3-(4-fluorophenyl)propionyl]~unino-4,4-diphenylheptanal in the presence of sodium cyanoborohydride as described in example 1 to give 7-[N 3-(4-fluorophenyl)propionyl]amino -1-[N (1,2,3,4-tetrahydro-1-benzyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane as a film:
MS showed (M+ H}+ @ 699; 'H-NIMR (CDC13, 8): 1.0-1.22 (m, 4H), 1.62-1.92 (broad m, 1H), 1.92-2.15 (m, 4H), :2.3-2.4 (t, 2H), :?.4-2.84 (m, SH), 2.84-2.95 (t, 2H), 3.0-3.2 (m, 4H), 3.5 (s, I 5 3 H), 3.6-3.7 (broad t, 1 H), 3.82 {s, :3H), 5.08 (broad s, 1 H), 5.83 (s, 1 H), 6.53 (s, 1 H), 6.87-7.03 (m, 4H), 7.08-7.33 (m, 15H). The hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-benzyl-6,7-dimethoxy-isoquinolinyl)]-4,4-diphenylheptane hydrochloride: mp 94-98 °C; Anal.
Calcd for C46Hs,N243F'HCl'0.75 H20: C, 73.157; H, 7.32; N, 3.73; Found: C, 73.71; H, 6.96; N, 3.57.
Example 1$
7-[N 3-(4-Fluoronhenyl)propi~nyllamino-I-fN (1.2,3,4-tetrahydro-I-(4-chlorobenz 6-7-.7-~dimethoxyisoguinolinvl)1-4,4-diphenvlheptane hydrochloride 1,2,3,4-Tetrahydro-1-(4-chloro)benzyl-6,7-dimethoxyisoquinoline was prepared by a procedure analogous to that described in example 17 for 1,2,3,4-tetrahydro-1-benzyl-6,7-dimethoxyisoquinoline, but substituting in the first step (4-chlorophenyl)acetyl chloride for phenylacetyl chloride.
The 1,2,3,4-tetrahydro-1-(4-chlorobenzyl)-6,7-dimethoxyisoquinoline was reacted with 7-[N 3-(4-fluorophe;nyl)propionyl]amino-4,4-diphenylheptan-1-al in the presence of sodium cyanoborohydride as described in example 1 to give 7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-I-(4-chlorobenzyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane as a film: MS showed (M+ H)+ (a7 '733; 'H-NMR (CDCl3, 8): 1.02-1.28 (broad m, 3H), 1.52-1.74 (broad m, SH}, 1.89-2.12 (broad m, 3H), 2.3-2.85 (broad m, 7H), 2.85-2.95 (t, 2H), 3.04-3.22 (m, 2H), 3.72-3.88 (m, 1H), 3.76 (s, 3H), 3.93 (s, 3H), 5.95 (broad s, 1H), 6.54 (s, 1H), 6.87-7.0 (m, 4H), i'.OS-7.32 (m, 14H). The hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluorophenyl)propionyI]amino-1-[N (1,2,3,4-tetrahydro-1-(4-chlorobenzyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride: mp 88-96 °C.
Exaraple 19 7-fN 3-(4-Fluorophenyl)propionyl]amino-1-fN (1,2.3.4-tetrahydro-1-(4-methoxvbenzvl)-6 7-dimethoxvisoquinolinvl)14.4-diphenylheptane hydrochloride 1,2,3,4-Tetrahydro-1-(4-metho:xybenzyl)-6,7-dimethoxyisoquinoline was prepared by a procedure analogous to that described in example 17 for 1,2,3,4-tetrahydro-1-benzyl-6,7-di-methoxyisoquinoline but substituting in the first step (4-methoxyphenyl)acetyl chloride for phenylacetyl chloride.
The 1,2,3,4-tet~~ahydro-1-(4-methoxybenzyl)-6,7-dimethoxyisoquinoline was reacted with 7-[N 3-(4-fluorophenyl)propionyl]amino-4,4-diphenylheptanal in the presence of sodium cyanoborohydride as described in example 1 to give 7-[N 3-(4-fluorophenyl)propionyl]amino-1-N [1,2,3,4-tetrahydro-1-(4-methoxybenzyl)]-6,7-dirnethoxyisoquinolinyl]-4,4-diphenylheptane as a film: MS showed (M+ H}+ @ 729; 1H-NMR (CDCl3, b): 1.0-1.22 (m, 4H), 1.91-2.10 (m, 4H), 2.3-2.4 (m, 2H), 2.4-2.85 (rn, 6H), 2.85-2.94 (t, 2H), 2.94-3.2 (m, 4H), 3.51-3.67 (m, 1H), 3.55 (s, 3H), 3.76 (s, 3H), 3.82 (s, :3H), 1H, (broad s, 5.13), 5.92 (s, 1H), 6.52 (s, 1H), 6.75-6.97 (m, 6H), 7.07-7.30 (m, 12H);1R (lIrIIC) a 3300, 2950, 1650, 1510 cm'. The hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluorophenyl)propionyl]-1-[N
(1,2,3,4-tetra-hydro-1-(4-methoxybenzyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride:
mp 100-108 °C.
Example 20 7-[N 3-(4-Fluorophen~r~propiony,~]iamino-1-[N (1.2.3,4-tetrah~dro-1-phenethyl-6,7-dimethoxy -isoquinolin~)1-4,4-diphenylheptane h~rdrochloride 1,2,3,4-Tetrahydro-1-phenethyl-6,7-dimethoxy-isoquinoline was prepared by a procedure analogous to that described in exarnple 17 for 1,2,3,4-tetrahydro-1-phenethyl-6,7-dimethoxy-isoquinoline.

WO 00!29380 PCT/US99/26584 The 1,2,3,4-tetrahydro-1-phenethyl-6,7-dimethoxyisoquinoline was reacted with ?-[N 3-(4-fluorophenyl)propionyl]amino-4,4-diphenylheptanal in the presence of sodium cyanoboro-hydride as described in example 1 to give 7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-phenethyl-6,7-dimethoxyisoquinolinyl}]-4,4-diphenylheptane as a film:
MS showed (M+ Fl)+ @ 713; ~H-lsfMR (CDC13, 8): 1.06-1.3 (broad m, 4H), 1.8-2.25 (m, 4H), 2.25-2.53 (m, 4H), 2.53-2.78 (m, 4H), 2.83-2.93 (t, 2H), 2.98-3.19 (m, 3H), 3.34-3.43 (broad m, 1 H), 3.64-3.72 (t, 1. H), 3.79 (s, 3 H;), 3.84 (s, 3H), 3.87 (s, 1 H), 3.94 (s, 1 H), 4.99 (broad s, 1 H), 6.43 (s, 1H), 6.53 (s, 1H), 7.87-7.98 (q, 2H), 7.04-7.35 (m, 17H). The hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluorophenyl)propionyl]amino-I-[N
{1,2,3,4-tetrahydro-I-phene;thyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride: mp 97-102 °C.
Example 21 7-fN 3-(4-Fluorophenyl)propionyl]amino-1-[(N [1,2.3,4-tetrah dY ro-1-i(4-aminobenzvl)-6 7-dimethoxyisoquinolinyl),l-4,4-diphen~lheptane dihydrochIoride 1,2,3,4-Tetrahydro-1-(4-nitrobenzyl)-6,7-dimethoxyisoquinoline was prepared by a procedure analogous to that described in example I7 for 1,2,3,4-tetrahydro-I-benzyl-6,7-dimethoxyisoquinoline but substituting in the first step (4-nitrophenyl)acetyl chloride for phenacetyl chloride.
1,2,3,4-Tetrahydro-1-(4-nitrobenzyl)-6,7-dimethoxyisoquinoline was reacted with 7-[N 3-(4-fluorophenyl)propionyl]amino-4,4-diphenylheptanal in the presence of sodium cyanoborohydride as described in example 1 to give 7-[N 3-(4-fluorophenyl)propionyl]-1-[N (1,2,3,4-tetrahydro-1-(4-nitrobe;nzyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane as a film: MS showed (M+ H)+ @ 744.
A solution of 7-[N (4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-(p-nitro)-benzyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane in methanol was hydrogenated in the presence of 10% Pd/C under 4 atm hydrogen gas pressure. The product was purified by preparative HPLC to give 7-[N 3-(4-fluorophenyl)propionyl]-1-[N (1,2,3,4-tetrahydro-I-(4-aminobenzyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane as a film:
MS showed (M+ I-I}+ @ 714. 7:'he hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluoro-phenyl)propionyl]-I-[N (I,2,3,4-tetrahydro-1-(4-aminobenzyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride: mp 138-I49 °C.

Example 22 7-fN 3-(4-Fluoronhenyl)nroDionyllarnino-11N (1 2 3 4 tetrahydro 1 aminometh,~
6 T-dimethoxyisoguinolinyl)1-4 4-diphenylheptane dihydrochloride Sten 1: 1,2,3,4-Tetrah~rdro-1-N (t~hthalimidomethyl)-6 7-dimethoxvisoguinoline To a mixture of 3,4-dimethoxyphenethylamine (Sg) and phthalimidoglycine (5.5 g) in methylene chloride (500 mL) and DMF (30 mL) was added HOBt (4.8 g) followed by triethylamine (11 mL) and EDCI (6.82 g). The reaction mixture was stirred at rt under nitrogen overnight and then concentrated in vacuo. Ethyl acetate was added to the residue and the mixture was washed with sodium lbicarbonate solution. The precipitate was filtered and dried to give (N 2-(3,4-dirnethoxyphenyl)ethyl]-N (phthalimido)acetyl amide (8.8 g): MS
showed (M+ H)+ @ 369.
Sten 2: 3,4-dihvdro-1-N (phthalimidomethvl)-6 7-dimethoxyiso4uinoline To a stirred suspension of [N 2-(3,4-dimethoxyphenyl)ethyl)-N
(phthalimido)acetyl amide (7.35 g) in toluene was added POC'.13 (29.6 g). The mixture was heated under reflux overnight, then cooled to 0 °C and basified with 4N NaOH to pH 10. The organic phase was separated.
The aqueous phase was extracted three times with ethyl acetate. The toluene and ethyl acetacte extracts were combined, washed with brine, dried (NazS04) and concentrated in vacuo. The solid residue was purified by a siIic:a gel column eluting with (98:2) methylene chloride/methanol 1:o give as a yellow foam 3,4-dihydro-1-N
(phthalimidomethyl)-6,7-di-methoxyisoquinoline (5.176 g): MS showed (M+ H)+ @ 351;'H-NMR (CDC13, b): 2.58-2.68 (t, 2H), 3.57-3.67 (t, 2H), 3.92 (two s, 6H), 4.92 (s, 2H), 6.7 (s, 1H), 7.07 (s, 1H), 7.68-7.76 (q, 2H), 7.83-7.92 (q, 2H).
Sten 3: 1,2.3.4-tetrahydro-1-N (phthalimidomethyl)-6 7-dimethoxvisoquinoline To a solution of 3,4-dihydro-1-i'V (phthalimidomethyl)-6,7-dimethoxyisoquinoline (4.8 g) in methanol {250 mL) was added sodium cyanoborohydride (1.033 g). The pH of the solution was adjusted to 5, by the addition of a few drops of acetic acid. The mixture was stirred under nitrogen at rt for 2 hr and then concentrated in vacuo. The residue was taken in ethyl acetate, washed with sodium bicarbonate anal brine solutions, dried and again concentrated in vacuo. The residue was purifcec! by a silica gel column eluting with (95:5) methylene chloride/methanol to give 1,2,3,4-tetrahydro-I-N (phthalimidomethyl)-6,7-dimethoxyisoquinoline (2.26 g): MS
showed (M+ H)+ @ 353;'H-NMR (CDCI3, 8): 1.92 (broad s, 1H), 2.64-2.75 (m, 2H), 2.92-3.OI
(m, 1 H), 3.25-3 .3 8 I;m, 1 H), 3.81-3.92 (m, 1 H), 3.85 (s, 3H), 3.89 (m, 3H), 4.02-4.12 (m, 1 H), 4.24-4.32 (two d, 11-I), 6.6 (s, 1H), ti.76 (s, 1H), 7.62-7.76 (q, 2H), 7.82-7.9 (q, 2H).
Step 4: 7-[~4-fluoronhenvl)propionyllamino-I-fN (1.2,3,4-tetrahydro-1-N
(phthalimido-methyl)-6.7-dimethoxyisoguinolinv~l)1-4,4-diphenylheptane hydrochloride 1,2,3,4-Tetrahydro-1-N (phthalimidomethyl)-6,7-dimethoxyisoquinoline was reductively alkylated with 7-[N-3-(4-fluorophenyl)propionyl]amino-4,4-diphenylheptan-1-al in the presence of sodium cyanoborohydride using the procedure described in example 1. After workup and chromatographic purification 7-[lV :3-(4-fluorophenyl)propionyl]amino-1-[N
(1,2,3,4-tetrahydro-I-N (phthalimidomethyl)-6,7-dimethaxyisoquinolinyl)]-4,4-diphenylheptane was obtained: MS
showed (M+ H)+ @ 768; ~H-NMR (CDCl3, b): 0.7i-1.13 (m, 3H), 1.56-2.04 (m, SH), 2.1-2.55 (m, SH), 2.61-2.85 (m, 2H), 2.85-2.98 (t, 2H), 2.98-3.42 (m, 3H), 3.62-3.75 (dd, 1H), 3.85-3.95 (dd, 1H), 3,82 (s, 3H), 3.86 (s, 3I-i), 3.95-4.12 (q, 1H), 5.73-5.82 (broad m, 1H), 6.57 (s, 1H), 6.63 (s, 1 H), 6.78-6.98 (m, 6H), 7.04-7.13 (m, 8H). The hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluorophenyl)propionyl]-1-[N (1,2,3,4-tetrahydro-1-N (phthalimido-methyl)-6,7-dimeihoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride: mp 114-121 °C (dec);
IR (MIC) v 3250, 2943, 1771, 1712., 1671, 1510 cm's; Anal. Calcd for C48H5°N305F'HCI: C, 71.67; H, 6.41; N, 5.22; Found: C,, '71.42; H, 6.21; N, 5.3 8.
Step 5: 7-[N 3-(4-fluorophenyl)propionyllamino-1-[N (1,2,3,4-tetxahvdro-1-aminomethvl-6,7-dimethoxvisoqt~inolinyl)1-4,4-diphenYlheptane dihydrochloride To a stirred solution of 7-[N 3-(4-fluorophenyl)propionyl]-1-[N (1,2,3,4-tetrahydro-1-N (phthalimidomethyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane (0.33 g) in ethanol (3 mL) was added hydrazine hydrate (2.5 mL) and the mixture was heated under reflux for 90 min. The solvent arid excess of reagent were removed in vacuo and to the residue was added 2N
HCl (2.5 mL). The mixture was stirred at rt for 2 hr and then concentrated in vacuo. The residue was purified by preparative HPLC t:o give 7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-aminomethyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane (0.150 g) as a white foam: MS showed (M(+ H)* @ 768; ~H-NMR (CDCl3, b): 1.0-1.3 (m, 4H), 1.94-2.24 (m, 7H), 2.32-:2.79 (m, 6H), 2.79-2.97 (m, 4H)~ 2.97-3.28 (m, 3H), 3.35-3.43 (t, 1H), 3.8 (s, 3H), 3.84 (s, 3H), 5.68-5.78 (broad t, 1H), 6.49 (s, 1H), 6.54 (s, IH), 6.86-6.97 (t, 2H), 7.08-7.32 (m, I2H). The hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluorophenyl-propionyl)]amino-l-[N (1,2,3,4-tetrahydro-1-aminomethyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane di:hydrochloride: mp 110-116 °C; Anal. Calcd for C4°Ha8N303F'2HCl: C, 67.60;
H, 7.09; N, 5.91; Found: C, 65.20; H, 7.12; N, 5.53.
Example 23 7-jN 3-(4-Fluorophenyl)propionyl]-I- jN (1.2.3.4-tetrahydro-1-(N-isopro~ylaminomethvl)-6.7-dimethoxyisoquinolinvl)1-4,4-diphenylheptane dihvdrochloride To a solution of 7-[N 3-(4-fluorophenyl)propionyl]-1-[N (1,2,3,4-tetrahydro-1-aminomethyl-6,7-dimethoxyisoquinolinyl)]-4,4-cliphenylheptane (0.030 g) in methanol (2 mL) was added acetone (0.3 mL), sodium cyanoborohydride (0.004 g) and three drops of acetic acid. The mixture was stirred at rt under nitrogen for 2 hr and then concentrated in vacuo. The residue was dissolved in ethyl acetate, washed with sodium bicarbonate and brine solutions, dried (Na2S04) and again concentrated in vacuo. Z'he residue was purified by preparative HPLC
to give 7-[N 3-(4-fluorophenyl)propionyl]-~1-[N (1,2,3,4-tetrahydro-I-(N
isopropylaminomethylr6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane: MS showed (M+ H)+ @ 680; ~H-NMR
(CDC13, 8): I.0-1.32 (m, lOH), 1.97-2.32 (rn, 6H), 1.98-2.54 (m, 4H), 2.6-3.18 (m, 9H), 3.2-3.35 (m, 1H), 3.55-3.68 (m, 1 H), 3.77 (s, 3H), 3.83 (s, 3H), 6.49 (s, I H), 6.52 (s, 1 H), 6.86-6.97 (t, 2H), 7.08-7.32 (m, 12H); IR (CHC13) a 3280, 2946, 1647, 1510 cm ~. The hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluorophenyl)propionyl]-1-(N (1,2,3,4-tetrahydro-1-(N iso-propylaminomethyl)-6,7-dimethox;yisoquinolinyl)]-4,4-diphenylheptane dihydrochloride: mp 114-122 °C; Anal. Calcd for C43HS,aN3O3F~2HC1: C, 68.60; H, 7.50; N, 5.58; Found: C, 65.69; H, 7.30; N, 5.16.
Example 24 7-[N 3-(4-Fluorophenyl)propionyllamino-I-j(N (1.2,3,4-tetrahydro-1-(4-N
phthalimidobutyl)-6 7-dimethoxyisoquinolinyl)1-4,4-diphenylheptane hydrochloride The synthetic procedure described in example 22 for 1,2,3,4-tetrahydro-1-N
(phthalimido-methyl)-6,7-dimethoxyisoquinolimyl)]-4,4-diphenylheptane was used but substituting S-N phthalimidopentanoic acid for N-phthalimidoglycine. After a silica gel column chromatography the desired product 7-[N 3-(4-fluorophenyl)propionyl]-1-[(N
[1,2,3,4-tetra-hydro-1-(4-phthalimidobutyl)-6,7-dimethoxyisoquinoIinyl)]-4,4-diphenylheptane was obtained:
MS showed (M+ H)+ @ 810; ~H-NMR (CDCl3, ~): 1.05-1.23 (m, 4H), 1.32-1.49 (q, 2H), 1.50-1.76 (m, 4H), I.96-2.2 (m, 4H), 2.28-2.50 (m, SH), 2.52-2.76 (m, 2H), 2.84-2.94 (t, 2H), 2.94-3.07 (m, 1H), 3.0'7-3.23 (m, 2H), 3.23-3.33 (m, 1H), 3.6-3.7 (t, 2H), 3.80 (s, 3H), 3.83 (s, 3H), :i 5.30-5.43 (broad t, 1 H), 6.46 (s, 1 H), 6.50 (s, 1 H), 6.84-6.95 (m, 2H), 7.04-7.27 (m, 12H), 7.64-7.83 (m, 4H); IR (MIC) a 3280, 2939, 1770, 1712, 1670, 1653, 1510 cm'1. The hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluorophenyl)propionyl]-1-[N (1,2,3,4-tetra-hydro-1-(4-N phthalimidobutyl)-fi,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydro-chloride: mp 112-128 °C; Anal. C:alcd for CS,HS6N305F~HCI: C, 72.37; H, 6.79; N, 4.96; Found:
1 (1 C, 72. 81; H, 7.01; N, 4.67.
Example 25 7- N 3- 4-l~luorophenyl)nropionvll-1-fN (1,2,3,4-tetrahydro-1-(4-aminobutyl)-6 dimethoxvisoaui:nolinvl)]-4 4-diphen~ptane dihydrochloride The synthetic procedure described in example 22 for the cleavage of the phthalimido group was adopted. After workup and preparative HPLC purification the desired product, 7-[N (3-(4-fluorophenyl)propionyl]-1-[N (1,2,3,4-tetrahydro-1-(4-aminobutyl)-6,7-dimethoxy-isoquinolinyl)]-4,4-diphenylhepta~le was obtained: MS showed (M+ H)+ @ 680;'H-NMR
(CDCl3, 8): I .04-1.29 (m, 4H), 1.3~ 1-1.76 (m, 7H), 1.94-2.20 (m, 4H), 2.30-2.42 (t, 2H), 2.42-2.53 (q, 2H), 2.58-2.81 (m, 6H), 2.82-2.94 (t, 2H), 2.98-3.18 (m, 3H), 3.34-3.43 (m, 1H), 3.83 (s, 6H), 5.54-5.64 (m,, 1 H), 6.47 (s, 1 l~), 6.52 (s, 1 H}, 6.87-6.96 (m, 2H), 7.07-7.30 (m, 12H). The hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluorophenyl)propionyl-1-[N [1,2,3,4-tetrahydro-1-(4-aminobutyl) -6,7-dimethoxyisoquinolinyl)]-4,4-diphenyl heptane dihydrochloride: mp 112-118 °C; IR (KBr) a 3410, 2936, 2835, 1646, 1510 cm's; Anal. Calcd for C43Hs4N303F'2,HC1~1.SH20: C, 66.22; H, 7.62; N, 5.38; Found: C, 65.89; H, 7.46; N, 5.21.
Example 26 7-fN 3-(4-FIuoronhenyl)propionyl]-1-[N (1 Zy3 4-tetrahydro-1-(4(N
isopropylaminobutvl) 6=7.-7~-dimethoxyisoguinolinyl)]-4.4-dphenylheptane dihydrochloride To a solution of 7-[N 3-(4-fluorophenyl)propionyl]-1-[N (1,2,3,4-tetrahydro-1-(4-amino-butyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane (0.0586 g) in methanol (2 mL) was -SO-added acetone (0.3 mL), sodium cyanoborohydride (0.007 g) and one drop of acetic acid. The mixture was stirred at rt under nitrogen for 2 hr and then concentrated in vacuo. The residue was dissolved in ethyl acetate, washed with sodium bicarbonate and brine solutions, dried (Na2S04) and again concentrated in vacuo. The residue was purified by preparative HPLC
to give S 7-[N 3-(4-fluorophenyl)propionylJamino-1-[N (1,2,3,4-tetrahydro-1-(4-N
isopropyl-aminobutyl)-6,'1-dimethoxyisoduinolinyl)]-4,4-diphenylheptane: MS showed (M+
H)+ @ 722;
'H-NMR (CDC'.13, 8): I.OS (s, 3H), 1.07 (s, 3H), 1.07-1.22 (m, 4H), 1.3-1.76 (m, 6H), 1.95-2.22 (m, SH), 2.3-2.:>0 (m, SH), 2.52 -2.86 (m, SH), 2.86-2.95 (t, 2H), 2.95-3.08 (m, 1 H), 3.08-3.18 {q, 2H), 3.28-3.37 (m, 1 H), 3.83 (s, 6H), 5.32-5.42 (s, 1 H), 6.48 (s, 1 H), 6.52 (s, 1 H), 6.82-6.97 (m, 2H), 7.04-7.29 (m, 12H); IR {C'.HC13) a 3299, 2934, 2832, 1669, 1648, 1510 cm-'. The hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluorophenyl)propionyl]-amino-1-[N (1,2,3,4-tetrahydro-1-(4-N isopropylaminobuty)1-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylhe;ptane: mp 118-128 °C.
Example 27 7-1N 3~4-Fluorphenyl)propionyllamino-1-[N (1,2,3,4-tetrahydro-1-L-N (cyclopropvlmethvlamino)butyll-6,7-dimethoxyisoquinolinyl)1-4~,4-diphenylhentane dihydrochloride The procedure described in example 26 was used but substituting cyclopropane-carboxaldehyde in place of acetone. After purification using a silica gel column chromatography 7-[N 3-(4-fluorophenyl)propionyl]-1-[N (1,2,3,4-tetrahydro-1-[4-N
(cyclopropylmethylamino)-butyl-6,7-dimethoxyisoquinolinyl))-4,4-diphenylheptane was obtained: MS showed (M+ H)+ @
734; ~H-NMR (CDC13, b): 0.1-0.2 (m, 2H), 0.43-0.60 (m, 2H), 0.86-1.05 (m, 1H), 1.05-1.3 (m, 4H), 1.3-1.78 (m, 6H), 1.93-2.:?2 (m, 4H), 2.33-2.80 (m, IOH), 2.84-2.95 (t, 2H), 2.95-3.21 (m, 3H), 3.23-3.52 (m, 3H), 3.82-3.87 (two s, 6H), 5.7-5.80 (broad t, 1H), 3.48 (s, 2H), 3.51 (s, 1H), 6.87-6.98 (t, 21-i), 7.08-7.32 (m~, 12H). The hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluorophenyl)propionyl]-I-[N-(1,2,3,4-tetrahydro-1-[4-N
(cyclopropyl-methylamino)t>utyl]-6,7-dimet',hoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride: mp 112-120 °C; IR (KBr) v 3422, 2939, 2590, 1655, 1510 cm ~; Anal. Calcd for C4~H6oN303F~2HC1:
C, 69.96; H, 7.74; N, 5.21; Found: C, 68.41; H, 7.92; N, 5.18.

Example 28 7-i[N 3-(4-Fluorophenyllpropionvl]-1-[N (1.2,3,4-tetrahvdro-1-(4-N
(cyclobutylamino)butyl)-6,7-dimethoxvisoauinolin~rl)]-4.4-diphenylheptane dihydrochloride The procedure described in example 26 was used but substituting cyclobutanone for acetone.
After purification of the product using silica gel column chromatography 7-[N
3-(4-fluoro-phenylpropionyl))amino-1-[N-[1,2,3,4-tetrahydro-1-[4-N (cyclobutylamino)butyl]-6,7-dimethoxyisoquinolinyl)-4,4-diphenylheptane was obtained: MS showed (M+
H)+ @ 734;
'H-NMR (CDCI3, 8): 1.05-1.54 (m, 6H), 1.54-1.96 (m, 7H), 1.96-2.31 (m, 8H), 2.32-2.83 (m, lOH), 2.85-2.97 (t, 2:H), 3.03-3.25 (3.3-3.51 (m, 1H), 3.58-3.68 (m, 1H), 3.83 (s, 3H), 3.86 (s, 3H), 4.35 (broad m, 1 H), 6.0 (t, 1 l~i), 6.5 I (s, 1 H), 6.54 (s, 1 H), 7.07-7.32 (m, 12H); IR (KBr) a 3421, 2942, 2742, 1641, 1510 cm"'. The hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluorophe:nyl)propionyl]-I-[N (1,2,3,4-tetrahydro-1-[4-(N
cyclobutylamino)butyl-6,7-dimethoxyisoquinolinyl))-4,4- diphenylheptane: mp 121-I28 °C; Anal.
Calcd for C47H6°N303F~2HCl: C, 69.96; H, 7.',74; N, 5.21; Found: C, 68.76; H, 7.97; N, 5.11.
Example 29 7-fN 3-(4-FluorophenYl)propionyl)-1-LN (1,2,3,4-tetrahydro-1-f4-(N
isobutylamino)butyll-6,7-dimethoxyisogui:nolin~)]-4,4-diphenylheptane dih~rdrochloride The procedure described in example 26 was used but substituting isobutyraldehyde for acetone. After workup and purification by a silica gel column chromatography 7-[N 3-(4-fluoro-phenyl)propionyl]-1-[N (1,2,3,4-tetrahydro-1-[4-(N-isobutylamino)butyl-6,7-dimethoxy-isoquinolinyl)j-4,4-diphenylheptane: MS showed (M+ H)+ @ 736;'H-NMR (CDC13, 8): 0.82-1.0 (m, IH), 1.0-1.1 (dd, 6H), 1.1-1.53 (m, 4H), 1.73-1.9 (m, 4H), 1.9-2.38 (m, 8H), 2.45-2.62 (m, 2H), 2.62-2.87 Im, 4H), 2.87-3.55 (m, lOH), 3.84 (s, 3H), 3.86 (s, 3H), 4.1 (broad s, 1H), 6.51 (s, 1H), 6.55 (s., 1H), 6.84-6.98 (m, 2H), 7.03-7.29 (m, 12H); IR (KBr) a 3421, 2950, 1650, 1510 cm's. The hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluoro-phenyl)propionyl]-l.-[N 1,2,3,4-tetrahydro-1-[4-(N isobutylamino)butyl-6,7-dimethoxy-isoquinolinyl))-4,4-diphenylheptanc~ dichlorohydrochloride: mp 114-128 °C; Anal. Calcd for C4~H62N303F~2HC1: C, 69.78; H, 7.97; N, 5.19; Found: C, 68.25; H, 8.06; N, 5.06.

Example 30 7 [N 3 (4 Fluorouhenvl)propionvl]amino-1-fN (1.2,3.4-tetrahvdro 1 (4-N isonentylamino)buty_11]-6 7-dimethoxyisoauinolinvl)1 4~4~-diphenylheptane dihydrochloride <i The procedure: described in example 26 was used but substituting isovalerylaldehyde for acetone. Afterworkup and purification by a silica gel column chromatography 7-[N 3-(4-fluoro-phenyl)propionyl]amino-1-[N ([1,2,3,4-tetrahydro-1-(4-(N isopentylamino)buty]1-6,7-di-methoxyisoquinolinyl]-4,4-diphenylheptane: MS showed (M+ H)+ @ 750;'H-NMR
(CDC13, 8):
0.86-0.94 (d, 6H)., 0.93-0.98 (m, 1H), 1.05-1.33 (m, 4H), 1.33-1.95 (m, 8H), 1.95-2.25 (broad m, 6H)., 2.45-2.58 (rn, 2H), 2.58-3.4 (broad m, 11H), 3.38-3.53 (m, 1H), 3.67-3.8 (m, 1H), 3.84 (s, 3H), 3.86 (s, 3H), 4.02-4.12 (m, 1. H), 6.54 (s, 2H), 6.7-6.78 (broad t, 1 H), 6.84-6.96 (m, 2H,), 7.0-7.29 (m, 12H); IR (KBr) a 3421, 2950, 1650, 1510 cm-'. The hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluorophenyl)propionyl]-1-N
(1,2,3,4-tetrahydro-1-[4-(N isopentylaminobutyl)-6,;~-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydro-chloride: mp 118-132 °C; Anal. Calcd for C4gH69N303F 2HCl: C, 70.05; H, 8.08; N, 5.1 l; Found:
C, 68.53; H, 8.46; N, 5.02.
Examale 31 2;0 7-jN-3-(4-Fluoraphenyllnropionyllamino-1-[N (1.2.3,4-tetrahvdro-1-~4-(N-a~ha-methylbenzvlaminolbutyl-6 7-dimethox~soauinolinvl)1 4 4- -diphenvlhentane dihvdrochloride The procedure described in example 26 was used but substituting acetophenone for acetone.
;t5 After workup and purification by a silica gel column chromatography 7-[N 3-(4-fluorophenyl)-propionyl]-1-[N.(i,2,3,4-tetrahydro-1-(4-(N alpha-methyl-benzyl)aminobutyl-6,7-dimethoxy-isoquinolinyl)]-X4,4-diphenylheptane: MS showed (M+ H)+ @ 784;'H-NMR (CDCl3, 8): 1.02-1.29 (broad m, 4H), 1.29-1.78 (m, 8H), 1.94-1.77 (m, 15H), 2.93-2.97 (t, 2H), 2.97-3.23 (m, 3H), 3.40 (broad m, 1 H), 3.72-3.85 (m, 1H), 3.83 (s, 6H), 6.44 (d, 1H), 6.51 (s, 1H), 6.87-6.98 (t, 2H), 30 7.08-7.42 (m, 19H); IR (KBr) v 3430, 2938, 2594, 1654, 1510 cm'. The dihydrochloride salt was prepared as in example 4 to~ give 7-[N-3-(4-fluorophenyl)propionyl]-amino-1-[N-(1,2,3,4-tetrahydro-1-(4-(N-alpha-methyl-benzylaminobutyl))-6,7-dimethoxy-isoquinolinyl)]-4,4-diphenylheptane: mp 120-132 °C; Anal. Calcd for Cs~H62N303F~2HCl: C, 71.48; H, 7.53; N, 4.90; Found: C, 70.1 l; H, 7.69; N, 4.85.
Examele 32 5; 7-Lld 3-i(4-Fluorophenyl)propionvllamino-1-fN (1,2,3,4-tetrahvdro-1-{4-N N dicvcloorovvlmethylamino)butyl-6 7-dimethoxyisoquinolinvl)1 4 4 -diphenvlh~tane dihvdrochloride The procedure. described in example 26 was used but substituting a large excess of cyclopropyl aldehyde acetone. After workup and silica gel column chromatography 7-[N 3-(4-fluorophenyl)-propionyl]-1-[N (1,2,3,4-tetrahydro-1-(4-{N,N
dicyclopropo-methylamino)butyl-6,7-dimethax;yisoquinolinyl)]-4,4-diphenylheptane was obtained: MS
showed (M+ H)+ ~'r~ 788;'H-NMR (CDC13, 8): 0.03-0.17 (q, 4H), 0.45-0.55 (m, 4H), 0.8-0.95 (m, 2H), 1.05-1.2:2 (m, 4H), 1.22-1.75 (m, 6H), 1.95-2.2 (m, 4H), 2.3-2.5 (m, 9H), 2.53-2.77 (m, 1:5 4H), 2.83-2.99 (t, 2H), 2.93-3.02 (m, 1 H), 3.02-3.19 (q, 2H), 3.26-3.36 (m, 1 H), 3.83 (s, 6H), 5.23 (broad s, 1 H), 6.47 (s, 1 H), E..S 1 (s, 1 H), 6.87-6.97 (m, 2H), 7.05-7.29 (m, 12H,). 3.72-3.85 (m, 1 H,), 3.83 (s, 6H), 6.44 (d, 1 H), 6.51 (s, 1 H), 6.87-6.98 (t, 2H), 7.08-7.42 (m, 19H); IR
(KBr) a 3423, 2938, 2595, 1657, 1 S 10 cm'' . The hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluorophenyl}propionyl]amino-I-[N (1,2,3,4-tetrahydro-1-(4-N,N-dicyclo-propylmethylamino)-butyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride:
mp 118-130 °C; Anal. Calcd far c~s,H66N303F~2HCl: C, 71.14; H, 7.96; N, 4.88; Found: C, 70.68; H, 8.14; N, 4.73.
Example 33 2.5 7_[N 3-(4-Fluorophenyl)yropionyl~amino-1-[N (1.2.3.4-tetrahvdro-I-(4-N,N dimethylaminolbutyl-6 7-dimethoxv_isoquinolinvl)1 4 4-diphenylheptane dihvdrochloride The procedure described in example 26 was used but substituting a large excess of 37%
:SO formaldehyde for acetone. After workup and purification by a silica gel column chromatography 7-[N 3-(4-fluorophenyl)propionyl]-I-[N (1,2,3,4-tetrahydro-1-(4-N,N-dimethylamino)butyl-6,7-dimethoxyisoqui.nolinyl)]-4,4-diphenylheptane was obtained: MS showed (M+ H)+
@ 708;'H-NMR (CDCl3, ~): I.OS-1.28 (m, 4H), 1.3-I .77 (m, 6H), 1.96-2.18 (m, SH), 2.23 (s, 6H), 2.25 2.50 (m, SH), 2.53-2.77 (m, 3H), f..84-2.95 (t, 2H), 2.84-2.95 (t, 2H), 2.95-3.08 (m, 1H), 3.08-3.19 (q, 2H), 3.28-3.39 (m, 1 H), 3..83 (two s ,6H), 5.30 (broad s, 1 H), 6.47 (s, 1 H), 6.S 1 (s, 1 H), 6.87-6.97 (m, 2H)., 7.OS-7.30 (rn, 1.2H); IR (MIC) v 3598, 2938, 2583, 2423, 1654, 1518 crri'.
The hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluorophenyl)propionyl]-1-[N {1,2,3,4-tetrahydro-1-(4-NN-dimethylamino)butyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride: mp 116-134 °C; Anal. Calcd for C45HS8N303F'2HCI: C, 69.22; H, 7.74; N, 5.38; Found: C., 68.82; H, 7.93; N, 5.27.
Example 34 7-fN 3-(4-Fluorophen~)propiooy_I]; 1-[N (1.2,3,4-tetrahydro-1-(4-N-acetylamino)butyl)-6,7-~dimethoxyisoquinolinyl)1-4,4-diphenvlhentane hydrochloride To a solution of 7-[N 3-(4-fluorophenyl)propionyl]-1-[N (1,2,3,4-tetrahydro-1-(4-amino-butyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane (0.157 g) in methylene chloride (10 mL) was added acetic anhydride (1mL) and N>N diisopropylethylamine (1 mL).
The solution was stirred at rt overnight and then poured into a separatory funnel and washed with brine. The organic phase was dried (Na2S04) and concentrated in vacuo. The residue was purified by a silica gel column chromatography to give the desired product 7-[N 3-(4-fluoro-phenyl)propionyl]amino-1-[N-(1,2 ,3,4-tetrahydro-1-{4-N acetylamino)butyl)-6,7-dimethoxy-2CI isoquinolinyl)]-4; I-diphenylheptane (0.084 g): MS showed (M+ H)+ @ 722;
'H-NMR (CDC13, 8): 1.02-1.33 (broad m, 4H), 1.33-1.79 (6H, m), 1.97 (3H, s), 1.96-2.2 (SH, broad m), 2.43-2.58 (2H, m), 2.63-3.0 (SH, m), 3.0-3.37 (m, 6H), 3.84 (s, 6H), S.3 (s, 2H), 6.43 (s, IH), 6.56 (s, 1H), 6.84-6.98 (m, 2H), 7.04-7.28 (m, 12H). The hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-(4-N
acetylamino)-2:i butyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride: mp 11 S-128 °C; Anal.
Calcd for CQSH56N304F'HCI: C, 71.27; H, 7.58; N, S.S4; Found: C, 69.53; H, 7.68; N, 5.41.
-SS-Example 35 7-[N 3-(4-Fluorophenyl)propionvllamino-1-LN (1 2 3 4-tetrahydro-1-(4-N
nicotinylamino) butyl-6 7-dimethoxyisoquinolinyll-4 4-diphenylheptane hydrochloride <;
To a solution of 7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-(4-amino)butyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane (0.206 g) in methylene chloride (10 mL) was added nicotinic acid (0.402 g) followed by HOBt (0.4775 g), triethylamine (0.8 mL) and EDCI (0.069 g). 'rhe mixture was stirred at rt under nitrogen for two days and then was washed with sodium bicarbonate and brine solutions. The organic phase was dried (Na2S04) and concentrated in vacuo to give a brown dry foam. This residue was purified by a silica gel column to yield 7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N
(1,2,3,4-tetrahydro-1-(4-N nicotinylamino)butyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane (0.2 g): MS
showed {M+ H)+ @ 785;'H-NMIZ (CDC13, 8): 1.05-1.24 (broad m , 2H), 1.5-1.84 (broad m, 1:5 6H), 1.97-2.18 (rn, SH), 2.34-2.8 (broad m, 6H), 2.80-2.98 (m, 3H), 3.0-3.64 (broad m, 7H), 3.83 (s, 3H), 3.89 (s, 3H,), 5.29 (s, 2H;), 6.43 (s, 1 H), 6.54 (s, 1 H), 6.83-7.0 (m, 2H), 7.0-7.28 (m, 12H), 7.30-7.37 (m, 1 H), 8.5 (broad m, 1 H), 8.66 (broad d, 1 H), 9.18 (broad s, 1 H); IR (MIC) a 3370, 2959, 2934, 2908, 2837, Ifi00, 1585, 1521 cm 1. The hydrochloride salt was prepared as in example 4 to give; 7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-(4-N
nicotinylamino)butyl-6,7-dimeth~oxyisoquinolinyl]-4,4-diphenylheptane dihydrochloride: mp 124-133 °C.
Example 36 7-fN 3- 4-Fluorophen l~propionyll-I-[N (1,2.3,4-tetrahydro-~;5 1 ~4-N-Qhthalimidomethyl)cyclohexvl-6,7-dimethoxvisoquinolinyl)1-4.4-diphenylheptane hydrochloride Step 1: N [(3,4-Dimethoxv)nhenylethyll-4-(N
nhthalimidomethvl)cyclohexvlcarbonvl amide To a stirred solution of 3,4-dimethoxyphenethylamine (3.6224 g) in methylene chloride :30 (100 mL) was added trans-4-{N phthalimidomethyl)cyclohexanecarboxylic acid (6.3224 g) followed by HO:Bt (2.9731 g), triethylamine (4.1 mL) and EDCI (4.2175 g). The reaction mixture was stirred at rt overnig:ht and then washed with sodium bicarbonate and brine solutions.
The organic phase was dried over Na2S04 and concentrated in vacuo. The obtained residue was crystallized from ethyl acetate to give IN [(3,4-dimethoxy)phenylethyl]-(4-N
phthalimido-methyl)cyclohexyl-carbonyl amide (5.5 g): MS showed (M+ H)+ @ 45 i; IH-NMR
(d6DMS0, 8): 0.85-1.06 (broad q, 2H), 1.08-1.38 {broad q, 2H), 1.54-1.76 (broad d, SH), I.94-2.09 (m, IH), 2.55-2.66 (t, 2H), 3.14-3.24 (q, 2H), 3.37-3.50 (d, 2H), 3.70 (s, 3H), 3.72 (s, 3H), 6.63-6.70 (dd, 1 H), 6.77 (d, 1 H), 6.8-6.88 (d, 1 H), 7.66-7.74 (t, 1 H), 7.80-7.93 (m, 3H).
Sten 2: 3,4-Dihydro-1-~ 4-(N-phthalimidomethylcyclohexyl)1-6 7-dimethoxyisoquinoline To a stirred solution of N [(3,4-dimethoxy)phenylethyl]-4-(N
phthalimidomethyI)-cyclo-hexylcarbonyl amide (4.3178 g) in benzene (200 mL) was added POC13 (10 mL) and the mixture was heated under reflux for 4 hr and then concentrated in vacuo. The residue was taken in ethyl acetate and washed with sodium bicarbonate and brine solutions. The organic phase was dried (Na2S04) and concentrated in vacuo. The residue was purified by a silica gel column chromatography eluting (9:1) merhylene chloride/methanol to give 3,4-dihydro-1-[(4-phthalimidomethyi)cyclohexyl]-Ci,7-dimethoxyisoquinoline {2.05 g): MS
showed (M+ H)+ @
1.'> 433; ~H-NMR (CDC13, 8): 1.13-1.32 (broad q, 21-i), I.47-1.68 (broad q, 2H), 1.82-2.05 (broad t, 5H), 2.6-2.7 (t, 2H), 2.77-2.93 (broad t, 1H), 3.57-3.72 (m, 4H), 3.94 (s, 3H), 3.96 (s, 3H), 6.71 (s, 1 H), 7.03 (s, 1 H), 7.67-7.77 (m, 2H), 7.8-7.92 (m, 2H).
Sten 3: 1,2.3,4-Tetrahvdro-I-f4-UV phthalimidomethyl)cyclohexyl]-6 7-dimethoxvisoquinoline To a stirred solution of 3,4-dihydro-1-[(4-N phthalirnidomethyl)cyclohexyl]-6,7-dimethoxy-isoquinoline (2.05~ g) in methanol (50 mL) was added sodium cyanoborohydride (0.3276 g) followed by three drops of acetic acid. The mixture was stirred at rt for 4 hr and then concentrated in vacuo. The residue was taken in ethyl acetate and washed with sodium bicarbonate and brine solutions. 'The organic phase was dried (NazS04) and concentrated in 2:i vacuo. The residue was purified iby a silica gel column chromatography eluting with (98:2) methylene chloride/methanol to give 1,2,3,4-tetrahydro-I-[4-(N
phthalimidomethyl)-cyclohexyl]-6,7-dimethoxyisoquinoline: MS showed (M+ H)+ @ 435; 'H-NMR (CDC13, 8):
0.91-1.24 (m, 3H), 1.32-1.52 (m, 2H), 1.52-1.92 (broad m ,7H), 2.52-2.63 (td, IH), 2.67-2.82 (m, 1 H), 2.84-2.97 (m, 1 H), 3.19-3.3CI (m, 1 H), 3.50-3.58 (d, 2H), 3.87 (s, 6H), 6.56 (s, 1 H), 6.61 (s, 1H), 7.68-7.76 (m, 2H), 7.8-7.88 (m, 2H).

Step 4: 7-fN 3-(4-Fluorophenyl)propionyl]amino-1-fN (1 2 3.4-tetrahydro-1- 4-N
phthalimidometh~!1)-cyclohexyl-6,7-dimethoxyisoquinolinyl~]-4 4-diphenylhept:ane hydrochloride To a solution of 7-[N 3-(4-fluorophenyl)propionyl]amino-4,4-diphenylheptan-1-al (0.5051 g) '_~ in methanol (50 rr~L) was added 1,2,3,4-tetrahydro-1-[4-{N
phthalimidomethyl)cyclohexyl]-6,7-dimethoxyisoquinoline (0.5077 g) followed by sodium cyanoborohydride (0.0811 g) and three drops of acetic acid. The mixture was stirred under nitrogen at rt for 2 hr. The mixture was concentrated in vacuo and the residue was taken in ethyl acetate and washed with sodium bicarbonate and brine solutions,. The organic phase was dried and concentrated (Na2S04) in vacuo. The residue was purified by a silica gel column chromatography to give 7-(N 3-(4-fluorophenyl)propionyl]amino-1-(N (I,2,3,4-tetxahydro-1-[4-(N
phthalimidomethyl)-cyclohexyl]-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane: MS showed (M+
H)+ @ 850;
'H-NMR {CDC13, b): 0.8-1.23 (broad m, 6H), 1.32-1.83 (broad m, 6H), 1.91-2.2 (m, 6H), 2.25-2.72 (m, 7H), 2.82:-2.97 (t, 2H), 2.97-3.23 (m, 3H), 3.79 (s, 3H), 3.83 (s, 3H), 3.83-3.89 (m, 1H), 5.07 (broad t , 1 H), 6.86-6.99 (m, 2H), 7.03-7.32 (m, 12H), 7.65-7.75 (m, 2H), 7.79-7.89 (m, 2H); IR (KBr) v 3397, 2929, 2852:, 1772, 1714, 1653, 1509 crri'. The hydrochloride salt was prepared as in example 4 to give T-[N 3-(4-fluorophenyl)propionyi]amino-1-(N
(1,2,3,4-tetrahydro-1-(4-N ~phthalimidomet:hyl)cyclohexyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenyl-heptane hydrochloride: mp 108-12:1 °C; Anal. Calcd for C54H6oN30sF~HCI:
C, 73.16; H, 6.94; N, 2f 4.74; Found: C, 6fi.33; H, 6.39; N,. 5.86.
Example 37 7-fN 3-(4-Fluom_phenyl)nropionyll-1-fN (1,2,3,4-tetrahydro-1-(4-aminomethvlcvclohexyl)-6--dimethoxvisoquinolinvl)]-4,4-diphenylheptane dihydrochloride To a solution of 7-[N-3-(4-fluorophenyl)propionyl]-1-[N (1,2,3,4-tetrahydro-1-(4-N
phthalimidomethylcyclohexyl]-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane (0.795 g) in ethanol ( 10 mL) was added hydra~:ine hydrate (2 mL) and the mixture was heated under reflux for 2 hr. Methanolic HCl (5 mL,) was added, the mixture was stirred at rt for 10 min and the precipitate was filtered. The filtrate was concentrated in vacuo and the residue was purified by preparative HPLC to give 7-[N 3-1;4-fluorophenyl)propionyl]-1-[.N (1,2,3,4-tetrahydro-1-(4-aminomethyl)cyclohexyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane:
MS
showed (M+ H)+ (~ 720. The hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluorophenyl)propionyl]-1-[N (1,2,3,4-tetrahydro-1-(4-aminomethyl)cyclohexyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride.
Exam-ple 38 7~-1N 3-(4-Fluoro~ahenvl)propion~,]-1-jN (1.2,3,4-tetrahydro-1-(4-N (~isopropylaminomethvl)cyclohexyl-6.7-dimethoxyisoquinolin~)1-4,4-diphenylheptane dihydrochloride To a stirred solution of 7-[N 3-(4-fluorophenyl)propionyl]-I-[N (1,2,3,4-tetrahydro-1-(4-aminomethyl)cyclohexyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane (0.80 g) in methanol (10 mL) was added acetone (1mL), sodium cyanoborohydride (0.0157 g) and three drops of acetic acid. The mixture was stirred under nitrogen at rt for 2 hr and concentrated in vacuo to give 7-[N-3-(4-fluorophenyl)propionyl]-1-[N (1,2,3,4-tetrahydro-1-(4-N isopropyl-aminomethyl)cyclohexyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane (0.125 g): MS
showed (M+ H)+ ~c~ 762;'H-NMR (CDCl3, S): 0.77-1.31 (m, 6H), 1.26 (d, 6H), 1.31-1.73 (broad m, 4H), 1.73-1.90 (broad t, 2H), 1.9-2.22 (m, 6H), 2.3-2.8 (m, lOH), 2.8-2.92(t, 2H), 2.92-3.23 (m, 4H), 3.82 (s, 3H), 3.83 (s, 3H), 5.29 (broad t, 1H), 6.4 (s, 1H), 6.54 (s, 1H), 6.87-6.98 (t, 2H), 7.03-7.30 (m, 12H1; IR (KBr) a 3400, 2950, 1740, 1 S I O cm'j. The hydrochloride salt was prepared as in exarnple 4 to give 7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N
(1,2,3,4-tetrahydro-1-(4-(N-isopropylaminomethyl)cyclohexyl-6,7-dimethoxyisoquinolinyl)]
4,4-diphenyIheptane dihydrochloride (0.115 g): mp 114-122 °C; Anal.
Calcd for C49H~4N303F~2HCl: C, 70.49; H, 7.97; N, 5.03; Found: C, 70.73; H, 7.86; N, 5.17.
Example 39 7-[N 3-(4-Fluorophenyl)propion~]-1-[N (1,2.3,4-tetrahydro-1-~4-Nphthalimidomethyl)-phenyl.-6 7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride Step 1: N [(3,4-dimethoxyphen l~lethyll(4-N phthalimidomethyl)benzoyl amide The procedure described in experiment 36 was used but substituting (4-N
phathalimido-methyl)benzoic acid for trans-(4-N'-phthalimidomethyl)cyclohexanecarboxylic acid in step 1 to give N [(3,4-dimethoxyphenyl)eth;yl](4-N phthalimidomethyl)benzoyl amide: MS
showed (M+
H)+ @ 445; 1H-NMR (d6DMS0, Vii): 2.73-2.85 (m, 2H), 3.37-3.53 (m, 2H), 3.73 (s, 6H), 4.83 (s, 2H), 6.7-6.77 {dd, 1 H), 6.8-6.9 (m, 2H), 7.37-7.44 (d, 1 H), 7.45-7.60 (m, 1 H), 7.76-7.98 (m, 6H), 8.6 (broad t, 1 H).
Sten 2: 3.4-dihvdro-1-f4-N=phthalimidomethyl)phen~l-6 7-dimethoxyisoquinoline N [(3,4-dimettvoxyphenyl)ethyl]-(4-N phthalimidomethyl)benzoyl amide was reacted with POCI3, using same: conditions as described in experiment 36, step 2, to give 3,4-dihydro-1-[4-N
phthalimidomethy:l)phenyl]-6,7-di:methoxyisoquinoline: MS showed (M+ H)+ @
427; 'H-NMR
(CDC13, 8): 2.64-2.74 (m, 2H), 3.T2 (s, 3H), 3.74-3.83 (m, 2H), 3.94 (s, 3H), 4.91 (s, 2H), 6.74-6.79 (d, 2H), 7.43-7.50 (d, 2H), 7.'.>-7.6 (d, 2H), 7.68-7.77 (m, 2H), 7.82-7.91 (m, 2H).
Sten 3: 1.2.3,4-tetrahvdro-1-f(4-N=phthalimidomethyl~phenvll-6 7-dimethox isoguinoline 3,4-Dihydro-1-[(4-N phthalimidomethyl)phenyl]-6,7-dimethoxyisoquinolinyl was treated with sodium cyano~borohydride, using same conditions as described in experiment 36, step 3, to yield 1,2,3,4-tetrahydro-1-[(4-N phthalimidomethyl)phenyl]-6,7-dimethoxyisoquinoline: MS
showed (M+ H)+ @ 429; 'H-NMP; (CDCl3, 8): 2.35 (broad s, 1H), 2.68-2.80 (m, IH), 2.82-3.04 (m, 2H), 3.09-3.20 (m, 1 H), 3.63 (s, 3H), 3.87 (s, 3H), 4.84 (s, 2H), 5.04 (s, 1 H), 6.22 (s, 1 H), 6.62 (s, 1H), 7.11-',1.22 (d, 2H), 7.33-7.42 (d, 2H), 7.65-7.75 (m, 2H), 7.8-7.88 (m, 2H).
Sten 4: 7-fN 3-(4-lFluorophenyl)propionvll-1~N (1 2 3 4-tetrahydro-I (4 N
phthalimidomethvll-nhenvl-6,7-dirnethoxyisoauinolinyl)]-4 4-dphenvlheptane hydrochloride 1,2,3,4-Tetrahydro-1-[4-(N phthalimidomethyl)phenyl]-6,7-dimethoxyisoquinoline was reacted with 7-[N ?~-(4-fluorophenyl)propionyl]amino-4,4-diphenylheptan-1-al in the presence of sodium cyanoborohydride, using tle same conditions described in experiment 36, step 4, to give 7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-{4-N
phthalimidomethyl)-phenyl-6,7-diinethoxyisoquinoliny:l)]-4,4-diphenylheptane: MS showed (M+ H)+ @
g44; jH-NMR (CDC13, 8): 0.94-1.25 (broad m , 4H), 1.57-I .78 (broad m, 2H), 1.89-2.48 (m, 8H), 2.56-2.77 (m, 1H), 2.77-3.0 (rn, 4H), 3.02-3.20 (broad m, 2H), 3.58 (s, 3H), 3.83 (s, 3H), 4.36 (broad m, 1 H), 4.77-4.92 (q, 2H), 6.10 (s, 1 H), 6.56 {s, 1 H), 6.82-6.96 (m, 2H), 7.0-7.4 (m, 16H), 7.67-7.76 (m, 4H), 7.77-7.88 (m, 2H); IR (KBr) a 3308, 3055, 2939, 1769, 1716, 1668, 1510 cm ~.
The hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluorophenyl)propionyl]-1-[N-(1,2,3,4-tetrahydro-1-(4-N phthalimidomethyl)phenyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride: mp 114-128 °C (dec.); Anal. Calcd for C54HsaN3OsF~HCI: C, 73.66; H, 6.30; N, 4.77; Found: C, 72.21; H, 6.37; N, 4.67.

Example 40 7-fN 3-(4-Fluoronhenyl)propionyl]-I-(N (1 2 3 4-tetrah~rdro-1-(4-aminomethylphen~rl)-6 7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride To a solution of 7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-(4-(N phthalimidomethyl)phenyl-6.,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane (0.265 g) in ethanol ( 10 mL) was added methyl hydrazine ( 1 mL) and the solution was stirred at rt for 15 min and then refluxed for 1 hr. The reaction mixture was concentrated in vacuo and the residue was taken up in ethyl acetate. The solution was washed with sodium bicarbonate and brine solutions, dried {Na2S04) and again concentrated in vacuo to give 7-[N 3-(4-fluorophenyl)propionyl]-amino-1-[N (1,2,3,4-tetrahydro-1-(4-aminomethylphenyl)-6,7-dimethoxyisoquinolinyl}]-4,4-diphenylheptane as solid foam: MS showed (M+ H)+ @ 714; ~H-NMR (CDC13, 8):
0.97-1.2 (m, 4H}, 1.56-1.92 (m, :3H), 1.93-2.27 (m, 4H), 2.28-2.48 (m, 4H), 2.6-2.78 (m, 1H), 2.82-2.98 (m, 4H), 3.03-3.17 (q, 2.H), 3.60 (s, 3H), 3.84 (s, 3H), 3.88 (s, 2H), 4.38 (s, 1H), 5.23 (broad t, 1H), 6.14 (s, 1H), 6,58 (s, 1H), 6,84-6.96 (m, 2H), 7.03-7.30 (m, 16H). The hydrochloride salt was prepared as in example 4 to give 7-[N-3-(4-fluorophenyl)propionyl]amino-I-[N
(1,2,3,4-tetrahydro-I-(4-aminomethyl)phenyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride: mp 126-134 °C (dlec.); Anal. Calcd for C46H52N303F~2HC1~2H20: C, 67.14; H, 7.10; N, 5.10; Found: C, 67.11;1-0, '1.11; N, 5. I 6.
Example 41 7-[N :3-(4-Fluorophenvl)propionyl]-I-[N (1,2,3.4-tetrahydro-1-(4-(N
isopropylaminomethyl)phenyl-6.7-dimethoxyisoquinolinyl)L
4,4-d iphen~ptane dihvdrochloride To a solution of 7-[N 3-(4-fluor~ophenyl)propionyl]amino-I-[N (1,2,3,4-tetrahydro-1-(4-aminomethyl)phenyl-6,7-dirnethoxyisoquinolinyl)]-4,4-diphenylheptane (0.102 g) in methanol (15 mL) was added acetone (0.010 mL), sodium cyanoborohydride (0.010 g) and three drops of acetic acid. The reaction mixture was stirred at rt for 3 hr and then concentrated in vacuo. The residue was taken in ethyl acetate and washed with sodium bicarbonate and brine solutions. The organic phase was dried (Na2S04) and concentrated in vacuo. The residue was purified by a silica gel column to give 7-[N 3-(4-fluorophenyl)propionyl]-1-[N-(1,2,3,4-tetrahydro-1-(4-N

isopropylarninomethyl)phenyl-6,7-dimethoxyisoquinolinyl}]-4,4-diphenylheptane (0.045 g);
(M+ H}+ @ 756; 'H-NMR (CDC13, 8): 0.9-1.1 (broad m, 2H), 1.13-1.31 (broad m, 3H), 1.33-1.47 (d, 6H), 1.76-2.22 (broad m, 4H), 2.35-2.58 (m, 2H), 2.70-2.93 (broad m, 6H), 2.98-3.13 (broad m, 2H), 3.13-3.42 (broad m., 3H), 3.58 (s, 3H), 3.86 {s, 3H), 4.03 (s, 2H), 4.94 (broad m, 1 H), 6.09 (s, 1 H), 6.63 (s, I H), 6.84-6.97 (m, 2H), 7.03-7.37 (m, 14H), 7.42-7.52 (d, 2H). The hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluorophenyl)propionyl]-I-[N (1,2,3,4-tetrahydro-1-(4-N-isopropylaminomethyl)phenyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride: mp 128-139 °C (dec.); Anal. Calcd for C49HS8N303F 2HC:l'H20: C, 69.48; H, 7.37; N, 4.96; Found: C, 69.44; H, 7.39;
N, 4.94.
Example 42 -3-~,4-Fluorophew~propionvl]-1-[N ( I ,2,3,4-tetrahydro-I -(4-N
c~.vclobutylaminometh~phenyl-6,7-dimethoxyisoguinolinyl)L
4.4-diphenylheptane dihydrochloride To a solution of 7-[N 3-(4-fluo:rophenyl)propionyl]-1-[N-(1,2,3,4-tetrahydro-I-(4-amino-methyl)phenyl-6,7-~dimethoxyisoquinolinyl)]-4,4-diphenylheptane (0.10 g) in methanol ( I 5 mL) was added cyclobutanone ((0.0108 g), sodium cyanoborohydride (0.0097 g) and three drops of acetic acid. The reaction mixture was stirred at rt for 3 hr and then concentrated in vacuo. The residue was taken in ethyl acetate aind washed with sodium bicarbonate and brine solutions. The organic phase was dried (Na2S04) and concentrated in vacuo. The residue was purified by a silica gel column to yield 7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N
(1,2,3,4-tetrahydro-1-(4-(N cyclobutylaminomethyl)phenyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane (0.020 g); (M+ H)+ @ 768; 'H-NMR (t~DCl3, b): 0.75-1.32 (broad m ,7H), 1.52-2.21 (m, 6H), 2.21-2.38 (m, 2H), 2.38-2.97 (m, 8H), 2.97-3.21 (m, 2H), 3.21-3.44 (m, 2H), 3.5$
(s, 3H), 3.58-3.74 (m, 1 H), 3.87 (s, 3H), 3.92 (s, 21-1), 5.3 (s, I H), 6.04 (s, 1 H), 6.62 (s, 1 H), 6.84-6.98 (m, 2H), 7.0-7.52 (m, 16H). The hydrochloride salt was prepared as in example 4 to give 7-[N-3-(4-fluoro-phenyl)propionyl]-I-[N (1,2,3,4-tevtrahydro-I-(4-N-cyclobutylaminomethyl)phenyl-6,7-di-methoxyisoquinolinyl)]-4,4-diphen,ylheptane dihydrochloride: mp 121-133 °C; Anal. Calcd for CS°HSgN303F'2HC1'H20: C, 69.91; H, 7.27; N, 4.89; Found: C, 69.82; H, 7.24; N, 4.87.

Example 43 7-IN 3-(4-Fluoronhenyl)propionyll I -[N ( I ~ 3 4-tetrah~dro-1-(4=N cycloprop~rlmeth~~aminometh~phenyl-6 7-dimethoxyiso4uinolinyl)1-4,4-diphenylheptane dihydrochloride The procedure described in example 42 was used but substituting cyclopropylcarboxaldehyde for cyclobutanone. After workup and silica gel column purification 7-[N 3-(4-fluorophenyl)-propionyl]-1-[N {1,.?,3,4-tetrahydro-1-(4-N cyclopropylmethyl aminomethyl)phenyl-6,7-di-methoxyisoquinolinyl)]-4,4-diphenylheptane was obtained: MS showed (M+ H)+ @
768; ~H-NMR (CDC13, 8): 0..07-0.22 (m, 2H), 0.45-0.6 (m, 2H), 0.92-1.24 (m, 5H), 1.6 (m, 1H), 2.0-2.28 {m, 2H), 2.29-2.49 (m, 5H), 2.5-2.7'7 (m, 3H), 2.82-3.0 (t, 4H), O1-3.18 (q, 2H), 3.6 (s, 3H), 3.85 (s, 3H), 3.91 (s, 2H), 4.19 (broad s, 2H), 4.39 (s, I H), 5.4 (t, 1 H), 6.11 (s, 1 H), 6.58 (s, 1 H), 6.85-6.97 (t, 2H), 7.0-7.34 (m, 16H). T'hc~ hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluorophenyl)propionyl]-ll-[N (1,2,3,4-tetrahydro-1-(4-N
cyclopropylmethylamino-methyl)phenyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride: mp 124-136 °C; Anal. Calcd for CS°HSgN303F~2HC1~H20: C, 69.91; H, 7.27; N, 4.89; Found: C, 69.8$; H, 7.31; N, 4.88.
Example 44 7- N 3-'4-Fluoro~hen~~nronionyl]-I-jN (1,2,3,4-tetrahydro-1-(4-N bis-c_yclopropylmethvlaminomethyl)phenvl-6 7-dimethoxyisoquinolin~rl)1 4 4-di~phenvlheptane di)~drochloride The procedure described in example 42 was adopted but using three equivalents of cyclopropylcarboxaldehyde for cyclobutanone. After workup and silica gel column chromatography 7-[lV 3-(4-fluorophenyl)propionyl]-I-[N (1,2,3,4-tetrahydro-1-(4-N bis-cyclopropylmethylaminomethyl)phenyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane was obtained: MS show:; (M+ H)+ @ 822; 'H-NMR (CDCI3, b): 0.25-0.36 (m, 4H), 0.66-0.80 (m, 4H), 1.0-1.18 (m, 6~:(), 1.66-1.81 (m, 1H), 1.9-2.22 (m, 3H), 2.29-2.83 {m, 6H), 2.83-3.22 (m, lOH), 3.61 (s, 3H), 3.85 (s, 3H), 4..11-4.33 (m, 2H), 4.62 (broad m, 1H), 5.67 (broad m, IH), 6.1 I
(s, 1H), 6.61 {s, IH), 6.82-6.97 (t, 2H), 7.01-7.3? (m, 14H), 7.37-7.50 (d, 2H). The hydrochloride WO 00/2938(1 PCT/US99/26584 salt was prepared as in example 4 to give 7-[N-3-(4-fluorophenyl)propionyl]-1-[N (1,2,3,4-tetrahydro-1-(4-N biscyclopropylmeahylaminomethyl)phenyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride: rnp 118-134 °C (dec.); Anal. Calcd for C54H~N303F~2HC1H320: C, 71.30; H, 7.50; N, 4.60; Found: C, 71.08; H, 7.54; N, 4.56.
Example 45 7-~'V 3-(4-Fluorophen~)propionyll-1 LN (1,2,3,4-tetrahydro-1-N-acetvlaminomethvl)phenyl-6,7-dimethoxyisoquinolin~)1-4,4-diphen~ptane hydrochloride To solution of 7-[N 3-(4-fluorophenyl)propionyl]-1-[N (1,2,3,4-tetrahydro-1-(4-amino-methyl)phenyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane (0.101 g) in methylene chloride { 10 mL) was added acetic anhydride ( 1 mL) and diisopropylethylamine ( 1 mL). The reaction mixture was stirred at rt overnight and then poured into a separatory funnel and washed with sodium bicarbonate and brine solutions. The organic phase was dried and concentrated in vacuo. The residue was purified by a silica gel column chromatography to yield 7-[N 3-(4-fluorophenyl)propionyl]-1-[N (1,2,3,4-tetrahydro-1-(4-(N
acetylaminomethyl)phenyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane (0.070 g): MS shows (M+ H)+ @
756. The hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluorophenyl)propionyl]-amino-1-[N (1,2,3,4-tetrahydro-1-(4~-N acetylaxninomethyl)phenyl-6,7-dimethoxyiso-quinolinyl)]-4,4-diphenylheptane hydrochloride: mp 118-132 °C (dec.);
Anal. Calcd for CasHsarl3DaF~HC1~0.75H20: C, 71.53; H, 7.60; N, 5.21; Found: C, 71.19; H, 7.08; N, 5.16.
Example 46 7-_[N 3-(4~-Fluorophenyl)t~ropion~l]-1-LN-(1,2,3,4-tetrahydro-1-methyl-6.7-dihydroxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride The procedure described in experiment 1 was used but substituting 1,2,3,4-tetrahydro-1-methyl-6,7-dihydroxyisoquinoline for 1,2,3,4-tetrahydro-1-methyl-6,7-dimethoxyisoquinoline.
After workup and purification by a silica gel column chromatography eluting with (95:5) methylene chloride/methanol 7-[~'-3-(4-fluorophenyl)propionyl]-1-[N (1,2,3,4-tetrahydro-1-methyl-6,7-dihydroxyisoquinolinyl)]-4,4-diphenylheptane was obtained: MS
shows (M+ H)+
@ 595; 'H-NMR {C'.DC13, 8): 1.05-1..20 (m, 2H), 1.27 (s, 3H), 1.88-2.19 (m, 7H), 2.33-2.51 (m, WO 00/2938() PCT/US99/26584 4H), 2.67-2.94 (m, 3H), 3.05-3. I 9 I;m, 2H), 3.30 (broad s, 1 H), 4. I2 (broad s, 1 H), 5.37 (t, 1 H), 6.28 (t, I H), 6.53 (s, 1 H), 6.59 (s, 1 H ), 6.83-6.97 (m, 2H), 7.04-7.30 (m, 12H). The hydrochloride salt was prepared as in example 4 to give 7-[N-3-(4-fluorophenyl)propionyl]-amino-1-[N-( I,2,3,4-tetrahydro-1-methyl-6,7-dihydroxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride.
Example 47 7-(N 3-(4-Fluorophenvl)propionyll-1-[N (1,2,3,4-tetrahydro-1-methylisoc~uinolinyl)j-4 4-diophenylheptane hydrochloride The procedure described in experiment 1 was used but substituting 1,2,3,4-tetrahydro-1-methylisoquinoline for 1,2,3,4-teoahydro-1-methyl-6,7-dimethoxyisoquinoiine.
After workup and purification by a silica gel column chromatography eluting with (95:5) methylene chloride/methanol i'-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-methyl-isoquinolinyl)]-4,4-diphenylheptanc: was obtained: MS shows (M+ 1-1)+ @ 563;
~H-NMR
(CDC13, 8): 1.07-1.17 (m, 2H), 1.18.-1.30 (m, SH), 2.01-2.15 (m, 4H), 2.30-2.38 (t, 2H), 2.42-2.58 (m, 2H), 2.58-;2.69 (m, 2H), 2.77-2.98 (m, 4H), 3.09-3.17 (m, 2H), 3.71-3.79 (q, 1H), 5.10 (broad s, 1H), 6.88-7.29 (m, 18H); lfR (KBr) a 3416, 3300, 2939, 1613, 1716, 1509 em''. The hydrochloride salt was prepared as :in example 4 to give 7-[N 3-(4-fluorophenyl)propionyl]-1-[N (1,2,3,4-tetrahydro-1-methylisoduinolinyl)]-4,4-diphenylheptane hydrochloride: mp 83-87 °C; Anal. Calcd for C3gH43N20F HCI 0.5H20: C, 72.30; H, 8.27; N, 5.11;
Found: C, 72.61; H, 7.42; N, 4.43.
Example 48 7_[N 3-(4-Fluorophen~propionyl]-1-[N~1.2.3,4-tetrahydro-1-methyl-6,7-dioxalane-isoquinolin~l)1-4,4-diphenylheptane hydrochloride The procedure described in experiment 1 was used but substituting 1,2,3,4-tetrahydro-1-methyl-6,7-dioxalane-isoquinoline for 1,2,3,4-tetrahydro-1-methyl-6,7-dimethoxyisoquinoline.
After workup and purification by silica gel column chromatography eluting with ethyl acetate 7-[N 3-(4-fluorophenyl)propionyl]-1-[N (1,2,3,4-tetrahydro-1-methyl-6,7-dioxalane-isoquinolinyl)]-4,4-diphenylheptane; was obtained: MS shows (M+ H)+ @ 607; 'H-NMR
(CDCl3, S): 1.08-1.26 (m, 7H), 2.0:?-2.14 (m, 4H), 2.33-2.38 (t, 2H), 2.3$-2.58 (m, 4H), 2.68-WO 00/2938(1 PCT/US99/26584 2.83 (m, 1 H), 2.83--2.94 (m, 3H), 3.10-3.18 (q, 2H), 3.57-3.64 (q, 1 H), 5.14 (broad s, 1 H), 5.88 (s, 2H), 6.48 (s, 1H), 6.51 (s, 1H;), 6.89-6.97 (t, 2H), 7.08-7.30 (m, 12H) );
IR {KBr) a 3420, 3296, 2939, 1643, 1550, 1510, 1482 cm-~. The hydrochloride salt was prepared as in example 4 to give 7-[N 3-{4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-I-methyl-6,7-dioxalane-isoquinolinyl)]-4,4-diphenylheptane hydrochloride: mp 91-95 °C; Anal. Calcd for C39H43N203F~HCl~:l.25H20: C, ?0.36; H, 7.30; N, 4.20; Found: C, 70.49; H, 7.00; N, 4.07.
Example 49 7-(N-3-(4-Fluoronhenyl)propion~]amino-I-[N (1,2,3,4-tetrahydro-I-metl~l-6,7-dioxane-isoquinolinyl)1-4,4-diphenylheptane hydrochloride The procedure described in experiment 1 was used but substituting 1,2,3,4-tetrahydro-1-methyl-6,7-dioxane~-isoquinoline for 1,2,3,4-tetrahydro-1-methyl-6,7-dimethoxyisoquinoiine.
After workup and purification by silica gel column chromatography eluting with (95:5) methylene chloride/methanol to give 7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-methyl-6,7-dioxane-is;oquinolinyl)]-4,4-diphenylheptane: MS shows (M+ H)+ @
621; 'H-NMR (CL)C13, 8): 1.04-1..32 (m, 7H), 1.97-2,13 {m, 4H), 2.28-2.59 (m, 6H), 2.61-2.67 (m, 1 H), 2.80-2.94 (m, 3H), 3.06-3.65 (m, 1 H), 4.22 (s, 4H), 5.04 (broad s, 1 H), 6.51 {s 1 H), 6.54 (s, 1H), 6.85-Ei.97 (t, 2H), 7.Ofi-7.28 (m, 12H); IR (KBr) a 3417, 3312, 2931, 2870, 1644, 1509 cm-~ . The hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluoro-phenyl)propionyl]amino-1-[N-( 1,2, 3,4-tetrahydro-1-methyl-6,7-dioxane-isoquinolinyl)]-4,4-diphenylheptane hydrochloride, mp 104-109 °C; Anal. Calcd for C4°HasN203F~HCl~H20:
C, 71.14; H, 7.16; N, 4.14; Found: C, 71.00; H, 7.21; N, 4.01.
Example 50 7- N 3- 4-Fluorophenyl)~propionvl]amino-1-jN (1,2.3.4-tetrah~dro-1-methyl-6-methoxyisoquioolin~]-4.4-diphenylheptane hydrochloride Step 1: [N 2-(3-Methoxynhenyl)ethyllace~l amide (Compound 12 Scheme 3) To a stirred solution of 3-methoxyphenethylamine (3.1 I g) in methylene chloride ( 150 mL) was added under nitrogen triethyla~nine (6.0 mL), acetic anhydride (2.1 mL) and DMAP (0.126 g). The mixture was stirred at rt overnight and then consecutively washed with solutions of sodium bicarbonate, IN hydrochloric acid and brine. The organic phase was dried (Na~S04) and WO 00/29380 PCT/US99/2ti584 concentrated in vac:uo to give [N=2~-(3-methoxyphenyl)ethyl]acetyl amide (3.65 g) as a yellow oil: MS shows (M~+- H)+ @ 194, {Nl+NH4)+ @ 211; 'H-NMR (CDC13, 8): 1.94 (s, 3H), 2.75-2.83 (t, 2H), 3.45-3.56 (~g, 2H), 3.80 (s, :3H), 5.64 (broad s, 1 H), 6.72-6.81 (m, 3H), 7.19-7.28 (m, 1 H);
IR (KBr) a 3285, 3080, 2935, 1651, 1584, 1490 cm''.
Step 2: 4,5-Dihydro-7-methox~-9b-methyl-oxazolo~2.3-alisoquinoline-2,3-dione (Compound 14. Scheme 3~
To a stirred solution of [N 2-(3~-methoxyphenyl)ethyljacetyl amide (3.65 g) in methylene chloride (175 mL) was added 2M oxalyl chloride solution in methylene chloride (10.4 mL) followed by a portionwise addition of FeCl3 (3.68 g). The mixture was stirred at rt overnight.
To the dark brown mixture was added 2N HCl {150 mL) and stirring was continued for 1 hr.
The mixture was poured in a separatory funnel and the layers were separated.
The organic phase was washed with brine, dried (MgS04) and concentrated in vacuo to give 1-(3-methoxy-phenethyl)-2-chlorooxazolidine-4,_'~-dione {3.60 g) as a dark brown solid: MS
shows (M+ H)+ @
248, (M+NH4)+ @ 265. This solid was recrystallized from ethyl acetate to give the 7-methoxy isomer (1.139 g) as the major product and the 9-methoxy isomer (0.128 g) as the minor one. The spectral data were consistent with the 7-methoxy isomer,'H-NMR (CDC13, 8):
2.84-2.91 (dd, 1 H), 3.10-3.20 (m, 1 H), 3.48-3.561',m, 1 H), 3.81 (s, 3H), 4.51-4.58 (dq, 1 H), 6.65 (d, 1 H), 6.85 6.89 (dd, 1H), 7.2-',x.25 {d, 1H);1R (KBr) a 33423, 2921, 1806, 1737 crri': mp 135-136 °C; Anal.
Calcd for C~3H~3NO4: C, 63.15; H, 5.29; N, 5.66; Found: C, 63.01; H, 5.27; N, 5.62.
Step 3: 3,4-Dihydro-6-methoxy-1-meth l~guinoline Compound 15, Scheme 3) To a stirred slurry of 4,5-dihydro-7-methoxy-9b-methyl-oxazolo[2,3-a]soquinoline-2,3-dione (2.27 g) in methanol (100 mL) was added conc. HZS04 (2 mL) and the mixture was heated at 75 °C overnight and then concentrated in vacuo. The residue was partitioned between ethyl acetate and water. The organic phase was washed twice with 2N HCI. The aqueous extracts were combined and basii:ied with NaOH solution to pH 11.0 and extracted with chloroform three times. The organic extracts were combined, dried (MgS04) and concentrated in vacuo to give 3,4-dihydro-6-methoxy-1-methylisoquinoline as a brown oil (1.503 g): MS shows (M+ H)+ @
176;'H-NMR (CDC13, S): 2.36 (t, :3H), 2.65-2.73 (t, 2H), 3.59-3.69 (dt, ZH), 3.85 (s, 3H), 6.68-6.72 (d, 1H), 6.72-ti.82 (dd, 1H), 7.4-7.46 (d, 1H}; IR (MIC) a 2937, 2837, 1627, 1569 cni'.

Sten 4: 1,2,3,4-Tetrahydro-6-methoxy-1-methylisoguinoline (Compound A Scheme 3) To a stirred solution of 3,4-dihydro-6-methoxy-1-methylisoquinolinyl (1.503 g) in methanol (100 mL) was added sodium cyanolborohydride (1.078 g). The solution pH was adjusted to pH
4-5 by the addition of few drops of acetic acid. The reaction mixture was stirred at rt overnight and then concentrated in vacuo. 'The residue was partitioned between ethyl acetate and sodium bicarbonate solution. The aqueous phase was washed three times with ethyl acetate. The organic extracts were combined and washed with brine, dried (MgS04) and concentrated in vacuo to give 1,2,3,4-tetrahydro-6-rnethoxy-1-methylisoquinoline (1.48 g) as brown oil: MS
shows (M+ H)+ @ 1~7g;'H-NMR (C:DCI3, 8): 1.60-1.67 (d, 3H) 2.87-3.0 (m, 1H), 3.02-3.17 (m, 1 H), 3.19-3.30 (m, 't H), 3.40-3.5 2 (:m, 1 H), 3.79 (s, 3H), 3.31-4.41 (m, 1 H), 5.10 (broad s, 1 H), 6.63-6.68 (d, I H), 6.77-6.82 (dd, 1 fI), 7.05-7.10 (d, 1 H).
1,2,3,4-Tetrahydro-6-methoxy-l-methylisoquinoline was reacted with 7-[N-3-(4-fluoro phenyl}propionyl]amino-4,4-diphen.ylheptan-1-al in the presence of sodium cyanoboro-hydride I 5 using the procedure described in ex;~mple 1. After workup and purification by a silica gel column chromatography 7-[N 3-(4-,Eluorophenyl)propionyl]amino-I-[N (1,2,3,4-tetrahydro-1-methyl-6-methoxyisoquinolinyl)]~-4,4-diphenylheptane was obtained: MS shows (M+ H)+ @
593;'H-NMR (CDCl3, 8): 1.05-1.2',~ (m, SH), 1.57-1.76 (m, 2H), 2.0-2.15 (m, 4H), 2.29-2.39 (t, 2H), 2.39-2.66 (m, 4H), 2.70-2.96 (m, 4H), 3.07-3. I 8 (q, 2H), 3.62-3.72 (q, I H), 3.78 (s, 3H), 5.05 (broad t, 1H), E~.57-6.60 (d, IH), 6.67-6.83 (dd, 1H), 6.87-6.97 (m, 3H), 7.06-7.30 (m, 12H);
IR (MIC) a 3296, 2943, 1644, i S09 cm ~. The hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluorophenyl)prop~ionyl]amino-1-[N (1,2,3,4-tetrahydro-I-methyl-6-methoxy-isoquinolinyI)]-4,4-diphenylheptane hydrochloride.
Example 51 7-[N 3~4-Fluoronhenvlnroo~ionyIl-1-IN (1,2,3,4-tetrahvdro-1-methyl-7-methoxy-isoquinolinyl)1-4,4-diphenylheptane hydrochloride The procedure described in experiment 50 was used but substituting 1,2,3,4-tetrahydro-7-methoxyisoquinoline for 1,2,3,4-tc:trahydro-6-methoxyisoquinoline. After workup and purification by a silica gel column chromatography 7-[N 3-(4-fluorophenyl)propionyl]-1-[N-(1,2,3,4-tetrahydro-I-methyl-7-rnethoxy-isoquinolinyl)]-4,4-diphenylheptane: MS shows (M+ H)+ @ 593; cH~-NMR (CDCI~, ~~): 1.08-1.30 (rn, 7H), 2.02-2.16 (m, 4H), 2.31-2.38 (t, 2H), 2.40-2.62 (m, 4H), 2.70-2.80 (m, 1 H), 2.86-2.97 {m, 3H), 3.09-3.18 (q, 2H), 3.64-3.72 (q, 1 H), 3.78 (s, 3H), 5.14 (broad s, 1H), 6.:56 (d, 1H), 6.67-6.72 (dd, 1H), 6.88-7.0 {m, 3H, m), 7.07-7.31 (12H, m); IR (MIC) a 3296, 2944., 1644, 1509 cm-~. The hydrochloride salt was prepared as in example 4 to give ',~-[N 3-(4-fluoropheny)propionyl]-1-[N (1,2,3,4-tetrahydro-1-methyl-7-S methoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride.
Example 52 7-[N 3-(4-Fluorophenyl)propionyl]-1-[N~1,2,3,4-tetrahydro-1-methyl-7-chloro-isoq_uinolin~)1-4.4-diphenylheptane hydrochloride The procedure described in experiment 50 was used but substituting 1,2,3,4,-tetrahydro-isoquinolinyl-I-methyl-7-chloroiso~quinoline for 1,2,3,4-tetrahydroisoquinolinyl-1-methyl-6-methoxyisoquinoline. After workup and purification by a silica gel column chromatography 7-[N 3-(4-fluoropheny)lpropionyl)-1-[N (1,2,3,4-tetrahydro-I-methyl-7-chloro-isoquinolinyl)]-4,4-1 S diphenylheptane was obtained: MS shows (M+ H)+ @ 597; 'H-NMR (CDC13, 8):
1.05-1.25 (m, 7H), 2.00-2.12 (m, 4H), 2.3-2.37 (t, 2H), 2.37-2.60 (m, 4H), 2.70-2.82 (m, 1 H), 2.82-2.93 (m, 3H), 3.09-3.17 (q, 2H), 3.60-3.68 (m, 1 H), 5.02 (broad s, 1 H), 6.88-7.00 (m, 3H), 7.02-7.29 (m, 14H); IR (MIC) a 3423, 3300, 29f~0, 1642, 1509 cm's. The hydrochloride salt was prepared as in example 4 to give 7-[N-3-(4-fl uorophenyl)propionyl]- I -[N ( 1,2,3,4-tetrahydro-1-methyl-7-chloroisoquinolinyl)]-4,4-diphenylheptane hydrochloride: mp 84-88 °C;
Anal. Calcd for C3gH42N20FC1~HC:U 1.25Hz0: C, 65.55; H, 6.98; N, 4.26; Found: C, 69.49; H, 6.97; N, 4.22.
Example 53 7-fN-3-(4-Fluorophen-yl)propion~]-1-[N (1,2,3.4-tetrahydro-1-methyl-7-fluoro-isoquinolinyl)]_ 4 4 dphenylheptane hydrochloride The procedure described in experiment SO was used but substituting 1,2,3,4-tetrahydro-1-methyl-7-fluoroisoquinoline for 1,2,3,4-tetrahydro-1-methyl-6-methoxyisoquinoline. After workup and purification by a silica gel column chromatography 7-[N 3-(4-fluorophenyl)-propionyl]-1-[N (1.,2,3,4-tetrahydro-1-methyl-7-fluoroisoquinolinyl)]-4,4-diphenylheptane was obtained: MS shows (M+ H)+ @ 581;'H-NMR (CDC13, 8): 1.05-1.29 (m, 7H), 1.98-2.15 (m, 4H), 2.29-2.37 (t, 2H), 2.37-2.62 (rn, 4H), 2.70-2.80 (m, 1H), 2.84-2.93 (m, 3H), 3.08-3.17 (q, 2H), 3.62-3.70 (q, 1 H), 5.16 (broad s, 1 H), 6.67-6.72 (dd, I H), 6.75-6.82 (td, 1 H), 6.88-6.95 (t, 2H), 6.95-7.02 (m, 1H), 7.05-7.20 (m, $H), 7.20-7.28 (t, 4H); IR (MIC) a 3291, 3086, 2943., 1643, 1552, 1509, 1500 cm's. The hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluorophemyl)propionyl]-I-[N (1,2,3,4-tetrahydro-1-methyl-7-fluoroisoquinolinyl)]-4,4-diphenylheptane hydrochloride: mp 80-84 °C; Anal. Calcd for C3gH42N20F2~HCl~H20: C, 71.85;
H, 7.13; N, 4.40; Found: C, 71.44; H, 7.08; N, 4.24.
Example 54 7-[N 3-(4-Fluorot~henyl)propionyll-1-fN (1,2,3,4-tetrahydro-1-methyl-7-vitro-isoquinolinyl)1-4,4-diphenylheptane hydrochloride The procedure described in experiment 50 was used but substituting 1,2,3,4,-tetrahydro-1-methyl-7-nitroisoquinoline for 1,2,3,4-tetrahydro-1-methyl-6-methoxyisoquinoline. After workup and purification by a silica gel column chromatography 7-[N-3-(4-fluorophenyl)-propionyl]-1-[N-(1,:?,3,4-tetrahydro-1-methyl-7-vitro-isoquinolinyl)]-4,4-diphenylheptane was obtained: MS shows (M+ H)+ (~ 608; ~H-NMR (CDC13, s): 1.08-I .32 (m, 7H), 2.0-2.18 (m, 4H), 2.32-2.42 (m, 2H), 2.42-2.57 (m, 2H), 2.58-2.68 (broad m, 1 H), 2.68-2.97 (t, 4H), 3.08-3. I 8 (q, 2H), 3.73-3.82 (m, ll H), 5. I 8 (broad m, 1 H), 6.88-6.97 (m, 2H), 7.07-7.30 (m, 13H), 7.88-7.98 (m, 2H); IR (MIC) a 3297, 3086, 2943, 1645, 1522 cm-~. The hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluorophenyl)propionyl]-1-[N (1,2,3,4-tetrahydro-1-methyl-7-nitroisoquinolinyl)]--4,4-diphenylheptane hydrochloride.
Example 55 7-[N 3-(4-Fluorophenyl)propionyr~-1-(N (1.2.3,4-tetrahydro-1-methyl-7-acet~rlamino-isoguinolinyl),]-4,4-diphenylheptane hydrochloride A solution of 7-~_IV 3-(4-fluorophenyl)propionyl]-1-[lV (1,2,3,4-tetrahydro-1-methyl-7-nitro-isoquinolinyl)]-4,4-diphenylheptane (0.060 g) in ethyl acetate ( 10 mL) was hydrogenated in the presence of 10% PdIC (0.030 g) to give 7-[N 3-(4-fluorophenyl)propionyl]-I-[N
(1,2,3,4-tetra-hydro-1-methyl-7-a~ninoisoquinolinyl)]-4,4-diphenylheptane (0.057 g). A
solution of this amine in methylene chloride ( 10 mL) was treated with triethylamine (0.021 mL), acetic anhydride ((0.010 mL), and catalytic amount of DMAP and stirred at rt overnight. The reaction mixture was diluted with methylene chloride: and the organic phase was washed three times with sodium bicarbonate and brine solutions, dried (Na2S04) and concentrated in vacuo. The residue was purified by a silica gel column chromatography to give 7-[N 3-(4-fluorophenyl)propionyl]-amino-1-[N (I,2,3,4-tetrahydro-I-methyl-7-acetylaminoisoquinolinyl)]-4,4-diphenylheptane (0.025 g): MS shows (M+ H)+ @ 620. The hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluorophenyl)propionyl]-1-[N-(I,2,3,4-tetrahydro-1-methyl-7-acetylamino-S isoquinolinyl)]-4,4-~diphenylheptane hydrochlorid: mp 114 OC; Anal. Calcd for CaoHa6N3~F~HC1~1.7SHz0: C, 69.85; H, 7.40; N, 6.I0; Found: C, 70.01; H, 7.49;
N, 5.90.
Example 56 7-I[N 3-(4-Fluorophenyllnroaionyl]-1-~N (1.2,3,4-tetrahydro-I-methyl-6,7-dichloro-isoquinolinyl)]-4,4-diphenylheptane hydrochloride The procedure described in experiment SO was used but substituting 1,2,3,4,-tetrahydro-1-methyl-6,7-dichloroisoquinoline for 1,2,3,4-tetrahydroisoquinoline-1-methyl-6-methoxy-isoquinoline. After workup and purification by a silica gel column chromatography 1 S 7-[N-3-(4-fluorophenyl)propiony l]-~ I -[N-( I,2,3,4-tetrahydro-1-methyl-6,7-dichloro-isoquinolinyl)]-4,4-diphenylheptane was obtained: MS shows (M+ H)+ @ 631;'H-NMR
(CDCl3, b): 1.08-1.18 (m, 2H), 1.18-1.32 (m, SH), 2.02-2.I4 (m, 4H), 2.32-2.40 (t, 2H), 2.4-2.64 (m, 4H), 2.70-2.81 (m, I H), 2.86-2,.95 (m, 3H), 3.10-3.19 (q, 2H), 3.62-3.71 (q, I H), 5.23 (broad s, 1H), 6.89-6.97 (t,, 2H), 7.07-7.30 (m, 14H); IR {KBr) a 3431, 2932, 1642, 1 S09 crri'. The hydrochloride salt was prepared as in example 4 to give 7-[N-3-(4-fluorophenyl)propionyl]-1-[N (1,2,3,4-tetrahy<iro-1-methyl-6,'7-dichloroisoquinolinyl)]-4,4-diphenylheptane hydrochloride.
Example 57 7-[N 3-(4-Fluorophen~prcpionyl]-1-[N (1,2,3,4-tetrahvdro-1-methyl-6-chloro-7-2S fluoroisoquinolinyl-4.4-diphenylheptane hydrochloride The procedure described in experiment SO was used but substituting 1,2,3,4, tetrahydro-I-methyl-6-chloro-7-fluoroisoquinoline fox 1,2,3,4-tetrahydro-1-methyl-6-methoxyisoquinoline.
After workup and purification by a silica gel column chromatography 7-[N 3-(4-fluorophenyl)-propionyl]-1-[N-(1..2,3,4-tetrahydro-1-methyl-6-chloro-7-fluoroisoquinoliny!)]-4,4-diphenyl-heptane was obtained: MS shows (1VI+ H)+ @ 61 S; 'H-NMR (CDC13, 8): 0.97-I .29 (m, 7H), 1.91-2.07 (m, 4H), 2.22-2.57 (m, 6:H), 2.60-2.71 (m, 1H), 2.71-2.85 (m, 3H), 3.0-3.11 (q, 2H), 3.50-3.61 (m, 1 H), 5.02 (broad m, I H), 6.7-6.74 (d, 1 H), 6.81-6.89 (t, 2H), 6.97-7.22 (m, 13H);
_7I_ IR (KBr) a 3285, f.942, 1642, 1509 cm's. The hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluorophenyl)propionyl]-1-[N-(1,2,3,4-tetrahydro-1-methyl-6-chloro-7-fluoroisoquinolinyl)]-4,4-diphenyllleptane hydrochloride: mp 97-99 OC; Anal.
Calcd for C3gH4,N20C1F2~HC:13H20: C, 68.b~5; H, 6.32; N, 4.21; Found: C, 68.29; H, 6.65;
N, 3.96.
Example S8 7-(N 3-(4-Fluorophenyl)propionvll-1-jN~1,2.3.4-tetrahydro-1-methyl-6 7-diacetaxvisoquinolinvl)1-4.4-diphenylheptane A methylene chloride solution of the dihydroxy compound (0.250 g), obtained from experiment 46, was. treated with acetic anhydride, triethylamine and DMAP at rt overnight.
After workup and purification by a silica gel column chromatography 7-[N 3-(4-fluorophenyl)-propionyl]-1-[N-( 1,2,3,4-tetrahydro-1-methyl-6,7-diacetoxyisoquinolinyl)]-4,4-diphenylheptane was obtained: MS shows (M+ H;I+ (a> 679; 1H-NMR (CDCl3, 8): 1.08-1.32 (m, 7H), 2.0-2.16 (m, 4H), 2.32-2.38 (t, 2H), 2.38-2.55 (nn, 2H), 2.55-2.64 (m, 2H), 2.72-2.83 (m, 1H), 2.85-2.95 (m, 3H), 3.07-3.18 (q, 2H), 3.66-3.74 (q, 1 H), 5.28 (broad s, 1 H), 6.79-6.98 (m, 2H), 7.07-7.40 (m, 14H); IR (KBr) a 3403, 2939, 1769, 1509 cm's.
Example 59 7-(N 3-(4-Fluorophenvl)pro~pionvl~ 1-(N (1.2,3,4-tetrahydro-1-methyl-6-bromo-7-yethoxyisoquinolinYl)],-4,4-diphenvlheptane hydrochloride The procedure described in experiment 50 was used but substituting 1,2,3,4,-tetrahydro-1 methyl-6-bromo-7-:methoxyisoquinoline for 1,2,3,4-tetrahydro-1-methyl-6-methoxyisoquinoline.
After workup and purification with a silica gel column chromatography 7-[N 3-(4-fluorophenyl)-propionyl]-1-[N (1,2,3,4-tetrahydro-1-methyl-6-bromo-7-methoxyisoquinolinyl)]-4,4-diphenyl-heptane was obtained: MS shows (rvI+ H)+ @ 673; ~H-NMR (CDC13, 8): 1.06-1.28 (m, 7H), 2.0-2.12 (m, 4H), 2.3-2.36 (t, 2H), 2.36-2.58 (m, 4H), 2.68-2.77 (m, 1H), 2.82-2.92 (m, 3H), 3.07-3.17 (q, 2H), 3.59-?..67 (q, 1 H), 3.84 (s, 3H), 5.04 (broad s, 1 H), 6.51 (s, 1 H), 6.87-6.94 (t, 1 H), 7.05-7.28 (m, 14H); IR (KBr) v 3419, 2936, 1643, 1509 cm-~. The hydrochloride salt was prepared as in exanriple 4 to give 7-[N 3-(4-fluorophenyl)propionyl]-1-[N
(1,2,3,4-tetrahydro-1-methyl-6-bromo-7-:methoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride: mp 104-108 °C;

Anal. Calcd for C39H4qN2O2BrF~HC:1~1.25Hz0: C, 64.10; H, 6.55; N, 3.85; Found:
C, 63.94; H, 6.55; N, 3.68.
Example 60 7-[N 3-(4-Fluorophenyl)prepionyl]-1-jN (1.2.3.4-tetrahydro-1-methyl-6-fluoro-7-tnethoxvisoquinolinyl)j-4,4-diphenylheptane hydrochloride The procedure described in experiment 50 was used but substituting 1,2,3,4-tetrahydro-1-methyl-6-fluoro-7-rnethoxyisoquinoline for 1,2,3,4-tetrahydro-1-methyl-6-methoxyisoquinoline.
After workup and purification with a silica gel column chromatography 7-[N 3-(4-fluorophenyl)-propionyl]-1-[N (1,:2,3,4-tetrahydro-1-methyl-6-fluoro-7-methoxyisoquinolinyl)]-4,4-diphenyl-heptane was obtained: MS shows (Pvl+ H)+ @ 61 l; ~H-NMR (CDC13, 8): 1.08-1.30 (m, 7H), 2.02-2.18 (m, 4H), :2.32-2.40 (t, 2H), 2.40-2.62 (m, 4H), 2.68-2.78 (m, 1H), 2.85-2.95 (m, 3H), 3.10-3.18 (q, 2H), 3.62-3.70 (q, 2H ), 3.84 (s, 3H), 5.25 (broad s, 1 H), 6.54-6.61 (d, 1 H), 6.72-6.78 (d, 1H), 6.89-6.97 (t, 2H)) 7.08-7.31 (m, 12H); IR (MIC) a 3298, 2941, 1644, 1510 cm''.
The hydrochloride :;alt was prepared as in example 4 to give 7-[N 3-(4-fluorophenyl)propionyl]-1-[N-( 1,2,3,4-tetrahydro-1-methyl-fi-fluoro-7-methoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride.
Example 61 7-fN 3-(4-Fluorophenyl)pro~ionyl]-1-[N (I.2.3.4-tetrahydro-1-methyl-6-methoxy-bromoisoquinolinyl)1-4,4-diphen~eptane hydrochloride The procedure described in experiment 50 was used but substituting 1,2,3,4-tetrahydro-1-methyl-6-methoxy-'7-bromoisoquinoline for 1,2,3,4-tetrahydro-1-methyl-6-methoxyisoquinoline.
After workup and purification with a silica gel column chromatography 7-[N 3-(4-fluorophenyl-propionyl)jamino-1-[N (1,2,3,4-tetnahydro-1-methyl-6-methoxy-7-bromoisoquinolinyl)]-4,4-diphenylheptane was obtained: MS shows (M+ H)+ @ 673; 'H-NMR (CDCl3, 8): 1.07-1.28 (m, 7H), 2.0-2.12 (m, 4H), 2.30-2.52 {rn, 4H), 2.60-2.77 (m, 3I-I), 2.83-2.94 (m, 3H), 3.07-3.16 (m, 2H), 3.65-3.70 (m, 1 H), 3.86 (s, 3H), 5.18 (broad s, 1 H), 6.70-6.75 (d, 1 H), 6.88-6.96 (m, 3H), 7.06-7.28 (m, 12H):; IR (MIC) a 32'93, 2939, 1646, 1509 cm-'. The hydrochloride salt was prepared as in example 4 to give 7-[N-3-(4-fluorophenyl)propionyl]-1-[N
(1,2,3,4-tetrahydro-1-methyl-6-methox;y-7-bromoisoquinolinyl)]-4,4-diphenyiheptane hydrochloride.

Exam-ple 62 7-fN 3-(4-Fluorophenyl)propionyl]'~-1-jN-(1,2,3,4-tetrahydro-1,6-dimethyl-7-methoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride The procedure described in experiment 50 was used but substituting 1,2,3,4-tetrahydro-1,6-dimethyl-7-mel:hoxyisoquinoline for 1,2,3,4-tetrahydro-1-methyl-6-methoxyisoquinoline.
After workup and purification with a silica gel colum chromatography 7-[N 3-(4-fluorophenyl)-propionyl)-1-[N (i,.2,3,4-tetrahydro-1,6-dimethyl-7-methoxyisoquinolinyl)]-4,4-diphenylheptane was obtained: MS shows (M+ H)+ @, 607; ~H-NMR (CDC13, 8): 1.07-1.20 (m, 2H), 1.22-1.38 (m, SH), 2.01-2.17 (m, 4H), 2.14 (s, 3H), 2.34-2.43 (t, 2H), 2.47-2.78 (m, SH), 2.85-2.94 (t, 2H), 2.94-3.05 (m, 1 H), 3. I 0-3. I 9 (q, 2I-I), 3.72-3.78 (m, 1 H), 3.78 (s, 3H), 5.59 (broad s, I H), 6.42 (s, 1 H), 6.81 (s, 1 H), 6.87-6.95 (t, 2H), 7.08-7.29 (m, 12H). The hydrochloride salt was prepared as in example 4 to give 7-[N-3-(4-fluorophenyi)propionyl]-I-[N (1,2,3,4-tetrahydro-1,6-di-1S methyl-7-methoxyisoquinolinyl)J-4~,4-diphenylheptane hydrochloride.
Example 63 7-jN 3-(4-Fluarophenyl~propionvl]-I-jN (1.2,3,4-tetrahydro-I-methyl-6-carbomethoxl-7-methoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride A solution 7-[N'-3-(4-fluorophe;nyl)propionyl]-I-[N (1,2,3,4-tetrahydro-I-methyl-7-methoxy-6-bromoisoquinolinyl)]-4,4-diphenylheptane (0.10 g) in methanol (25 mL) was treated with [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (0.025 g) and lutidine (0.032 g) heated at 120 °C under 180 psi pressure of carbon monoxide for 22 hr. The catalyst was filtered and the solution was concentrated in vacuo.
The residue was purified by a silica gel column chromatography to give 7-[N 3-(4-fluorophenyl)propionyl]-I-[N (1,2,3,4-tetrahydro-1-methyl-6-carbomethoxy-7-methoxyisoquinolinyl))-4,4-diphenyl-heptane: MS show:; (M+ H)+ @ 651. The hydrochloride salt was prepared as in example 4 to give 7-[N 3-{4-fluorophenyl-propionyl)]amino-1-[N-(1,2,3,4-tetrahydro-1-methyl-6-carbo-methoxy-7-methoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride: mp 92 °C; Anal. Calcd for C4,H4~N204F~HC1~2.SH20: C, 67.18; H, 6.55; N, 3.82; Found: C, 67.15; H, 6.93; N, 3.62.

WO 00/2938(1 PCT/US99/26584 Example 64 7-LN 3-f4-Fluorophenyl~propion~yl]amino-1-[N (1,2,3,4-tetrahydro-I-cyclobutyl-6-bromo-7-yethoxyisoquinolin~ll-4.4-diphenvlheptane hydrochloride The procedure described in example 50 was used but substituting 1,2,3,4-tetrahydro-I-cyclobutyl-6-bromo-7-methoxyisoquinoline for substituting 1,2,3,4-tetrahydro-I-methyl-6-bromo-7-methox;yisoquinoline. After workup and purification with a silica gel column chromatography 7-~[N 3-(4-fluorophenyl)propionyl]-1-[N (1,2,3,4-tetrahydro-I-cyclobutyl-6-bromo-7-methox;yisoquinolinyl)]-4,4-diphenylheptane was obtained: MS shows (M+ H)+ @
713; ~H-NMR (CDC13, 8): 1.07-1.13 (m, 4H), 1.51-I .91 (m, 6H), 1.91-2.18 (m, 6H), 2.27-2.58 (m, 6H), 2.60-2.80 (m, 2H), 2.86-3..24 (m, 3H), 3.84 (s, 3H), 5.03 (broad s, 1 H), 6.48 (s, 1 H,), 6.89-6.97 (t, 2H), 7.08-7.30 (m, 13H); IR (MIC) a 3295, 2941, 1644, 1509 cm-'.
The hydrochloride salt was prepared as in example 4 to give 7-[N-3-(4-fluorophenyl)propionyl]-I-[N (1,2,3,4-tetrahydro-1-cyclobutyll-6-bromo-7-methoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride.
Example 65 7- N-3- 4-Fluorophenvl)~ropionyll-1-[N j1,2,3.4-tetrahydro-I.3-dimethvl-6.7-dimethoxvisoctuinolinyl)1-4.4-diphenylheptane hydrochloride The procedure described in example 50 was used but substituting 1,2,3,4-tetrahydro-1,3-dimethyl-6,7-dimel:hoxyisoquinoline for 1,2,3,4-tetrahydro-I-methyl-6-methoxyisoquinoline.
After workup and purification with a silica gel column chromatography 7-[N-3-(4-fluorophenyl}-propionyl]-1-[N (1,2,3,4-tetrahydro-I,3-dimethyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenyl-heptane was obtained: MS shows (:M+ H)+ @ 637;'H-NMR (CDCI3, 8): 0.98-1.34 (m, 8H), 1.54-1.68 (m, 2H), 1.33- 2.10 (m, 4H), 2.28-2.40 (m, 4H), 2.28-2.40 (t, 2H), 2.45-2.64 (m, 4H), 2.72-2.94 (q, 2H), :3.60-3.77 (m, 1 I~), 3.84 (s, 6H), 5.05 (broad s, 1 H), 6.52 (s, 1 H), 6.57 (s, 1 H), 6.86-6.97 (t, 2H), i'.05-7.29 (m, 12H); IR (KBr) a 3414, 2933, 1646, 1509 cm ~. The hydrochloride salt 'was prepared as in example 4 to give 7-[N-3-(4-fluorophenylpropionyl)]-amino-1-[N (1,2,3,4-tetrahydro-I,3-dimethyl-6,7-dimethoxyisoquinoIinyl)]-4,4-diphenylheptane hydrochloride: mp 97-108 °C.

Example 66 7-_1N 3~,~4-Fluorophenyl~pronionyll-1-fN (1,2,3,4-tetrahydro-3-methyl-6 7 dimethoxvisoquinolinyl)1-4,4-diphenylhentane hydrochloride The procedure described in example 50 was used but substituting 1,2,3,4-tetrahydro-3-methyl-6,7-dimethoxyisoquinoline for 1,2,3,4-tetrahydro-1-methyl-6-methoxyisoquinoline.
After workup and purification with a silica gel column chromatography 7-[N 3-(4-fluorophenyl)-propionyl]-1-[N (1,2,3,4-tetrahydro-3-methyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane was obtained: MS shows (M+ H)+ (~ 623; 'H-NMR (CDC13, s): 0.94-1.04 (d, 3H), 1.04-1.30 (m, 4H), 1.98-2.15 (m, 4H), 2.27-2.60 (m, SH), 2.76-2.94 (m, 4H), 3.05-3.18 (q, 2H), 3.36-3.59 (m, 2H), 3.83 (s, 6I-1), 5.03 (broad s, 1 H), 6.47 (s, 1 H), 6.53 (s, 1 H), 6.87-6.98 (m, 2H), 7.06-7.30 (m, 12H); IR (KBr) a 3384, 2934, ll 646, 1 S 10 cm ' . The hydrochloride salt was prepared as in example 4 to give 7-[N-3-(4-fluorophenyl)propionyl]-1-[N-(1,2,3,4-tetrahydro-3-methyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphe;nylheptane hydrochloride: mp 87-91 °C; Anal. Calcd for CaoHa~N2D3F~HC1'I-120: C, 70.93; I:I, 7.44; N, 4.13; Found: C, 70.49; H, 7.28;
N, 3.85.
Example 67 7- N 3- 4-Fluorophenyl)propionyl]-1-fN (1,2,3,4-tetrahydro-1,1-dimethyl-6,7-dimethoxvisoauinolinyl)],-4,4-diphenylheptane hydrochloride The procedure described in example 50 was used but substituting 1,2,3,4-tetrahydro-1,1-dimethyl-6,7-dimethoxyisoquinolimyl for 1,2,3,4-tetrahydro-1-methyl-6-methoxytetra-hydroisoquinoline. After workup and purification with a silica gel column chromatography 7-[N 3-(4-fluorophenyl)propionyl]-1-[N (1,2,3,4-tetrahydro-1,1-dimethyl-6,7-dimethoxy-isoquinolinyl)]-4,4-diphenylheptanf: was obtained: MS shows (M+ H)+ @ 637; 'H-NMR
(CDC13, 8): 1.08-1.:?3 (m, 4H), 1.:3T (s, 6H), 2.01-2.12 (m, 2H), 2.12-2.21 (m, 2H), 2.31-2.39 (t, 2H), 2.39-2.48 (trroad rn, 2H), 2.56-2.70 (m, 4H), 2.87-2.95 (t, 2H), 3.10-3.19 (q, 2H), 3.83 (s, 3H), 3.89 (s, 3H), 5.13 (broad s, 1H), 6.51 (s, 1H), 6.72 (s, 1H), 6.89-6.96 (t, 1H), 7.08-7.30 (m, 13H); IR (KBr) a 3388, 2932, 1646, 1510 cm-'. The hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluorophenyl)propionyl]-1-[N (1,2,3,4-tetrahydro-1,3-dimethyl-6,7 dimethoxyisoquinol.inyl)]-4,4-diphenylheptane hydrochloride: mp 104-107 °C; Anal. Calcd for C4~H4gN2O3F'HCl'1.25Hz0: C, 70.77; H, 7.60; N, 4.20; Found: C, 70.76; H, 7.57;
N, 3.84.

Example 68 7-fN 3-(4-Fluoronhenyl'Ipropion~]-1-[N (1 2 3 4-tetrahydro-1 3-dimethvl 7-methoxvisoguinolinvl)1-4,4-diphenvlheptane hydrochloride The procedure described in example 50 was used but substituting 1,2,3,4-tetrahydro-1,3-di methyl-7-methoxyisoquinoline for 11,2,3,4-tetrahydro-1-methyl-6-methoxytetrahydro-isoquinoline. After workup and purification with a silica gel column chromatography 7-[N 3-(4-fluorophenyl)propionyl]-1-[N (1,2,3,4-tetrahydro-1,3-dimethyl-7-methoxy-isoquinolinyl)]-4,4-diphenylheptane~ was obtained: MS shows (M+ H)+ @ 607; IR
(KBr) a 3273, 2934, 1616, 1509 crn'~. The hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1,3-dimethyl-7-methoxy-isoquinolinyl)]-4,4-~iiphenylheptane~ hydrochloride.
Example 69 7-jN 3-(4-Fluoronhenyl)propion~Ll-fN (2,3,4,5-tetrahydro-1-methyl-7.8-dimethoxv 1H-2-benzazepinvl)1-4,4-diphenylheptane hydrochloride The procedure described in example 50 was used but substituting 2,3,4,5-tetrahydro-1-methyl-7,8-dimetho:xy-1H-2-benzazepine for 1,2,3,4-tetrahydro-1-methyl-6-methoxy-isoquinoline. After workup and purification with a silica gel column chromatography 7-[N-3-(4-fluorophenyl)propionyl]-1-[IV (2,3,4,5-tetrahydro-1-methyl-7,8-dimethoxy-1H-2-benzazepinyl)]-4,4-diphenylheptane was obtained: MS shows (M+ H)+ @ 637; ~H-NMR
(CDCl3, 8): 1.04-1.21 (m, 4H), 1.''1~-1.35 (broad m, 1H), 1.43-1.52 (d, 3H), 1.52-1.68 (m, 2H), 1.87-1.99 (m, 2H), 1.99-2.12 (m, 3Hf), 2.14-2.46 (m, 3H), 2.68-2.85 (broad m, 1H), 2.85-3.02 (m, 3H), 3.06-3.17 (t, 2H), 3.18-3.32 (broad m, 1H), 3.80 (s, 3H), 3.84 (s, 3H), 5.48 (broad s, 1H), 6.48 (broad s, 1H), Ei.62 (s, 1H), 6.8'7-6.97 (t, 2H), 7.03-7.30 (m, 12H). The hydrochloride salt was prepared as in example 4 to give 7-[N-3-(4-fluorophenyl)propionyl]-1-[N
(2,3,4,5-tetra-hydro-1-methyl-7,8-dimethoxy-1H :Z-benzazepinyl)]-4,4-diphenylheptane hydrochloride.
_77_ Example 70 6- N 3- 4-Fluoronhenvl)~ronionvl]amino-1-fN ( 1 2 3 4 tetrahydro 1 methyl 6 7-methox isoauinolinyl)1-3.3-dinhenylhexane h~rdrochloride Step 1: 4,4-Dinhenyl-6-methoxyhex-5-enenitrile (Compound 16 Scheme 4) To a solution of (methoxymethyl)triphenylphosphonium chloride (9.83 g, 28.7 mmol, 1.1 eq.) in anhydrous THF (60 mL) cooled to 0-5 °C under nitrogen was added dropwise a solution of n-butyllithium ( 13.7 mL of 2M solution. in pentane). The reaction mixture was stirred at the same temperature far 1 hr. Then a solution of 4,4-diphenyI-4-formylbutyronitrile (Compound 1, Scheme 2) (6.5 g, 26.1 mmol) in 'THF (20 mL) was added via syringe and stirnng was continued for 16 hr. The reaction mixture was. concentrated in vacuo and the residue was purified by silica gel column chromatography (eluted with 3% to 10% ethyl acetate/hexane) to give the desired product as a yellow oil (4.2 g, 58 %;): ~H-NMR (CDC13, b): 2.06-2.17 (m, 2H), 2.81-2.86 [2.62-2.68] (m, 2H), 3.57 (s, 3H), 4.76 (d, J= 7.3 Hz, 1H), 5.95 (d, J= 7.3 Hz, 1H), 7.15-7.42 (m, l OH).
Step 2: 4.4-Dinhenyl-5-formvlpent~u~onitrile (Compound 17 Scheme 4) To a solution of 4,4-diphenyl-6-methoxyhex-5-enenitrile (4.0 g, 14.4 mmoI) in diethylether (60 mL) was added HC1 (2 mL, 3'7 °.'°). The reaction mixture was stirred at room temperature for i 6 hr and then the solvent was evaporated in vacuo . The residue was dissolved in dichloro-methane and filtered through a plug of silica gel to give the desired aldehyde as an oil (3.78 g, 99%): ~H-NMR (CDC13, 8): 2.03 - 2.I0 (m, 2H), 2.56 - 2.64 (m, 2H), 3.12 (d, J=
3 Hz, 2H), 7.14 - 7.41 (m, lOH), 9.34 (t, J= 3 l lz, 1H). Anal. Calcd for C,gH,~NO: C, 82.10; H, 6.51; N, 5.32. Found: C, 82.10; H, 7.02; N, 4.78.
Step 3: 6-Amino-3.3-diphenylhexan-I-of (Compound 18 Scheme 4) To a suspension ~of lithium aluminumhydride (0.57 g, 15 mmol) in anhydrous THF
(20 mL) was added carefully dropwise a solution of 4,4-diphenyI-5-formylpentanonitrile ( 1.96 g, 7.4 mmol) in anhydrous THF (20 mL). The mixture was stirred at rt for 1.5 hr.
The reaction mixture was quenched by careful addition of SN NaOH (2.S mL) and followed by water (1.5 mL). The mixture was stirred at room temperature for 10 min and then filtered and the solid was washed twice with diethylether. The organic filtrates were combined, dried (NazSO4) and -78_ concentrated to give the desired product as solid foam (1.60 g, 80%): MS
showed (M+ H)+ @
270;'H-NMR (CDCl3, 8): 1.17-1..34 (m, 2H), 2.12-2.22 (m, 2H), 2.31-2.43 (m, 2H), 2.62-2.74 (m, 2H), 3.30-3.40 (m, 2H), 7.11-7.34 (m, lOH).
Sten 4: 6-fN 3-(4-1~luorophenyl)propionv~lamino-3 3-diphenylhexan-1-of (Compound 19, Scheme 4 .
To an ice-cold and stirred solution of 6-amino-3,3-diphenylhexan-I-of (0.54 g, 2 mmol) in methylene chloride solution (10 mL) was added 3-(4-fluorophenyl)propionic acid (0.37 g, 2.2 mmol) followed by 1-hydroxybenzotriazole hydrate (HOBt) (0.297 g, 2.2 mmol), triethylamine (0.31 mL), and 1-(3-climethylaminopropyl)-3-ethylcarbodiimide (EDCI) (0.422 g, 2.2 mmol). The reaction mixture was stirred at rt overnight and then diluted with methylene chloride (30 mL) and the solution eras washed first with water and then with brine. The organic phase was dried (Na2S04) and concentrated in vacuo. The residue was purified by a silica gel column using ( 1:1 ) ethyl acetate/he:xane yielding the desired compound as amorphous solid (0.24 g): MS showed (M+ H)+ @ 4:20; ~H-NMR (CDC13, 8): 1.10-1.21 (m, 2H), 2.05-2.12 (m, 2H), 2.37 (dd, 4H, .,l = 7, 14 Hz), 2.'90 (t, 2H, J = 7.5 Hz), 3.14 (dd, 2H, J
= 7, 13 Hz), 3.41 (t, 2H, J= 7 Hz), 5.29 (bs, 1H), 6.91.-T.02 (m, 4H), 7.10-7.30 (m, lOH).
Step 5: 6-[N 3-(4-F'luorophenvllpropionyi)amino-3,3-di~henylhe~l mesylate (Compound 20, Scheme 4 .
To a solution of 6-[N 3-(4-fluon~phenyl)propionyl]amino-3,3-diphenylhexan-1-of (0.20 g, 0.49 mmol) in methylene chloride (S mL) was added at 0 °C
methanesulfonyl chloride (0.046 mL) followed by triethylamine (0.074 mL). The solution was stirred at 0 °C for 30 min.
The reaction mixture was washed with 1 N HC1, water and brine. The organic phase was dried and concentrated in vacuo to give the desired product as an oil (0.227 g, 93%): MS showed (M+ H)+ @ 498; ~H-NMR (CDC13, 8): 1.12-1.22 (m, 2H), 2.06-2.13 (m, 2H), 2.42 (t, 2H, J=7.5 Hz), 2.56 (t, 2H, J='7.5 Hz), 2.87-2.96 (m, SH), 3.16 (dd, 2H, J=7.3, 12.2 Hz), 3.94 (t, 2H, J=7 Hz), 5.39 (bs, 1H),15.89-6.98 (m, 4H), 7.09-7.31 (m, lOH); Anal. Calcd for C28H32NO4FS: C, 67.58; H, 6.48; N, 2.81; Found: C'., fi7.80; H, 6.64; N, 2.74. This was used in the next step without further purification.

Step 6: 6-fN 3-(4-F'luoronhenyl)nronionyllamino-1-[N-(1 2 3 4-tetrahydro-1-methyl 6 7 dimethoxy-isoquinoline))-3 3-diphenvlhexane hydrochloride fComnound III Scheme 4) 6-[N 3-(4-Fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-methyl-6,7-dimethoxy-isoquinoline)]-3,3-diphenylhexane hydrochloride was prepared using the procedure described in example 4 but substituting 6-[N 3-(4-fluorophenyl)propionyl]amino-3,3-diphenylhexyl mesylate for 7-[N 3-(4-fluorophenyl)propiony!)amino-4,4-diphenylheptyl mesylate and 1,2,3,4-tetrahydro-I-methyl-6,7-dimethoxy-isoquinoline hydroiodide for 1-cyclopropyl-4,5-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydroiodide. The obtained residue was purified by a silica gel column chromatography (ethyl acetate to ethyl acetate/methanol (95:5)) to give the product as an amorphous solid: N1S showed (M+ H)+ ~ 609; ~H-NMR (CDC13, 8): 1.11-1.28 (m, SH), 2.00-2.1 I (m, 2H), 2.22 :?.28 (m, IH), 2.35-2.62 (m, 6H), 2.68-3.02 (m, SH), 3.06-3.24 (m, 2H), 3.81 (s, 3H), 3.82 (s, 3H), 3.88 (q, 1 H, J==7 Hz), 5.95 (bt, 1 H), 6.43 ( 1 H, s), 6.49 ( 1 H, s), 6.90-6.97 {2H, m), 7.10-7.29 (12H, m). This .compound was treated with methanol/HCI, the solution was concentrated in vacuo and the residue was dissolved in (1:1) acetonitrile/water and lyophilized to give the hydrochloride salt: IR (MIC) a 3300, 2942, 1646 cm-~; Anal. Calcd for C39HasN203F~HC1 ~ X0.5 H20: C, 71..'>9; H, 7.24; N, 4.28; Found: C, 71.35; H, 7.13; N, 4.01.
Example 71 8-fN 3-(4-Fluoro~henyl)proQOnyllamino-1-fN (1,2.3 4-tetrahydro-1-methyl-6 7-d:imethoxvisoquinolinyl)1-5.5-diphenyloctane hydrochloride Step I : Methyl 7-cyano-5.5-diphenyl-hept-2-enoate !Compound 21, Scheme S) A mixture of 4,4-diphenyl-5-fonmylpentanonitrile ( 1.87 g, 7.1 mmol) and (carbomethoxymethylene)triphenyl phosphorane (2.85 g, 8.5 mmol) in toluene (50 mL) was heated under reflux :for three days. 'I'he reaction mixture was concentrated in vacuo and the residue was purified by silica gel column chromatography to give the desired product as a colorless oil {1.56 g, 69%): MS showed (M+ I-I)+ @ 320; ~H-NMR (CDC13, 8): I
.97-2.02 (m, 2H), 2.44-2.51 (m, 2H), 3.00 (dd, 2H, J=1.4, 7.4 Hz), 3.68 (s, 3H), 5.82 (dt, 1H, J=1.4, 15.6 Hz), 6.52 (dt, IH, J=7.3, 15.6 Hz), 7.10-7.55 (m, 4H), 7.21-7.35 (m, 6H); Anal.
Calcd for C2,H2,N02:
C, 78.97; H, 6.63; N, 4.39; Found: C.', 78.68; H, 6.85; N, 4.27.

Step 2: Methyl 7-cyano-5 5-dphenvlh~tanoate (Compound 22 Scheme 5) To a solution of methyl 7-cyano-5,5-diphenyl-hept-2-enoate ( 1.41 g, 4.41 mmol) in MeOH
(100 mL) was added Pd/C (0.14 g). The reaction mixture was hydrogenated at 4 atm for 21 hr.
The catalyst was filtered and the filtrate was evaporated in vacuo. The oily residue (2 g) was purified by a silica gel column chromatography (eluting with 15:85 mixture of ethyl acetate/hexane) to yield the desired product as a colorless oil (96 %): MS
showed (M+H)+ @
322;'H-NMR (CDCl3, 8): 1.25-1.36 (m, 2H), I.98-2.13 (m, 4H), 2.26 (t, 2H, J=
7.1 Hz), 2.49-2.58 (m, 2H) 3.65 (s, 3H), 7.10-7.I'7 (rn, 4H), 7.21-7.36 (m, 6H); IR (MIC) a 2951, 2247, 1735, 1444, I I96 cm ~; Anal. Calcd for C;Z,Hz~N02: C, 78.47; H, 7.21; N, 4.36;
Found: C, 78.58; H, 7.12; N, 4.14.
Step 3: 8-Amino-5.5-diphenylocta-1-of (Compound 23, Scheme 5~
To a solution of methyl 7-cyano-5,5-diphenyl-heptanoate (1.26 g, 3.92 mmol) in anhydrous THF (7 mL) was added dropwise a aolution of LAH (7.8 mmol) in anhydrous THF
(7.8 mL).
The mixture was stirred at rt for 2 hr. The reaction mixture was quenched by careful addition of 5N NaOH (2.5 mL).. The mixture was stirred at rt for 10 min and then filtered.
The solid was washed twice with diethylether. The organic filtrates were combined, dried (MgZS04) and concentrated in vacuo to give the desired product as solid foam ( 1.03 g, 88 %): MS showed (M+ H)+ @ 298; IH-NMR (CDC1,3, S): 1.00-1.I8 (m, 4H), 1.41-1.57 (m, 2H), 2.05-2.19 (m, 4H), 2.62 (t, J= 7 Hz, 2F1), 3.52 (t, J= 7 Hz, 2H), 7.10-7.36 (m, lOH); IR (MIC) a 3171, 2945, 1597, 1495, 1079 cm''; Anal. Calcd for C2;oI-12~N0 . 0.5 H20: C, 78.38; H, 9.20; N, 4.59; Found: C, 78.92; H, 8.89; N, 4.30.
Sten 4: 8-fN 3-(4-Fluoro~henyl nropionyl~amino-5 5-diphenvloctan-1-of (Compound 24, Scheme 5) To an ice-cold and stirred solution of 8-amino-5,5-diphenylocta-1-of (0.53 g, I .79 mmol) in methylene chloride solution (5 mL) and DMF {0.5 mL) was added 3-{4-fluorophenyi)propionic acid (0.452 g, 2.7 mmol) followed by 1-hydroxybenzotriazole hydrate (HOBt) (0.363 g, 2.7 mmol), triethylamine (0.278, '?.T mmol), and 1-(3-dimethylaminopropyl)-3-ethylcarbo-diimide (EDCI) (0.518 g, 2.7 mmol). The reaction mixture was stirred at room temperature overnight and then concentrated in vacuo. The residue was dissolved in methanol (50 mL) and a solution of LiOH ( 1 M, 8 mL) was added and stirred overnight. The volatiles were evaporated, the residue was diluted with water (10 mL) and extracted with ethyl acetate (3 x 15 mL). The combined organic layers were washed with water, 1 M HCI, water and brine, dried (MgS04) filtered and concentrated in vacuo. The residue was purified by a silica gel column chromatography (e:luting with a gradient of 60 % to 100% ethyl acetate/hexane) yielding the desired compound .as amorphous solid: MS showed (M+ H)+ @ 448; 'H-NMR (CDC13, 8): 0.96-1.16 (m, 4H), 1.37-1.54 (m, 2H), 2..01-2.12 (m, 4H), 2.35 (t, J= 7.2 Hz, 2H), 2.90 (t, J= 7.8 Hz, 2H), 3.08-3.17 (m, 2H), 3.56 (t, J=~ 7 Hz, 2H), 5.16 (bt, 1H), 6.88-6.97 (m, 2H), 7.10-7.36 (m, 12H); Anal. Calcd for CZ9H34FNOz: C, 77.82; H, 7.66; N, 3.13; Found: C, 77.72;
H, 7.76; N, 3.15.
Sten 6: 8-fN 3-(4-Fluoronhenyl)nr~pion~lamino-5.5-diphen~octyl mesylate (Compound 25, Scheme 5~
To a solution of 8-[N-3-(4-fluorophenyl)propionyl]amino-5,5-diphenyloctan-1-of (0.181 g, 0.404 mmol) in methylene chloride (3 mL) was added at 0 °C
methanesulfonyl chloride (0.034 mL) followed by triethylarnine (0.085 mL). The solution was stirred at 0 °C for 30 min.
The reaction mixture was washed mith water, 1 N HCI, water and brine. The organic phase was dried (MgS04) and concentrated in vacuo to give the desired product as an oil (0.201 g, 95%):
MS showed (M+ H)+ @ 526; 'H-NMR (300 MHz, CDCl3, b): 1.00-1.17 (m, 4H), 1.62-1.73 (m, 2H), 2.01 - 2.11 (m., 4H), 2.37 (t, J~= 7.2 Hz, 2H), 2.90 (t, J= 7.8 Hz, 2H), 2.92 (s, 3H), 3.08 -3.18 (m, 2H), 4.16 (t, J = 7 Hz, 2H), 5.24 (bt, 1 H), 6.89-6.96 (m, 2H), 7.10-7.29 (m, 12H). This was used in the next step without further purification.
Step 7: 8-[N 3-(4-F'luorophenvl)propionyllamino-1-[N-(1,2,3,4-tetrahydro-1-methyl-6 7-dimethoxyisoquinolin~15.5-diphenyloctane (Compound IV, Scheme 5) 8-[N 3-(4-Fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-methyl-6,7-dimethoxy-isoquinolinyl)]-5,5-diphenyloctane was prepared using the pracedure described in example 4 but substituting 8-[N 3-(4-fluorophenyl)propionyl]amino-5,5-diphenyloctyl mesylate for 7-{N 3-(4-fluorophenyl)propionyl]amino-4,4-diphenylheptyl mesylate and 1-methyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydroiodide for 1-cyclopropyl-6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinoline hydroiodide. The residue was purified by a silica gel column chromatography using a gradient of (95:5) of ethyl acetate/methanol to give the desired product as an amorphous solid:
MS showed (M+ H)+ @ 637;'H-NMR (CDC13, 8): 0.94-1.13 (m, 5H), 1.27 (d, J= 6.6 Hz, 3H), 1.46-1.55 (m, 2H), 11.99-2.10 (m, 4I-1), 2.32 (t, J= 7.5 Hz, 2H), 2.42 - 2.60 (m, 3H), 2.b7-2.80 (m, 2H), 2.88 (t, J== 8 Hz, 2H), 2.94 - 3.00 (m, 1H), 3.10 (q, J= 6.8 Hz, 2H), 3.73 (q, 1H, J=6.6 Hz), 3.82 (s, 6H), _'>.08 (bt, I H), 6.5 I ( 1 H, s), 6.54 ( 1 H, s), 6.88-6.95 (2H, m), 7.08-7.24 ( 12H, m); IR (MIC) a 33()6, 2935, 1653, 1510, 1224 em-°. This compound was treated with methanol/HCI, the solution was concentrated in vacuo and the residue was dissolved in ( 1:1 ) acetonitrile/water and lyophilized to give 8-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-methyl-6,T-dimethoxy-isoquinolinyl)]-5,5-diphenyloctane hydrochloride: Anal. Calcd for C,~,H4yN203F~HC1 ~ 1.5 H20: C, 70.31; H, 7.62;
N, 4.00; Found:
C, 70.11; H, 7.57; N, 4.22.
Example 72 s-LNs_4-Fluorophenylacetvl) amino-1-[N~1 2 3.4-tetrahydro-1-methyl 6-7-dimethox~isoduinolinyl)]-5,5-diphenyloctane hydrochloride Sten 1: 8-(4-Fluorophenylacetyl)amino-5,5-d~henyloctan-1-of To an ice-cold and stirred solution of 8-amino-5,5-diphenylocta-I-of (Compound 23, Scheme 5) (0.437 g, 1.47 mmol) in methylene chloride solution (5 mL) and DMF
(0.5 mL) was added 4-fluoro-phenylacetic acid (0.34 g, 2.2 mmol) followed by 1-hydroxybenzotriazole hydrate (HOBt) (0.30 g, 2.2 mmol), triethylamine (0.22 g, 2.2 mmol), and 1-(3-dimethylamino-propyl)-3-ethylcarbodiimide (EDCI) (0.422 g, 2.2 mmol). The reaction mixture was stirred at room temperature overnight and then concentrated. The residue was dissolved in methanol (50 mL) and a solution of LiOH ( 1 M, 8mL) was added and stirred overnight.
The volatiles were evaporated, the residue was treated with water ( 10 mL) and extracted with ethyl acetate (3 x 15 mL). The combined organic layers were washed with water, 1 M HCI, water and brine, dried (MgS04) filtered and concentrated in vacuo. The residue was purified by a silica gel column chromatography (using a gradient of 60 % to 100% of ethyl acetate in hexane) yielding the desired product as amorphous solid: MS showed (M+ H)+ @ 434; ' H-NMR
(CDC13, 8):
0.91-1.17 (m, 4H), 1.39-1.51 (m, 2H), 1.95-2.12 (m, 4H), 3.04-3.16 (m, 2H), 3.45 (s, 2H), 3.52 (t, J= 7 Hz, 2H), 5.50 (bt, 1H), 6.95 - 7.36 (m, 14H); Anal. Calcd for C2gH32FN02: C, 77.57; H, 7.44; N, 3.23; Found: C, 77.34; H, 7.55; N, 3.18.
Sten 2: 8-(4-Fluorophenylacetyl)amino-5,5-d~henylhexvl mesvlate To a solution of 8- (4-fluorophenyl)propionylamino-5,5-diphenyloctan-I-of {0.189 g, 0.436 mmol) in methylene chloride (3 mL) was added at 0 °C methanesulfonyl chloride (0.037 mL) followed by triethylamine (0.091 mL). The solution was stirred at 0 °C
for 30 min. The reaction mixture was washed with water, 1 N HCI, water and brine. The organic phase was dried (MgS04) and concentrated in vacuo to give the desired product as an oil (0.198 g, 89 %). This was used in the nexa step without fiarther purification: MS showed (M+ H)+ @ S
12; IH-NMR
S (CDCI3, 8): 1.00-1.14 (m, 4H), 1.63-1.71 (m, 2H), 1.97-2.09 (m, 4H), 2.93 (s, 3H), 3.1 I-3.20 (m, 2H), 3.48 (s, 2H), 4.15 (t, J= 7 Hz, 2H), 5.30 (bt, IH), 6.98-7.28 (m, 14H).
Step 3: 8-[N (4-Fluorophen~rlacetyl~lamino-I-fN (1,2,3,4-tetrahydro-1-methyl-6 7-dimethoxy-isoquinoline)]-S,S-<iiphenyloctane 8-[N (4-Fluorophenylacetyl)]amino-1-[N (1,2,3,4-tetrahydro-1-methyl-6,7-dimethoxy-isoquinoline)]-S,S-diphenyloctane was prepared using the procedure described in example 4 but substituting 8-(4-fluorophenylacetyl)amino-S,S-diphenylhexyl mesylate for 7-[N
3-(4-fluoro-phenyl)propionyl]amino-4,4-diphenylheptyl mesylate and l-methyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydroiodide for 1-cyclopropyl-4,S-dimethoxy-1,2,3,4-tetrahydroiso-1 S quinoline hydroiodi.de. The residue: was purified by a silica gel column chromatog-raphy (using a gradient of 100% to 9S% of ethyl acetate/methanol) to give the desired product as an amorphous solid: MS showed (M+ H)+ @ 623; ~H-NMR (CDC13, 8): 0.94-I.01 (m, 2H), 1.07-1.17 (m, 2H), 1.30 (d, J= 6.7 Hz, 3H), 1.45-I.S6 (m, 2H), 1.96-2.09 (m, 4H), 2.43-2.62 (m, 3H), 2.69-2.86 (m, 2H), 2.97-3.OS {m, 1 H), 3.13 {q, J = 6. I Hz, 2H), 3.45 (s, 2H), 3.77 (q, 1 H, J=6.S
Hz), 3.83 (s, 6H), S..2S (bt, IH), 6.51 (1H, s), 6.54 (s, 1H), 6.97-7.04 (2H, m), 7.07 - 7.25 (12H, m). ; IR (MIC) a 3301, 2934, 1648, 1509, 1225, 1033 crn-~. This compound was dissolved in methanol/HCI, the solution was concentrated in vacuo and the residue was dissolved in ( 1:1 ) acetonitrile/water and lyophilized to give 8-[N (4-fluorophenylacetyl)]amino-1-[N (1,2,3,4-tetrahydro-1-methyl-6,7-dimethoxyisoquinolinyl)]-S,S-diphenyloctane hydrochloride: Anal.
2S Calcd for C4°H47N2O3F'HCl ~ 0.75 HzO: C, 71.40; H, 7.41; N, 4.16;-Found: C, 71.37; H, 7.31; N, 4.06.

Example 73 7-(N 3-(4-Fluoro~hen~~,proniormllamino-1-fN (1,2,3.4-tetrahydro-1-methyl-7-methoxy-3 methox~bonyliso~uinolinyl)1-4.4-diphenylheptane hydrochloride Sten I: 3,4-Dihvdro-7-methoxy-3-methoxycarbonyl-1-methyl-isoquinoline To a solution of N acetyl-D-methyltyrosine methyl ester ( 10 g, 39.8 mmol) in anhydrous dichloromethane (350 mL) was added oxalyl chloride (44 mL, 2 M solution). The reaction mixture was stirred for 1 hr and then cooled to - 10 °C and to it anhydrous iron (III) trichloride (7.75 g, 47.8 mmol) was added portionwise. The stirring was continued overnight at room temperature and then the reaction mixture was treated with 2 M HCl ( 100 mL) for 2 hrs. The organic phase was separated, washed with water and brine, dried (MgS04) and concentrated in vacuo. Methanol (130 mL) and concentrated sulfuric acid (6 mL) were added to the foamy residue and reaction was heated to reflux for 8 hrs. The reaction mixture was concentrated in vacuo, diluted with water ( I 00 mIJ) and extracted with ethyl acetate (2 x 50 mL). The water layer was basified with ammonium hydroxide to pH > 9 and extracted with dichloromethane (3 x SO mL). The oxganic phase was washed with water, brine, dried (MgS04) and concentrated in vacuo. The dark yellow product (8.7 g) was purified by a silica gel column chromatography eluting with (1: I ) ethyl acetate/ hexane to yield 5.61 g (60 %) of yellow product: 'H-NMR
(CDCl3, b): 2.45 (d, J= 2 Hz, 3H), 2.82 - 3.00 (m, 2H), 3.82 (s, 3H), 3.83 (s, 3H), 4.19 (qq, J=
2, 6.8 Hz, 1 H), 6.93 (dd, J = 2.7, 7.5~ Hz, 1 H), 7.05 (d, J = 2.7 Hz, 1 H), 7. I 4 (d, J = 7.5 Hz, 1 H):
MS showed (M+H) + @ 234; Anal. Calcd for C,3H,SN03: C, 66.94; H, 6.48; N, 6.00; Found: C, 66.78; H, 6.36; N, 5.96.
Sten 2: 1,2.3,4-Tetrahvdro-7-methoxv-3-methoxvcarbonyl-1-methyl-isoquinoline To a solution of 3,4-dihydro-7-methoxy-3-methoxycarbonyl-1-methyl-isoquinoline (2.0 g, 8.57 mmol), obtained from the previous step, in MeOH (150 mL) was added Pd/C
(0.2 g). The reaction mixture was hydrogenated i~or 21 hr at 4 atm hydrogen pressure. The catalyst was filtered off and the filtrate was concf:ntrated in vacuo. The oily residue (2 g) was purified by a silica gel column using (1:1) ethyl acetate/ hexane to yield a yellowish oil (94 %): IR (MIC) a 3340, 2951, 1739, 1616, 1503, 1436, 1290, 1228, 1035 cm's; ~H-NMR (CDCl3, 8):
1.51 (d, J=
6.6 Hz, 3H), 2.75 (b:road s, 1H), 2.89 - 3.03 (m, 2H), 3.72 (dd, J= 4.5, 11.1 Hz, 1H), 3.79 (s, 6H), 4. I 4 (q, J = 6.6 Hz, 1 H), 6.71 - 6.75 (m, 2H), 7.02 (d, J = 7.8 Hz, 1 H): MS showed (M+H) +

@ 236; Anal. Calcd for C,3H,~N03 . HCI: C, 57.46; H, 6.68; N, 5.15; Found: C, 57.42; H, 6.64;
N, 5.02.
Step 3: 1,2,3,4-Tetrah~dro-7-methoxv-3-methoxvcarbonvl-I-meth 1-isoquinoline hydroiodide To a solution of 1,2,3,4-tetrahyclro-7-methoxy-3-methoxycarbonyl-1-methyl-isoquinoline (0.526 g, 2.24 mmol) in methanol ( 10 mL) cooled to 0 °C was added dropwise a solution of 57%
HI solution (0.33 mL). The ice bath was removed and the solution was stirred at rt for 20 min.
To the bright orange solution was added ether ( 100 mL) and the mixture was stirred for 10 min.
The light yellow precipitate was filtered and dried in vacuo (P20;) to give the desired salt (0.736 g).
Step 4: 7-fN-3-(4-F'luorophenyl)propionyllamino-I-[N-(1,2,3,4-tetrahvdro-I-methyl-7-methoxv-3-methoxycarbonylisoquinolinyl)1-4.4-diphenylheptane l~drochloride 7-[N 3-(4-Fluorophenyl)propionyl}amino-1-[N (1,2,3,4-tetrahydro-1-methyl-7-methoxy-3-methoxycarbonylisoquinolinyl)}-4,4-diphenylheptane hydrochloride was prepared in a manner analogous to Examl>le 4 but substituting 7-methoxy-3-methoxycarbonyI-I-methyl-1,2,3,4-tetrahydroisoquinoline for I-cyclopropyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydroiodide. The residue was purifiied by a silica gel column chromatography (eluting with a gradient of 100% to 95% of ethyl ac:etate/methanol) yielding an amorphous solid. MS showed (M+ H)+: @ 651; IR: (MIC) a 3303, 2948, 1734, 1647, 1509, 1222, 1034 crri': ~H-NMR (CDCl3, 8): 1.02 - 1.20 (m, 4H), 1.23 {d, J= 6.8 Hz, 3H), 1.99 - 2.06 (m, 4H), 2.35 (t, J= 7.2 Hz, 2H), 2.57 - 2.68 (m, 2H), 2.81 (dd, J= 15.8, 4.8 Hz, 1H), 2.89 (t, J= 7.8 Hz, 2H), 3.01 (dd, J= 15.8, 8.4 Hz, 1H), 3.12 (q, J= 6.1 Hz, 2H), 3.39 - 3.45 (m, IH), 3.63 (s, 3H), 3.70 -3.75 (m, 1H), 3.76 (s, 3H), 5.20 (bt, 1 H), 6.57 (d, J = 2.4 Hz, 1 H), 6.70 (dd, J = 2.4, 8.4 Hz, l H), 6.86 - 6.95 (m, 2H), 7.00 (d, J= 8.4, 1H), 7.07 - 7.25 (12H, m). This compound was dissolved in methanol/HCI, the solution was concentrated in vacuo and the residue was dissolved in (l:l) acetonitrile/water and lyophilized to g ve 7-[N 3-(4-fluorophenyl)propionyl}amino-1-[N (1,2,3,4-tetrahydro-1-methyl-7-methoxy-.c-methoxycarbonylisoquinolinyl)}-4,4-diphenylheptane hydrochloride: Anal.
Calcd for C4,H4~N204F~HCl ~ 0.5 I-IZO: C, 70.72; H, 7.09; N, 4.02; Found: C, 70.84; H, 7.19; N, 3.87.

Example 74 7-(N 3~~(4-Fluorophenyl)propionvllamino-1-[IV (I,2.3 4-tetrahydro-3-(2 hvdroxyethylaminocarbonvl)- I -methyl-7-methoxyisoquinolinyfl 4,4-diphen~ptane hydrochloride 7-[N 3-(4-Fluorophenyl)propionyl] amino-1-[N (1,2,3,4-tetrahydro-1-methyl-7-methoxy-3-methoxycarbonyl:isoquinoline)]-4,4-diphenylheptane (72 mg) was dissolved in DMF (0.5 mL) and ethanolamine (1 mL) and the solution was stirred for 3 days at room temperature. The reaction mixture was concentrated in vacuo to give an oily residue which was purified by a silica gel column chromatography (eluting with a gradient of 100% to 95% of dichloromethane/
methanol). MS showed (M+ H)+ @ 680; IR (MIC) a 3304, 2938, 1651, 1510, 1222, 1032 cm'';
'H-NMR (CDC13, 8): 0.95 - 1.30 (rra, 7H), 1.92 - 2.09 (m, 4H), 2.34-2.53 (m, 4H), 2.76-3.70 (m, 12H), 3.77 (s, 3H), :5.23 (broad t, 1 H), 5.48 (broad t, 1 H), 6.57 - 6.60 (m, 1 H), 6.69-6.74 (m, 1 H), 6.86-6.95 (m, 2H), ',x.07-7.25 (m, 13H). This compound was dissolved in methanol/HCI, the solution was concentrated in vacuo and the residue was dissolved in (1:1 ) acetonitrile/water and lyophilized to give ;~-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-3-(2-hydroxyethylaminocarbonyl)-1-methyl-7-methoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride; Anal. Calcd for Cd2Fi5oN304F~HC1: C, 70.42; H, 7.18; N, 5.87;
Found: C, 69.96;
H, 7.35; N, 5.71.
Example 75 7~N ~~4-Fluorophenyl)propionyl]amino-1-jN-( 1,2,3,4-tetrahydro-(3-h~~.roxyprop ~~lamir~ocarbonyl)-I-methyl-7-methoxyisoquinoline)1-4,4-diphenylheptane hydrochloride The procedure described in exannple 74 was used but substituting 3-amino-I-propanol for ethanolamine. The obtained residue was purified by a silica gel column chromatography (using a gradient of 100% t:o 95% dichloromethane/methanol) to yield the desired product as an amorphous solid: IV(S showed (M+ H)~ @ 694; IR (MIC) a 3296, 2943, 1669, 1510, 1201 cm-~;
1H-NMR (CDC13, 8;1: 0.95-1.37 (m, 7H), 1.50-1.76 (m, 2H), 1.90-2.08 (m, 4H), 2.34-2.59 (m, 4H), 2.80-3.56 (m, 12H), 3.77 (s, 3I-i), 5.36 (bs, 2H), 6.58-6.75 (m, 2H), 6.84-6.93 (m, 2H), 7.07-_87_ 7.25 (m, 13H). This compound was dissolved in methanolJHCI, the solution was concentrated in vacuo and the residue was dissolved in ( 1:1 ) acetonitrile/water and lyophilized to give 7-[N 3-(4-fluorophc;nyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-3-(3-hydroxypropyl-aminocarbonyl)-1-methyl-7-methoxyisoquinoline)]-4,4-diphenylheptane hydrochloride: Anal.
Calcd for C43HSZN3~04F~HC1: C, 70.71; H, 7.31; N, 5.75; Found: C, 70.40; H, 7.38; N, 5.60.
Example 76 7- N 3-~(4-Fluoronhenyl)pronionvllamino-1-[N (1 2 3.4-tetrahvdro-3-(4 hydroxybutylaminoc;arbonyl)-1-methyl-7-methoxyisoquinolinyl,)]_ 4,4-diphenvlheptane hydrochloride The procedure described in example 74 was used but substituting 4-amino-1-butanol for ethanolamine. The .crude residue was purified by a silica gel column chromatography (eluting with a gradient of 100% to 95% of dichloromethane/methanol) to yield the desired product as an amorphous solid: NIS showed (M+ H)+ @ 708; IR (MIC) a 3294, 2938, 1653, 1510, 1221 cm-~;
'H-NMR (CDC13, 81: 0.98-1.50 (m, 11H), 1.92-2.06 (m, 4H), 2.34-2.53 (m, 4H), 2.80-3.62 (m, 12H), 3.78 (s, 3H), X4.22 (t, J = 8.8 Hz, 1 H), 5.39 (broad t, 1 H), 5.51 (broad t, 1 H), 6.61-6.73 (m, 2H), 6.87-6.95 (m, 2H), 7.02-7.29 (rn, 13H). This compound was dissolved in methanol/HCI, the solution was concentrated in vacuo and the residue was dissolved in (1:1) acetonitrile/water and lyophilized to give 7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-3-(4-hydroxybutylarninocarbonyl)-1-methyl-7-methoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride; Anal. Calcd for C44H54N3~4F HCl ~ HzO: C, 70.14; H, 7.49; N, 5.61; Found: C, 69.97; H, 7.51; N, 5.37.
Example 77 7-[N 3-(4-Fluoro_phery~nronionyl]amino-1-[N (1,2,3,4-tetrahvdro 1-methyl-7~-methoxv-3-~2-(N-pyrrolidinvl)ethvlaminocarbonyl isoquinolinyl)1 4,4-diphen~heptane hydrochloride The procedure described in exarr~ple 75 was used but substituting N (2-hydroxyethyl)-pyrrolidine for ethanolamine. The residue was purified by a silica gel column chromatography (using a gradient of :100% to 95% of dichloromethane/methanol) to yield the product as an amorphous solid: MS showed (M+ fl)+ (c~ 733;'H-NMR (CDCl3, b): 0.79-1.12 (m, 4H), 1.36 (d, _88_ J= 6.8 Hz, 3H), 1.75-2.17 (m, 8H;), 2.38-2.58 (m, 9H), 2.84-2.95 (m, SH), 3.08-3.19 (m, 4H), 3.24-3.30 (m, 1 H), 3.47 (q, J = 6.8 Hz, 1 H), 3.77 ( s, 3H), 5.77 (bt, 1 H), 6.64 (d, J = 3.4 Hz, 1 H), 6.70 (dd, J = 3.4, 8..1 Hz, 1 H), 6.8(i-6.95 (m, 2H), 7.03 (d, J = 8.1 Hz, 1 H), 7.07 - 7.26 (m, 12H}.
This compound was dissolved in methanol/HCI, the solution was concentrated in vacuo and the residue was dissolved in ( 1:1 ) acetonitrile/water and lyophilized to give 7-[N 3-(4-fluorophenyl) propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-methyl-7-methoxy-3-(2-(N
pyrrolidinyl)-ethyl aminocarbonyl)isoquinolinyl))-4,4-diphenylheptane hydrochloride.
Example 78 7-IN 3-(4-Fluorophen~l~ropionvl]amino-1-[N-(1.2,3,4-tetrahvdro-1-methvl-3-hydroxymethyl-7-metho xyisoquinolinyl)1-4,4-diphenylh~tane hydrochloride Step 1: 1,2,3,4-Tetrahydro-1-methyl-3-hydroxymethyl-7-methoxyisoguinoline To a solution of 1,2,3,4-tetrahydro-1-methyl-3-methoxycarbonyl-7-methoxyisoquinoline I S (0.67 g, 2.87 mmol) (described in example 73) in anhydrous tetrahydrofuran (5 mL) was added dropwise 1 M solution of lithium aluminium hydride (5.7 mmol) in anhydrous tetrahydrofuran (5.7 mL). The mixture was stirred at rt for 3 hr. The reaction mixture was quenched by a careful addition of SN NaOH (2 mL). The mixture was stirred at room temperature for 10 min and then filtered and the solid was washed twice with diethylether. The organic filtrates were combined, dried {MgS04) and concentrated in vacuo to give the desired product as solid foam (0.486 g, 82 %): ' H-NMR (CDC13, b) 1.48 (d, J = 6.3 Hz, 3H), 2.46-2.67 (m, 2H), 3.04-3.12 (m, 1 H), 3.72 (dd, J = 8.4, 11.1 1-I:z, 1 H), 3.72-3.8~ 1 (m, 1 H), 3.79 (s, 3H), 4.08 {q, J
= 6.3 Hz, 1 H), 6.71 - 6.75 (m, 2H), 7.02 (d, J = 7.8 Hz, 1 H): rvlS showed (M+H) + @ 208.
Step 2: 1,2,3,4-Tetrahydro-1-methyl-3-hydroxvmethyl-7-methoxvisoquinoline hvdroiodide To a solution of 1,2,3,4-tetrahydro-1-methyl-3-hydroxymethyl-7-methoxyisoquinoline (0.486 g, 2.3 mmol) in methanol (10 mL) cooled to 0 °C was added dropwise a solution of 57%
HI solution (0.34 rr~L). The ice bath was removed and the solution was stirred at rt for 20 min.
To the bright orange solution was added ether (100 mL) and the mixture was stirred for 10 min.
The light yellow precipitate was filtered and dried in vacua {P2O5} to give the desired salt.

Step3: 7-[N 3-(4-Fluorophenyl)prcrpionyllamino-1-~N (1,2,3,4-tetrahydro-1-methyl-3-hydroxymethvl-7-methoxyisoquinoline)]-4,4-dinhenylheptane 7-[N 3-(4-Fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-methyl-3-hydroxy-S methyl-7-methoxyi~soquinoline)J-4,4-diphenylheptane was prepared using the procedure described in example 4 but substituting 1,2,3,4-tetrahydro-1-methyl-3-hydroxymethyl-7-methoxyisoquinoline hydroiodide, from previous step, for 1,2,3,4-tetrahydro-1-cyclopropyl-4,5-dimethoxyisoquinoline hydroiodide. The residue was purified by a silica gel column chromatography (eluting with a gradient of 100% to 95% of ethyl acetate/methanol) to yield an amorphous solid: MS showed (M+ H)+ @ 623; IR (MIC) a 3290, 2929, 1647, 1510, 1222, 1032 cm-~;'H-NMR (CI7C13, 8): 0.83-1.18 (m, 4H), 1.41 (broad d, 3H), 2.01-2.11 (m, 4H), 2.43 (t, J=
7.5 Hz, 2H), 2.57-2..78 (m, 3H), 2..9:2 (t, J= 7.2 Hz, 2H), 3.01 (dd, J= 15.8, 8.4 Hz, 1H), 3.13-3.20 (m, 2H), 3.44-:3.72 {m, 2H), 3.'77 (s, 3H), 5.75 (bs, 1 H), 6.58 (d, J =
2.4 Hz, 1 H), 6.70 (dd, J
= 2.4, 8.4 Hz, I H),15.88-6.97 (m, 2H), 7.04 (d, J = 8.4, 1 H), 7.08-7.28 ( 12H, m). This compound was dissolved in methanol/HC1, the solution was concentrated in vacuo and the residue was dissolved in (1:1) ac;etonitrile/water and lyophilized to give 7-[N 3-(4-fluorophenyl)propionyl]-amino-1-[N (1,2,3,4~-tetrahydro-1-methyl-3-hydroxymethyl-7-methoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride.
Example 79 The procedure described in example 1 was used wherein the appropriate acids were substituted for 3-(4-fluorophenyl)propionic acid. After workup and chromatographic purification the following compounds were obtained:
(79a) 7-[N 3-(phen,~l)nropion2rllamino-I-fN (1,2,3,4-tetrahydro-1-methyl-6 7-dimethoxyisoquinolinyl)1-4 4-diphenylheptane hydrochloride: MS showed (M+ H)+
@ 605.
(79b) 7- N 3- 3 4-dichloronhenvl)nronionyliamino-1-jN (1,2.3,4-tetrahydro-I-meth dimethoxyisoquinolinvl)]_,4,4-diphe:nvlheptane hydrochloride: MS showed (M+
H)+ @ 675.
(79c) 7- N 3- 3,4-difluorophem~)propionyllamino-1-fN (1,2,3,4-tetrahydro-1-m_ethyl-6 7-dimethoxyisoquinolinvl)1-4,4-diphe:n~heptane hydrochloride: MS showed (M+ H)+
@ 64I; mp 96-99 °C; Anal. Calcd for C4°Ha6Nz'~3Fz~HCI 1.25H20: C, 68.65;
H, 7. i 2; N, 4.00; Found: C, 68.45; H, 7.12; N, 3.99.
~79d) 7-jN 3-y3-fluoro-4-chloro=phenyl,)propionyllamino-1-[N (1 2 3 4-tetrahydro-1-methvl-6,7-dimethoxyisoquinolinyll~]-4.4-dinhen~lheptane hydrochloride: MS
showed (M+ H)+

@ 658; mp 99-103 °C; Anal. Calcd for C4°Ha6N243C1FHC1~1.25Hz0:
C, 66.65; H, 6.99; N, 3.88;
Found: C, 66.96; H(, 6.99; N, 3.93.
(79e) 7-fN 3-(4-fluoro-3-chloro-phenyl)t~ropionyllamino-I-[N (I 2 3 4-tetrahydro 1 methyl-6.7-dimethoxvisoquinolinyl)]-4 4-diphenvlheptane hydrochloride: MS
showed (M+ H)+
@ 658.
(79fj 7-fN 3-13 4-dimethoxyphenyl)propionyl]amino-1-fN (1 2 3 4 tetrahydro 1 methy_I
6,7-dimethoxyisoquinolinyl)1-4 4-diphenvlheptane hydrochloride: MS showed (M+
H)+ @ 681.
(79g) 7- N 3-(4-methoxyphenyl)nronionyllamino-I-fN (1,2 3 4-tetrahydro-I-methyl-6 7-dimethoxvisoguinolinyl)]-4.4-diphenylheptane hydrochloride: MS showed (M+ H)+
@ 651.
(79h) 7- N 3-(4-chlorophenvl)pronionvllamino-I jN-(1 2.3 4-tetrahydro-1-methyl-dimethoxyisoquinoiinvl)]-4,4-diphenylheptane hydrochloride: MS showed (M+ H)+
@ 640.
(79i) 7-[N-3-(4-fluoro~henyl)acetyIlamino-I-[N-(1.2,3,4-tetrahydro-1-methyl-6 dimethoxYisoquino(inyl)j-4,4-diphen~ptane hydrochloride: MS showed (M+ H)+ @
609.
Example 84 7-[N 3-(4-Fluorophenyl)propionyllamino-I-[N (1,2,3,4-tetrahydro-1-(3-N
phthalimidopropyll 6_7~~dimethoxvisogyinolin~)]-4,4-diphenvlheptane hydrochloride The procedL~re described in .example 22 was used substituting in the first step 4-N
phthalimidobutyric acid for N phthalimidoglycine. After work up and chromatographic purification 7-[N-3-(4-fluorophenyl)propionyi]amino-I-[N (1,2,3,4-tetrahydro-1-(3-N
phthalimidopropyl)~-6,7-dimethoxyisoquinolinyl))-4,4-diphenylheptane was obtained: MS
showed (M+ H)+ @ 797. The hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluorophe;nyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-(3-N
phthalimidopropyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride.
Example 81 7-[N 3-(4-Fluorophen~l)propionvllamino-1-[N-(1,2.3 4-tetrah dro-1 ~3-amino~pronyl) 6 7-dimethoxyisoqu~inolinyl)1-4.4-diphenylheptane hydrochloride The procedure described in example 22 was used but substituting 4-N
phthalimidobutyric acid for N phthalimidoglycine in stc;p 1. After work up and chromatography 7-[N 3-(4-fluora-phenyl)propionyl]amino-I -[N-( 1,2,3,4-tetrahydro-1-(3-aminopropyl)-6,7-dimethoxy-isoquinolinyl)]-4,4-diphenylheptane was obtained: MS showed (M+ H)+ @ 666. The hydrochloride salt was prepared as in example 4 to give 7-[N 3-{4-fluorophenyl)propionyl]-amino-1-[N (1,2,3,4-tetrahydro-1-(3-aminopropyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenyl-heptane hydrochloride: Anal. Calcd for C42Hs2FN303~2HC1~1.25H20: C, 66.26; H, 7.48; N, 5.51;
Found: C, 66.02; H, 6.96; N, 5.52.
Example 82 7- N 3-(4-Fluorophenyl)nropionyl]amino-1-[N-(1 2 3 4-tetrahydro-1 j3-iV-(biscyclobuyilamino)nropvll-6,7-dimethoxyisoquinolinyl~]
4.4-diphenvlheptane dihydrochloride The procedure described in example 28 was used but using an excess of cyclobutanone in the reductive alkylation step. After workup and chromatographic purification 7-[N 3-(4-fluoro-phenyl)propionyl]a~nino-I-[N (1,2,:3,4-tetrahydro-1-[3-N
(biscyclobutylamino)propyl]-6,7-dimethoxyisoquinolinyl)]-4,4-diphewylheptane was obtained: MS showed (M+ H)+ @
774. The hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluorophenyl)propionyl]-amino-1-[N (1,2,3,4-tetrahydro-I-[3-N (biscyclobutylamino)propyl]-6,7-dimethoxy-isoquinolinyl)]-4,4-diphenylheptane; dihydrochloride: Anal. Calcd for CSOH6aFN303~2HC1~H20:
C, 68.01; H, 7.99; N, 4.75; Found: C, 67.37; H, 7.79; N, 4.82.
Example 83 7-[N 3-(4-Fluorophenyl)propionyllamino-1-LN (1 2 3 4-tetrahydro-1-f 3-N (biscycloprop~me;thylamino)propel]-6,7-dimethoxyisoquinolinyl)1 4.4-diphenylheptane dihydrochloride The procedure described in example 82 was used but substituting cyclopropylcarbox-aldehyde for cyclobutanone. After workup and chromatographic purification 7-[N
3-(4-fluoro-phenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-[3-N (biscyclopropylmethyl-amino)propyl}-6,7-dimethoxyisoquinolinyl)]-4,4-di.phenylheptane was obtained: MS showed (M+
H)+ @ 775.
The hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluoro-phenylpropionyl)]-I-[N (1,2,3,4-tetrahydro-I-[3-N (bis;cyclopropylmethylamino)propyl]-6,7-dimethoxy-isoquinolinyl)]-4,4-diphenylheptane dihydrochloride: Anal. Calcd far CSoH~FN303~2HC1~H20:
C, 68.35; H, 7.97; N, 4.78; Found: C:, 68.10; H, 7.57; N, 4.83.

Example 84 7-IN 3-(4-Fluorophenyl)propionyl]amino-I-[N-(1.2.3.4-tetrahydro-1-j;3-N (dimethylamnino)propvll-6,7-dimetho~isoquinolinvl)1-4,4-diphenylheptane dihydrochloride The procedure described in example $2 was used but substituting formaldehyde for cyclobutanone. After workup and chromatographic purification 7-[N 3-(4-fluorophenyl-propionyl)]amino-I-[N (1,2,3,4-tetrahydro-I-(3-N (dimethylamino)propyl]-6,7-dimethoxy-isoquinolinyl)]-4,4-diphenylheptane; dihydrochloride was obtained: MS showed (M+ H)+ @ 693.
The hydrochloride :.alt was prepared as in example 4 to give 7-[N 3-(4-fluorophenyl)propionyl]-amino-1-[N (1,2,3,4-tetrahydro-I-[3-N {dimethylamino)propyl]-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptanc~ dihydrochloride.
1 S Example 85 7~-3-(4-Fluorophenyl,)propionyl]iamino-1-[N (1,2,3,4-tetrahvdro-1-[3-N-(isopropyl)-propyl]-6,7-dimethoxyisoguinolinyl)1-4.4-diphenvlheptane dihydrochloride The procedure described in example $2 was used but substituting acetone for cyclobutanone. After workup and chromatographic purification 7-[N 3-(4-fluorophenyl-propionyl)]amino-1~-[N (1,2,3,4-tetrahydro-I-(3-(N-isopropyl)propyl)-6,7-dimethoxy-isoquinolinyl)]-4,4-diphenylheptane; dihydrochloride was obtained: MS showed (M+ H)+ @ 70$.
The hydrochloride salt was prepared as in example 4 to give 7-[N 3-{4-fluorophenyl)propionyl]-1-[N (1,2,3,4-tetrah;ydro-I-[3-N (isopropyl)-propyl]-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride.

Example 86 7-[N 3-(4-Fluorophenyl)propionyl]amino-1-1N (1,2,3,4-tetrahydro-1-(5-N phthalimidopentyl)-6,7-dimethoxyiso~uinolin~)1-4.4-dliphenvlheptane hydrochloride The procedure described in example 22 was used but substituting 6-N
phthalimido-hexanoic acid for N phthalimidoglycine in step 1. After work up and chromatographic purification 7-[N-3-(4-fluorophenyl)propionyl]amino-I-[N (1,2,3,4-tetrahydro-1-(5-N phthalimidopentyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane was obtained:
MS showed (M+ H)+ @ 824. 'the hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluorophe:nyl)propionyl]-1-[lV (1,2,3,4-tetrahydro-1-(5-N
phthalimidopentyl)-6,7-dimethoxyisoqu:inolinyl)]-4,4-diphenylheptane hydrochloride.
Example 87 7-[N 3-(4-Fluorophenyl)propionyl amino-1-jN (1,2,3,4-tetrahydro-1-(5-aminopentyl)-6,7-dimethoxyisoauinolinvl)j;4.4-diphenylheptane dihydrochloride The procedure described in example 22 for cleavage of the phthalimido group from 7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-(5-N
phthalimidopentyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane was used. After work up and chromatographic 7-[N 3-(4-fluorophenyl)propionyl]amino-I-[N (1,2,3,4-tetrahydro-1-(5-aminopentyl)-6,7~-dimethoxyisoquinolinyl)]-4,4-diphenylheptane was obtained: MS showed (M+ H)+ @ 694. The hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluoro-phenyl)propionyl]-amino-1-[N (1,2,:3,4-tetrahydro-I-(5-aminopentyl)-6,7-dimethoxyiso-quinolinyl)]-4,4-diphenyl-heptane diihydrochloride: Anal. Calcd for C44H;6FN3U3~2HC1~HZO: C, 67.33; H, 7.70; n, 5.:35; Found: C, 6'7.10; H, 7.24; N, 5.24.

Example 88 7- N 3- 4-~Fluorophenvl)aropionvllamino-1-[N (1,2,3,4-tetrahvdro-1-f5-N (bis-c clout loo)pentyll-6,7-dimethoxyisoauinolinvl)1-4.4-diphenvlheQtane dihvdrochloride The procedure described in example 82 was used but substituting 7-[N 3-{4-fluoro-phenyl)propionyl]amino-1-[N {1,2,3,4-tetrahydro-1-(5-aminopentyl)-6,7-dimethoxy-isoquinolinyl)]-4,4-diphenylheptane for 7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-(3-aminopropyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane.
After work up and chromatographic purification 7-[lV 3-(4-fluorophenyl)propionyl]amino-1-[N
(1,2,3,4-tetrahydro-I-[5-N (biscyclobutylamino)pentyl]-6,7-dimethoxyisoquinolinyl)]-4,4-diphenyl-heptane was obtained: MS showed (M+ H)+ @ 802. The hydrochloride salt was prepared as in example 4 to give T-[N 3-(4-fluoro~phenyl)propionyl]amino-1-[N {1,2,3,4-tetrahydro-1 [5-N (biscyclobutyl.amino)pentyl]-ti,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride.
Example 89 7-LN 3 ~4-Fluorophenyl)propionvllamino-1 jN~1.2.3.4-tetrahydro-1 5-N biscyclopropylmethylamino)pentyll-6.7-dimethoxyisoquinolinylll 4,4-diphenylheptane dihydrochloride The procedure described in example 88 was used but substituting cyclopropylcarbox-aldehyde for cyclobutanone. After work up and chromatographic purification 7-[N 3-(4-fluoro-phenyl)propionyl]amino-1-[N (1,2,:3,4-tetrahydro-1-[5-N
(biscyclopropylmethylamino)pentyl]-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane was obtained: MS showed (M+
H)+ @ 802.
The hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluorophenyl)-propionyl]amino-1-[N (1,2,3,4-tetrahydro-1-[5-N (biscyclopropylmethyl-amino)pentyl]-6,7-dimethoxyisoquinolinyl)]-4,4-diphesnylheptane dihydrochloride: Anal. Calcd for Cs2H6sFNs~3'ZHCI~HZO: C, 68.55; H, 8.18; N, 4.61; Found: C, 67.87; H, 7.84; N, 4.59.

Example 90 7-[N-3-(4-Fluoronhenvl)propionyllamino-1-fN (1.2,3,4-tetrahydro-1-[5-N~dimethylamino)pentyll-6,7-dimethoxyisoquinolinyl)1-4,4-diphenvlheptane dihydrochloride The procedure described in example 88 was used but substituting formaldehyde for cyclobutanone. After work up and chromatographic purification 7-[N-3-(4-fluorophenyl)-propionyl]amino-1-~=N-( 1,2,3,4-tetrahydro-1-[5-N-(dimethylamino)pentyl]-6,7-dimethoxy-isoquinolinyl)]-4,4-diphenylheptane was obtained: MS showed (M+ H)+ @ 722. The hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluorophenyl)propionyl]-amino-1-[N (1,2,3,4-tetrahydro-1-[S-N (dimethylamino)pentyl]-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane: dihydrochlorid~e.
Example 91 7- N-3-(4-Fluorophenyl)propionyl]amino-1-[N (1.2.3.4-tetrahydro-1-j5-N-(isopropylamino)pentyl]-6,7-dimethox~quinolinvl)1-4,4-dinhenylheptane dihydrochloride The procedure described in example 88 was used but substituting acetone for cyclobutanone. After work up and chromatographic purification 7-[N 3-(4-fluorophenyl-propionyl)]amino-I-~[N (1,2,3,4-tetrahydro-1-[5-N-(isopropylamino)pentyl]-6,7-dimethoxy-isoquinolinyl)]-4,4-diphenylheptane was obtained: MS showed (M+ H)+ @ 736. The hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluorophenyl)propionyl]-amino-1-[N (1,2,3,4-tetrahydro-1-[5-N (isopropylamino)pentyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane: dihydrochloride: Anal. Calcd for C47H62FN3O3~O.7S H2O: C, 75.15; H, 10.33; N, 5.59; Found: C, 74.99; H, 8.34; N, 5.51.
Example 92 7-[N 3-(4-Fluorophenyl?propionyll 1-[,N-11,2,3.4-tetrahydro-1-cyclobutyl-6-fluoro-7-methoxyisoquino~lin~l)1-4,4-diphen~ptane hydrochloride The procedure described in example 9 was used but substituting 1,2,3,4-tetrahydro-I-cyclobutyl-6-fluoro-7-methoxyisoquinoline for 1,2,3,4-tetrahydro-1-cyclobutyl-6,7-dimethoxy-isoquinoline. After workup and chromatographic purification 7-[N 3-(4-fluorophenyl)-propionyl]-1-[N (1,2,3,4-tetrahydro-1-cyclobutyl-6-fluoro-7-methoxyisoquinolinyl)]-4,4-diphenylheptar~e was obtained: MS showed (M+ H)+ @ 651;'H-NMR (CDC13, 8):
1.05-I.21 (m, 4H), 1.62-1.90 (m, SH) 1.90-2.17 (m, SH), 2.25-2.58 (m, 6H), 2.60-2.76 (m, 2H), 2.84-2.92 (t, 2H), 2.97-3.09 (m, 1H), 3.09-3.:?0 (m, 3H), 3.81 (s, 3H), 5.11 (broad m, 1H), 6.47-6.53 (d, 1H), 6.69-6.76 (d, 1H), 6.86-6.95 (t, 2H), 7.05-7.29 (m, 12H); IR (MIC) a 3310, 2940, 1630, 1510 cm ~. The hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluorophenyl)propionyl]-1-[N (1,2.,3,4-tetrahydro-1-cyclobutyl-6-fluoro-7-methoxyisoquinolinyl)J-4,4-diphenylheptane hydrochloride.
Example 93 7-[7V'~4-Fluorophenyl)propionyl]amino-1-((N [1,2,3.4-tetrahydro-1-~4-N-phthalimidobutyl)-6-methyl-7-methoxy isoquinolin~)1-4.4-diphenvlheptane The synthetic procedure described in example 24 was used but substituting 1,2,3,4-tetrahydro-1-(4-N-phthalimidobutyl)-6-methyl-7-methoxyisoquinoline for substituting 1,2,3,4-tetrahydro-1-(4-N-phthalimidobutyl)-6,7-dimethoxyisoquinoline. After workup and purification with a silica gel column chromatography 7-[N 3-(4-fluorophenyl)propionyl]amino-1-[(N [1,2,3,4-tetrahydro-1-(4-N=plhthalimidobutyl)-6-methyl-7-methoxyisoquinolinyl)]-4,4-diphenylheptane was obtained: MS. showed (M+ H)+ @ 794; ~H-NMR (CDCI~, 8):
1.08-1.23 (m, 4H), 1.38-1.51 (m, 2H), 1.56-1.79 (m, SH), 1.98-2.13 (m, 3H), 2.14 (s, 3H), 2.29-2.52 (m, SH), 2.56-2.74 (m, 2H), 2.87-2.93 (t, 2I;f), 2.95-3.08 (m, 1H), 3.09-3.24 (m, 2H), 3.29-3.37 (m, 1H), 3.61-3.72 (t, 2H), 3..78 (s, 3H), 5.4.?-5.50 (broad m, 1H), 6.43 (s, 1H), 6.58 (s, 1H), 6.87-6.95 (t, 2H), 7.07-7.29 (m, 12H); IR (KBr) a 2940, 1755, 1720, 1510 cm's.
Example 94 7-[N 3-(4-Fluoronhenvl)propior~yl]-1-j(N-(1,2,3,4-tetrahydro-1-(4-aminobutyl)-6-methyl-7-methoxyisoquinolinYl)~ 4.4-diphenylheptane The synthetic procedure described in example 22 for the cleavage of the phthalimido group was used. After workup and purification with a silica 7-[N 3-(4-fluorophenyl)propionyl]-amino-1-[(N-[ 1,2,3,4-tetrahydro-1-(4-aminobutyl)-6-methyl-7-methoxyisoquinolinyl)]-4,4-diphenylheptane was obtained: MS showed (M+ H)~ @ 664; 'H-NMR (CDC13, 8): 1.04-1.28 (m, 4H), 1.34-1.76 (m, 6H), 1.95-2.13 (m, 3H), 2.14 (s, 3H), 2.30-2.41 (m, 3H), 2.41-2.48 (t, 2H), 2.56-2.76 (m, 4H), 2.82-2.92 (t, 2H}, 2.95-3.22 (m, 6H), 3.32-3.41 (broad q, 1 H), 3.27 (s, 3H), 5.65-5.73 (broad t, 1 Vii), 6.41 (s, 1 H), 6.78 (s, 1 H), 6.87-6.94 (t, 2H), 7.07-7.28 (m, 12H); IR
(KBr) a 3280, 2940, 1630, 1510 cm"'.
Example 95 7- N 3~-(4-Fluorophen~)propionyl]amino-I-j(N-(1,2,3.4-tetrahydro-1-(4-l~l iso~ropylaminobu~l)-6-methyl-7-methoxyisoquinolinvl)1-4,4-dinhenylheptane 7-[N-3-(4-Fluorophenyl)propionyl]amino-1-[(N-( 1,2,3,4-tetrahydro-1-(4-aminobutyl)-6-methyl-7-methoxyisoquinolinyl)]-4;4-diphenylheptane was reductive alkylated upon treatment with acetone and sodium cyanoborohydride as described in example 26. After workup and purification with a silica 7-[N 3-(4-fluorophenyl)propionyl]amino-I-[(N-[1,2,3,4-tetrahydro-1-(4-N-isopropylamir~obutyl)-6-methyl-7-methoxyisoquinolinyl)]-4,4-diphenylheptane was obtained: MS showed (M+H)+ @ 706; ~H-NMR (CDC13, 8): 1.02-1.29 (m, SH), 1.13-1.16 (d, 6H), 1.33-1.48 (m, 2H), l.Sl-1.75 (m, 4H), 1.94-2.12 (m, 4H), 2.14 (s, 3H), 2.28-2.48 (m, SH), 2.53-2.71 (m, 4H), 2.83-3.04 (m, 4I-1), 3.07-3.18 (broad q, 2H), 3.32-3.42 (m, 1H), 3.77 (s, 3H), 5.52-5.59 (broad t, 1 H), 6.41 (s, 1 H}, 6.78 (s, 1 H), 6.88-6.96 (t, 2H), 7.07-7.29 (m, 12H); IR
(KBr) a 3280, 2940, 1630, 1510 cm~~.
Example 96 7-fN 3-(4-Fluoro~henyl)propiony~amino-I-[(N-(1,2,3,4-tetrahydro-1-cyclobut ~~1-6-methyl-7-methoxvisoauinolinvl)L4,4-diphenylheptane h~rdrochloride The procedurE: described in ex~unple 92 was used but substituting 1,2,3,4-tetrahydro-1-cyclobutyl-6-methyl-7-methoxyisoquinoline for 1,2,3,4-tetrahydro-1-cyclobutyl-6-fluoro-7-methoxyisoquinoline. After workup~ and purification by a silica gel column 7-[N-3-(4-fluoro-phenyl)propionyl]amino-1-[(N [1,2.,3,4-tetrahydro-1-cyclobutyl-6-methyl-7-methoxy-iso-quinolinyl)]-4,4-diphenylheptane: MS showed (M+ H)t @ 647; 'H-NMR (CDC13, 8):
1.04-1.22 (m, 4H), 1.62-2.0 (m" 6H), 2.0-2.15 (m, 4H), 2.17 (s, 3H), 2.23-2.58 (m, 6H), 2.61-2.77 (m, 2H), 2.83-2.92 (t, 2H), 2.98-3.08 (m, 1H), 3.08-3.21 (m, 3H), 3.75 (s, 3H), 5.06-5.10 (broad t, 1H), 6.39 (s, 1H), 6.79 (s, IH), 6.85-6.96 (t, 2H), 7.05-7.28 (m, 12H); IR (KBr) a 3320, 2940, 1635, 1510 cm ~. The hydrochloride salt was prepared as in example 4 to give 7-[N 3-(4-fluoro-phenyl)propionyl]amino-1-[(N [1,2,3,4-tetrahydro-1-cyclobutyl-6-methyl-7-methoxy-isoquinolinyl)]-4,4-diphenylheptane hydrochloride.
LHRH ANTAGONIST ACTIVITY
Representative compounds of the present invention were evaluated in vitro for potency against for LHRH rat pituitary receptor binding [pK, ]. Methods for the assay procedures are described in F. Haviv, et al. J. Med. C~~em., 32: 2340-2344 (1989).
Values of pK, are the negative logarithms of the equilibrium dissociation constant of the particular antagonist 'test compound for the receptor binding. Typically values of 7.0 or greater are indicative of good LHRI~ antagani~,st potency, with values of 8.0 or greater being preferred.
Leuprolide LHRH agonist, disclosed and claimed in U.S. Pat. No. 4,005, 063, has the structure 5-oxo-Pro'-Hisz-Trp3-Ser4-Tyrs-D-I,eu~'-Leu~-Arg$-Pro9-NHEt.
Results for the assay of representative compounds within the scope of the invention are summarized in Tables 1-3. pK~ value:. for compounds of formula (I) wherein 1 is 2, m is 3,p is I, X is flourine, Y is hydrogen, RZ is hydrogen, and W and Z are both -OCH3, as represented by formula (V) below 0~
F I ~ ~~N.H

tCH2)n'-N

(V) are described by the corresponding value of n and the substituent R, in Table 1.

Table 1.
Example n R~ pit 1 3 t ~H3 8.80 2 3 I:R) CH3 8.25 3 3 (S) CH3 7.0 4 3 9.87 8.80 ~---~ 8.80 'CH3 7 3 / 7.34 8 3 9.41 3 10.07 3 8.54 11 3 ~ 8.71 N

12 3 8.08 ~OCH3 13 3 8.46 14 3 oC~3 8.14 Table 1. (continued) 15 3 ~~NHZ 8.53 16 3 ~. 8.53 17 3 ~~ 8.56 18 3 ~ ci 7.41 19 3 ~ 8.23 20 3 ~ 7.60 21 3 ' ~,~.~ NHZ 10.14 ~NH2 22 3 9.24 23 3 ;~~cH3 8.91 24 3 '~- 9.39 25 3 NHZ 9.73 26 3 ~ 8.56 H 'CH3 27 3 ~ ~ 10.0 28 3 9.60 H

TahlP 1 lrnntinuedl ~~ CH3 29 3 ~ 8.60 ~' ~CH3 30 3 ~~-~cH3 8.00 31 3 , H I 8.40 r 32 3 ~~/~ 9.20 ~CHa 33 3 ~cH 8.9 H CHa 34 3 8.63 i 35 3 H ~ 8.61 o 36 3 ~ ~ 8.27 a 37 3 NHz 8.40 CHa 38 3 ' ~ CHa 8.80 H

Table 1. lcontinuedl 39 3 ~ ~ cH3 8.0 ' H
40 3 ~ 7.70 41 3 ~ 7.80 42 3 ~ 8.30 43 3 ', !; ~ ~ ~. CH3 8.10 s' i 44 2 C'.H3 7.1 S
45 4 C:H3 7.45 Examples 46-71 pK, values for compounds of formula (I) wherein 1 is 2, m is 3, n is 3, X is fluorine, Y is hydrogen, and an isoquinolinyl moiety is denoted by R as represented below by formula (VI):
O
'~N~H
R
(VI) are summarized according to the substituent R in Table 2 below.
Table 2.
Example 7.81 46 ~/ / off "'i3 47 7.84 "'i3 48 N ~ 8.00 /.

7.90 49 ~/ ~ /

"- OCH3 50 /rv ~ / 8.60 Hs 51 ~/ ~OCH3 8.98 1.:H3 8.45 CI
~;H3 53 ~/ ~ ~F 7.84 (..H3 Table 2. ~continuedl 54 ~~ 8.36 ~/ ~ NOZ

O
55 N ~ 8.06 CI
56 /N ~ ~ cl 8.43 ~~3 CI
57 /N ~ / F 8.60 "' i3 7.91 58 ~/ ' ~ ococH3 ~i3 -- Br 8.72 59 ~/ ' ~ ocH3 CIi3 '- F
8.77 60 ~/ ~ ocH3 ~~3 8.43 61 ~/ /
~H~

Table 2. (continued) 9.30 62 ~/ ~ ocH3 "":3 Co~CH
8.17 63 ~/N / ocH3 ~3 64 ~~ ~ocH3 8.22 H3C ' OCH3 65 ~.N ~ ocH 10.44 :H3 H3G ' OCH3 66 NN ~ 9.21 8.60 67 ~/ ~ ~ -~ ocH3 Hs vCHs 8.60 68 ~ w / ocH3 69 ~ / 7.90 oCH3 :H3 -i 06-Table 2. (continued) 7.66 70 i ~ / \oCH3 ~Ha ~~~N
71 7.80 .~ OCH3 Examples 72-80 pK~ values for compounds of formula (I) wherein m is 3, n is 3,p is 1, Ri is methyl, R2 is H, W and Z are both -OCH3, and the substitution of the primary amine is denoted by R', as represented below b~y formula (VII) ~I
'OCH3 (VII) are according to the substituent R' i:n Table 3 below.
Table 3.
Example R' 72 ~ ~ 8.50 R.WN~H

Table 3. (continued) .~ O _ 73 O \~ 8.66 c .- O _ 74 F \~;~ 11.40 F
11.48 F
.- O _ 76 F ~ \' 8.40 c o 77 Me ~ 8.30 Me O
78 Me ~ ~ 9.54 O
79 '\ 9.71 80 F ~ ~\ ~ 11.64

Claims (20)

WHAT IS CLAIMED IS:
1. A compound having a formula:

or a pharmaceutically acceptable salt, ester, or prodrug thereof, wherein:
l, m, and n are each independently 1, 2, 3, or 4;
p is 1 or 2;
R1 is selected from the group consisting of:
(a) alkyl, (b) cycloalkyl, (c) aryl, (d) cyano, (e) -(CH2)q-R4, wherein q is 0 to 10, (f) -cycloalkyl-R5, and (g) -aryl-R5;
R2 is selected from the group consisting of:
(a) alkyl, (b) hydrogen, (c) alkoxycarbonyl, (d) hydroxymethyl, and (e) -(CH2)q-R4, wherein q is 0 to 10;

R4 is selected from the group consisting of:

(a) alkyl, (b) alkoxy, (c) aryl, (d) aryloxy, (e) cyano, (f) cycloalkyl, (g) hydroxy, (h) halogen, (i) phthalimido, (j) -cycloalkyl-R5, (k) -aryl-R5, and (l) -NR6R7;
R5 is selected from the group consisting of:
(a) alkyl, (b) alkoxy, (c) cyano, (d) hydroxy, (e) halogen, (f) trifluoromethyl, and (g) -(CH2)9 NR6R7, wherein q is 0 to 10;
R6 and R7 are independently selected from the group consisting of:
(a) hydrogen, (b) alkyl, (c) cycloalkyl, and (d) aryl, or R6 is hydrogen and R7 is a group of the formula -COR8, wherein R8 is selected from the group consisting of:
(a) alkyl, (b) aryl, and (c) heterocycle;
X and Y are independently selected from the group consisting of:
(a) hydrogen, (b) halogen, (c) alkoxy, (d) alkyl, and (e) trifluoromethyl; and W and Z are independently selected from the group consisting of:
(a) hydrogen, (b) hydroxy, (c) alkyl, (d) alkoxy, (e) alkoxycarbonyl, (f) nitro, (g) N acyl, (h) halogen, and (i) trifluoromethyl, or W and Z taken together form a cyclic ring.
2. A compound according to Claim 1, wherein 1 is 2, m is 3, n is 3, and p is 1.
3. A compound according to Claim 1, wherein R1 is selected from the group consisting of alkyl, cycloalkyl, and -(CH2)q-R4, wherein q is 0 to 10, and R4 is a group of the formula -NR6R7, wherein R6 and R7 are each independently selected from hydrogen, alkyl, and cycloalkyl.
4. A compound according to Claim 3, wherein R1 is selected from the group consisting of methyl, cyclopropyl, cyclobutyl, aminomethyl, aminoethyl, aminopropyl, aminobutyl, N [cyclopropylmethyl]aminobutyl, and N [bis-cyclopropylmethyl]aminobutyl.
5. A compound according to Claim 1, wherein R2 is selected from the group consisting of hydrogen and methyl.
6. A compound according to Claim 1, wherein X and Y are independently selected from the group consisting of hydrogen and halogen.
7. A compound according to Claim 1, wherein W and Z are independently selected from the group consisting of hydrogen and methoxy.
8. A compound according to Claim 1, selected from the group consisting of (R,S) 7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-methyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
(R) 7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-methyl-6,7-dimethoxyisoquinolinyl)]-4,4-diiphenylheptane hydrochloride;
(S) 7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-methyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-cyclopropyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-ethyl-6,7-dimethoxy-isoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-isopropyl-6,7-dimethoxyisoquinolinyl]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-phenyl-6,7-dimethoxy-isoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propiomyl]amino-1-[N-(1,2,3,4-tetrahydro-1-cyclopentyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-cyclobutyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-cyclohexyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-cyanomethyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-methoxymethyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;

7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-benzyloxymethyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-(p-methoxy)phenyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-(4-aminophenyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-[4-(N-isopropyl-amino)phenyl]-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-benzyl-6,7-dimethoxy-isoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-(N-(1,2,3,4-tetrahydro-1-(4-chlorobenzyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-(4-methoxybenzyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-phenethyl-6,7-di-methoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-(4-aminobenzyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-aminomethyl-6,7-di-methoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-(N-isopropyl-aminomethyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-(4-N-phthalimido-butyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-(N (1,2,3,4-tetrahydro-1-(4-aminobutyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-[4-(N
isopropyl-amino)butyl]-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-[4-(N-cyclopropyl-methylamino)butyl]-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-[4-(N-cyclobutyl-amino)butyl]-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-[4-(N-isobutyl-amino)butyl]-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;

7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-[4-(N-isopentyl-amino)butyl]-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-[4-(N-alpha-methyl-benzylamino)butyl]-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-[4-(N,N
dicyclopropyl-methylamino)butyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-(N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-(4-(N,N-dimethyl-amino)butyl]-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-[N-3-(4-fluorophenyl)propionyl)amino-1-[N-(1,2,3,4-tetrahydro-1-[4-(N-acetyl-amino)butyl]-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-[4-(N-nicotinyl-amino)butyl)-6,7-dimethoxyisoquinolinyl]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-[4-(N-phthalimido-methyl]cyclohexyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-(4-aminomethyl-cyclohexyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-(4-N-isopropylamino-methyl)cyclohexyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-(N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-(4-N-phthalimido-methyl)phenyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-(4-aminomethyl-phenyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-(4-N-isopropylamino-methyl)phenyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-(4-N-cyclobutylamino-methyl)phenyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-(N-(1,2,3,4-tetrahydro-1-(4-N-cyclopropyl-methylaminomethyl)phenyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-(4-N-biscyclopropyl-methylaminomethyl)phenyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-(4-N-acetylamino-methyl)phenyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-methyl-6,7-dihydroxy-isoquinolinyl)]-4,4-diphenylheptane hydrochloride;

7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-methylisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-methyl-6,7-dioxalane-isoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl)amino-1-[N-(1,2,3,4-tetrahydro-1-methyl-6,7-dioxane-isoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-methyl-6-methoxy-isoquinolinyl))-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-methyl-7-methoxy-isoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-methyl-7-chloro-isoquinolinyl))-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl)amino-1-[N-(1,2,3,4-tetrahydro-1-methyl-7-fluoro-isoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-methyl-7-nitro-isoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-methyl-7-acetylamino-isoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-methyl-6,7-dichloro-isoquinolinyl))-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-methyl-6-chloro-7-fluoroisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl)amino-1-[N-(1,2,3,4-tetrahydro-1-methyl-6,7-diacetoxy-isoquinolinyl))-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl)amino-1-[N-(1,2,3,4-tetrahydro-1-methyl-6-bromo-7-methoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl)amino-1-[N-(1,2,3,4-tetrahydro-1-methyl-6-fluoro-7-methoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-methyl-6-methoxy-7-bromo-isoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1,6-dimethyl-7-methoxy-isoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-methyl-6-carbo-methoxy-7-methoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;

7-[N-3-(4-fluorophenyl)propionyl)amino-1-[N-(1,2,3,4-tetrahydro-1-cyclobutyl-6-bromo-7-methoxy-isoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1,3-dimethyl-6,7-di-methoxyisoquinolinyl))-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-3-methyl-6,7-dimethoxy-isoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1,1-dimethyl-6,7-di-methoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1,3-dimethyl-7-methoxy-isoquinolinyl))-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]-1-[N-(2,3,4,5-tetrahydro-1-methyl-7,8-dimethoxy-1H-2-benzazepinyl)]-4,4-diphenylheptane hydrochloride;
6-[N 3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-methyl-6,7-methoxy-isoquinolinyl)]-3,3-diphenylhexane hydrochloride;
8-[N 3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-methyl-6,7-dimethoxy-isoquinolinyl)]-5,5-diphenyloctane hydrochloride;
8-[N-3-(4-fluorophenyl)acetyl]amino-1-[N-(1,2,3,4-tetrahydro-1-methyl-6,7-dimethoxy-isoquinolinyl))-5,5-diphenyloctane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-methyl-7-methoxy-3-methoxycarbonylisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-3-(2-hydroxyethyl-aminocarbonyl)-1-methyl-7-methoxyisoquinolinyl))-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl)amino-1-[N(1,2,3,4-tetrahydro-(3-hydroxypropyl aminocarbonyl)-1-methyl-7-methoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-3-(4-hydroxybutyl-aminocarbonyl)-1-methyl-7-methoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl)amino-1-[N-(1,2,3,4-tetrahydro-1-methyl-7-methoxy-3-(2-(N-pyrrolidinyl)ethylaminocarbonyl)isoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-methyl-3-hydroxy-methyl-7-methoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(phenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-methyl-6,7-dimethoxy-isoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(3,4-dichlorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-methyl-6,7-dimethoxyisoquinolinyl))-4,4-diphenylheptane hydrochloride;

7-[N-3-(3,4-difluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-methyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(3-fluoro-4-chloro-phenyl)propionyl)amino-1-[N-(1,2,3,4-tetrahydro-1-methyl-6,7-dimethoxy-isoquinolinyl))-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluoro-3-chloro-phenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-methyl-6,7-dimethoxy-isoquinolinyl))-4,4-diphenylheptane hydrochloride;
7-[N-3-(3,4-dimethoxyphenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-methyl-6,7-dimethoxyisoquinolinyl))-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-methoxyphenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-methyl-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-chlorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-methyl-6,7-dimethoxy-isoquinolinyl))-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)acetyl]amino-1-[N-(1,2,3,4-tetrahydro-1-methyl-6,7-dimethoxy-isoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-(3-N-phthalimido-propyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-(3-aminopropyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-[3-N-(biscyclobutyl-amino)propyl]-5,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-[3-N-(biscyclopropyl-methylamino)propyl]-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-[3-N-(dimethylamino)-propyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-[3-N-(isopropyl)propyl]-6,7-dimethoxyisoquinolinyl))-4,4-diphenylheptane dihydrochloride;
7-[N-3-(4-fluorophenyl)propionyl)amino-1-[N-(1,2,3,4-tetrahydro-1-(5-N-phthalimido-pentyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-(5-aminopentyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-[5-N-(biscyclobutyl-amino)pentyl]-6,7-dimethoxyisoquinolinyl))-4,4-diphenylheptane dihydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-[5-N-(biscyclopropyl-methylamino)pentyl]-6,7-dimethoxyisoquinolinyl))-4,4-diphenylheptane dihydrochloride;

7-[N-3-(4-fluorophenyl)propionyl)amino-1-[N-(1,2,3,4-tetrahydro-1-[5-N-(dimethylamino)-pentyl]-6,7-dimethoxyisoquinolinyl))-4,4-diphenylheptane dihydrochloride;
7-[N-3-(4-fluorophenyl)propionyl)amino-1-[N-(1,2,3,4-tetrahydro-1-[5-N-(isopropylamino)-pentyl)-6,7-dimethoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-cyclobutyl-6-fluoro-7-methoxyisoquinolinyl))-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-(4-N-phthalimidobutyl)-6-methyl-7-methoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride;
7-[N 3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-(4-aminobutyl)-6-methyl-7-methoxyisoquinolinyl))-4,4-diphenylheptane dihydrochloride;
7-[N-3-(4-fluorophenyl)propionyl]amino-1-[N-(1,2,3,4-tetrahydro-1-(4-N-isopropylamino-butyl)-6-methyl-7-methoxyisoquinolinyl)]-4,4-diphenylheptane dihydrochloride;
and 7-[N-3-(4-fluorophenyl)propionyl)amino-1-[N-(1,2,3,4-tetrahydro-1-cyclobutyl-6-methyl-7-methoxyisoquinolinyl)]-4,4-diphenylheptane hydrochloride.
9. A process of preparing a compound of formula:

or a pharmaceutically acceptable salt, ester, or prodrug thereof, wherein l, m, n, p, R1, R2, W, X, Y, and Z represent the groups as defined in Claim 1, comprising the steps of:
(a) treating a diphenyl-substituted aminoalkanol of the formula:

wherein m and n are as defined above, with a compound of the formula:

wherein l, X, and Y are as defined above, and R3 is selected from hydroxy, halo, or an aryl ring substituted with an electron withdrawing group, to obtain an N substituted aminoalkanol;
(b) oxidizing alcohol moiety of the N-substituted aminoalkanol to an aldehyde moiety; and (c) alkylating the aldehyde moiety with an isoquinoline ring of the formula:

wherein p, R1, R2, W and Z are as defined above.
10. A compound according to Claim 9, wherein R1 is selected from the group consisting of alkyl, cycloalkyl, and -(CH2)q-R4, wherein g is 0 to 10, and R4 is a group of the formula -NR6R7, wherein R6 and R7 are each independently selected from hydrogen, alkyl, and cycloalkyl.
11. A compound according to Claim 9, wherein X and Y are independently selected from the group consisting of hydrogen and halogen.
12. A compound according to Claim 11, wherein the acylating reagent is 3-(4-fluorophenyl)propionic acid.
13. A process of preparing a compound of formula:
or a pharmaceutically acceptable salt, ester, or prodrug thereof, wherein l, m, n, p, R1, R2, W, X, Y, and Z represent the groups as defined in Claim 1, comprising the steps of:
(a) treating a diphenyl-substituted aminoalkanol of the formula:
wherein m and n are as defined above, with a compound of the formula:
wherein l, X and Y are defined above, and R3 is selected from hydroxy, halo, or an aryl ring substituted with an electron withdrawing group, to obtain an N substituted aminoalkanol;
(b) preparing a reactive leaving group from the alcohol moiety of the N
substituted aminoalkanol to obtain a compound of the formula:
wherein R9 is selected from the group consisting of halide and mesylate; and (c) alkylating the reactive N substituted aminoalkanol with an isoquinoline ring of the formula:
or the hydroiodide salt thereof, wherein p, R1, R2, W and Z are as defined above.
14. A compound according to Claim 13, wherein R1 is selected from the group consisting of alkyl, cycloalkyl, and -(CH2)~-R4, wherein ~ is 0 to 10, and R4 is a group of the formula -NR6R7, wherein R6 and R7 are each independently selected from hydrogen, alkyl, and cycloalkyl.
15. A compound according to Claim 13, wherein X and Y are independently selected from the group consisting of hydrogen and halogen.
16. A compound according to Claim 13, wherein the acylating reagent is 3-(4-fluorophenyl)propionic acid.
17. A pharmaceutical composition for inhibiting the release of luteinizing hormone comprising a therapeutically effective amount of a compound according to Claim 1 and a pharmaceutically acceptable carrier.
18. A pharmaceutical composition for inhibiting the release of luteinizing hormone comprising a therapeutically effective amount of a compound according to Claim 8 and a pharmaceutically acceptable carrier.
19. A method of modulating luteinizing hormone release in humans and other mammals in need of such treatment comprising administering, to a patient in need thereof, a therapeutically effective amount of a compound according to Claim 1.
20. A method of modulating luteinizing hormone release in humans and other mammals in need of such treatment comprising administering, to a patient in need thereof, a therapeutically effective amount of a compound according to Claim 8.
CA002351187A 1998-11-13 1999-11-09 Tetrahydroisoquinoline derivatives as lhrh antagonists Abandoned CA2351187A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/191,511 1998-11-13
US09/191,511 US5981521A (en) 1998-11-13 1998-11-13 Tetrahydroisoquinoline derivatives as LHRH antagonists
PCT/US1999/026584 WO2000029380A1 (en) 1998-11-13 1999-11-09 Tetrahydroisoquinoline derivatives as lhrh antagonists

Publications (1)

Publication Number Publication Date
CA2351187A1 true CA2351187A1 (en) 2000-05-25

Family

ID=26795886

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002351187A Abandoned CA2351187A1 (en) 1998-11-13 1999-11-09 Tetrahydroisoquinoline derivatives as lhrh antagonists

Country Status (4)

Country Link
EP (1) EP1129076A1 (en)
JP (1) JP2002529534A (en)
CA (1) CA2351187A1 (en)
WO (1) WO2000029380A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100386319C (en) * 2005-12-05 2008-05-07 中国人民解放军第二军医大学 Tetrahydroisoquinolines or their salts having antifertility and antifungal activity
CN113416140B (en) * 2021-06-03 2023-01-13 万华化学集团股份有限公司 Method for preparing 2-methyl pentanediamine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8500615D0 (en) * 1985-01-10 1985-02-13 Lundbeck & Co As H Organic compounds
CA2163325A1 (en) * 1994-11-21 1996-05-22 Kaneyoshi Kato Amine compounds, their production and use

Also Published As

Publication number Publication date
EP1129076A1 (en) 2001-09-05
WO2000029380A1 (en) 2000-05-25
JP2002529534A (en) 2002-09-10

Similar Documents

Publication Publication Date Title
US6380207B2 (en) Glucocortiocoid-selective antiinflammatory agents
DE69725608T2 (en) INDOLIN-2-ONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND THE MEDICAMENT THEREOF
EP0819121B1 (en) Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US3301857A (en) Spiro
US3489770A (en) 1-cyclo(lower)alkanoyl or admantanylcarbonyl - 3 - (2-substituted ethyl)indoles
AU2003276047A1 (en) Aspartyl protease inhibitors
JPH0665077A (en) Method for use of spirocyclic oxytocin antagonist
EP0319429B1 (en) 9-Acylamino-tetrahydroacridine derivatives and memory enhancing agent containing said derivative as active ingredient
EP0113782A1 (en) Bicyclic nitrogen heterocyclic ethers and thioethers, and their pharmaceutical uses
WO2008009215A1 (en) Tetrahydro isoquinoline derivatives, preparation methods and medicinal uses thereof
IE902787A1 (en) 1,3-Dihydro-1-(pyridinylamino)-2H-indol-2-ones, a process for their preparation and their use as medicaments
KR20010015881A (en) Potassium channel openers
US5981521A (en) Tetrahydroisoquinoline derivatives as LHRH antagonists
Ogawa et al. Orally active, nonpeptide vasopressin V1 antagonists. A novel series of 1-(1-substituted 4-piperidyl)-3, 4-dihydro-2 (1H)-quinolinones
DE60201415T2 (en) BISARYL DERIVATIVES WITH FSH RECEPTOR MODULATING ACTIVITY
CA2351187A1 (en) Tetrahydroisoquinoline derivatives as lhrh antagonists
MXPA01004792A (en) Tetrahydroisoquinoline derivatives as lhrh antagonists
US4537895A (en) Isoquinoline derivatives
US3880862A (en) 6{62 -Azido-17-cycloalkylmethyl-4,5{60 -epoxymorphinan-3-ols
Sugasawa et al. Extension of Bischler-Napieralski reaction—I: Synthesis of isoquinoline derivatives: A synthesis of rac.-apomorphine dimethyl ether
EP0051190A2 (en) N-(amino(or hydroxy) phenethyl)-1,2,3,4-tetrahydroisoquinolines, precursors thereof, and methods of preparation
US4526891A (en) Substituted alkyl amine derivatives of 6,11-dihydro-11-oxodibenz[b,e]oxepins
US3476755A (en) 8,13-diazasteroids
US2785159A (en) Azacarbocycles and process for their manufacture
EP0187619A2 (en) 1,3-Disubstituted tetrahydropyridines

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead